Stockwinners Market Radar for September 06, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

DKNG

Hot Stocks

20:06 EDT Cathie Wood's ARK Investment bought 153K shares of DraftKings today
EXAS

Hot Stocks

20:05 EDT Cathie Wood's ARK Investment bought 188K shares of Exact Sciences today
SQ

Hot Stocks

20:05 EDT Cathie Wood's ARK Investment bought 86K shares of Block today
RIG

Hot Stocks

19:07 EDT Transocean announces $181M in contracts for Deepwater Asgard - Transocean announced that the ultra-deepwater drillship, Deepwater Asgard, received two contract awards in the U.S. Gulf of Mexico for a total of approximately 14 months of work, adding $181M in firm backlog. The first award is a one-well contract with Murphy Oil Corporation at $395,000 per day. The contract is expected to commence late this fall after the rig completes its current contract and a planned out-of-service period. The contract also includes an option for a second well at the same dayrate. The backlog for the firm contract is approximately $20M. The second award, a one-year contract with another operator at $440,000 per day (plus up to $40,000 per day for additional products and services), is expected to commence in the first half of 2023. This contract also includes three, one-year option periods at mutually agreed dayrates. The firm backlog associated with the contract is estimated to be approximately $161M, excluding any revenue associated with the additional products and services.
GBT

Hot Stocks

19:03 EDT Global Blood Therapeutics CFO sells $2.14M in common stock - In a regulatory filing, Global Blood Therapeutics disclosed that its CFO Jeffrey Farrow sold 31.4K shares of common stock as part of option exercise in a total transaction of $2.14M.
PRIM

Hot Stocks

18:49 EDT Primoris awarded $120M contract for 60 miles of pipeline in Texas - Primoris Services announced a pipeline award valued over $120M. The contract was secured by the Pipeline Services Segment. The award is for the construction of nearly 60 miles of pipeline in Texas. Work is scheduled to commence in the Q3 of 2022 and completion is expected in the Q2 of 2023.
GILD

Hot Stocks

18:47 EDT Gilead's Kite says European Commission approved its CAR T-cell therapy Tecartus - Kite, a Gilead Company, "announced that the European Commission has approved its CAR T-cell therapy Tecartus, or brexucabtagene autoleucel, for the treatment of adult patients 26 years of age and above with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. The approval is supported by data from the ZUMA-3 international multicenter, single-arm, open-label, registrational Phase 1/2 study of adult patients with relapsed or refractory ALL. This study demonstrated that 71% of the evaluable patients achieved complete remission or CR with incomplete hematological recovery with a median follow-up of 26.8 months. In an extended data set of all pivotal dosed patients the median overall survival for all patients was more than two years and almost four years for responders. Among efficacy-evaluable patients, median duration of remission was 18.6 months."
MSFT

Hot Stocks

18:18 EDT Microsoft CFO sells $19.55M in common stock - In a regulatory filing, Microsoft disclosed that its CFO Amy Hood sold 75,351 shares of common stock on September 2nd in a total transaction size of $19.55M.
CS NTB

Hot Stocks

17:57 EDT Credit Suisse signs deals with Butterfield, Gasser to sell global trust business - Credit Suisse (CS) has signed two agreements to sell the Credit Suisse Trust business to Butterfield (NTB) and Gasser Partner. All parties are committed to ensuring a seamless transition with a focus on the continuation of services for clients. Credit Suisse has signed separate agreements with The Bank of N.T. Butterfield & Son Limited and Gasser Partner Trust for the sale of Credit Suisse's global trust business, while CST entities will continue to operate with a limited number of clients. Under separate agreements, Butterfield will acquire CST's businesses based in Guernsey, Singapore, and The Bahamas, while Gasser Partner will acquire CST's Liechtenstein business. The transaction with Butterfield is expected to close in the first half of 2023 and is subject to customary conditions, including regulatory approvals. The transfer of the trust structures in Liechtenstein will occur on a rolling basis and is also expected to complete in the first half of 2023. Upon completion of the transactions, Butterfield and Gasser Partner will take over the ongoing management and administration of most of the trust structures in the respective jurisdictions. A significant portion of CST's employees are expected to transfer to Butterfield. The CST-related legal entities and any residual business will be wound down by Credit Suisse over the next few years.
GOOG GOOGL

Hot Stocks

17:49 EDT Google announces October 6 event for debut of new phones and first watch - Google said in a tweet on its Made By Google Twitter page, "Our September software update begins rolling out today to all supported Pixel devices running #Android13 and will continue over the next week. The updates include improvements to: Battery & charging, Bluetooth connectivity and User interface." Reference Link
IOT

Hot Stocks

17:37 EDT Warburg Pincus takes 7.3% passive stake in Samsara - Warburg Pincus disclosed a 7.3% stake in Samsara, which represents over 7.08M shares. The filing does not allow for activism.
SRNE

Hot Stocks

17:30 EDT Sorrento Therapeutics co-founder bought $109K in common stock - In a regulatory filing, Sorrento Therapeutics disclosed that its co-founder Henry Ji bought 55.5K shares of common stock on September 6th in a total transaction size of $109K.
ADES

Hot Stocks

17:27 EDT Advanced Emissions to sell Marshall Mine to Caddo Creek - Advanced Emissions Solutions announced that it has signed a definitive agreement to sell Marshall Mine the entity that owns the former lignite mine currently being reclaimed located in Marshall, Texas, to Caddo Creek Resources Company. The Company had previously taken over the Marshall Mine upon entering into its activated carbon supply agreement with Norit Activated Carbon. The Company does not expect any cash proceeds from the Transaction and will pay out a purchase price of $2.4M from cash balances that are currently restricted. As a result of the Transaction, Caddo Creek will assume Marshall Mine's assets as well as the asset retirement obligation related to the mine of $4.8M. Upon completion of the Transaction, the Company expects to record a gain of approximately $2.4M. Additionally, the elimination of the asset retirement obligation is expected to result in the release of a portion of the Company's restricted cash balance when the Transaction closes which is expected to occur in the first half of 2023. The closing of the Transaction is subject to certain customary closing conditions including obtaining applicable regulatory approvals. "Although the reclamation work performed at the Marshall Mine has gone extremely well and is under budget, this sale allows us to continue to de-risk our balance sheet and to focus on growing our consumables revenues," said Greg Marken, CEO of ADES. "The removal of the surety bond associated with the Marshall Mine and the expected release of restricted
PINC

Hot Stocks

17:23 EDT Premier's Contigo Health to acquire contracts with 900K providers for $177.5M - Premier subsidiary Contigo Health "announced an agreement to acquire key assets from TRPN Direct Pay, Inc. and Devon Health, Inc. for $177.5M in cash. Acquired assets will include contracts with more than 900,000 providers across 4.1 million U.S. locations, including acute care hospitals, surgery centers, physicians, ancillary facilities, MRI centers, laboratories, radiology centers, urgent care clinics, home health services, durable medical equipment suppliers, chiropractors, physical therapists and mental health practitioners. Under the terms of the agreement, Contigo Health also will license TRPN's proprietary cost containment technology. The transaction is expected to close in the second quarter of fiscal 2023, subject to customary closing conditions and regulatory clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. Premier currently anticipates the transaction to generate adjusted earnings per share accretion of $0.01 to $0.02 in fiscal 2023. In addition, the company expects the transaction to result in $40 million to $60 million in incremental annual net revenue and contribute 40 percent to 50 percent in adjusted EBITDA margin once fully scaled in the next three to five years."
WEST

Hot Stocks

17:16 EDT Westrock Coffee director Ford Buys $499K in shares of company stock - Director of Westrock Coffee Joe Ford disclosed in a regulatory filing that he had purchased 45,500 shares of company stock at $10.97 per share on September 1, for a total transaction amount of $499,135.
LGIH

Hot Stocks

17:10 EDT LGI Homes reports 504 home closings in August 2022 - LGI Homes announced it closed 504 homes in August 2022. As of August 31, 2022, the Company had 93 active selling communities.
AVYA

Hot Stocks

17:05 EDT Avaya sees $23M-$26M in pre-tax charges from workforce reduction - According to a regulatory filing, on September 5, 2022, Avaya Holdings authorized a reduction in force, which together with incremental cost reduction actions unrelated to the workforce reduction, will operationalize more than $250M of annual cost reductions, allowing the company to realize the higher end of the company's plans to achieve annual cost reductions of between $225M to $250M, as announced on July 28, 2022. The reduction in force better aligns the size of Avaya's workforce with its operational strategy and cost structure. The company estimates that it will incur approximately $23M to $26M in pre-tax restructuring charges, all of which are expected to be in the form of cash-based expenditures and substantially all of which are expected to be related to employee severance and other termination benefits. The company will amend this Current Report on Form 8-K to provide its estimate of aggregate costs incurred related to these actions once available, if materially different than the range noted herein.
IBTX

Hot Stocks

17:02 EDT Independent Bank appoints Dan Strodel as chief banking officer - Independent Bank announced the appointment of Dan Strodel as executive VP and chief banking officer. In his new role, Strodel will be responsible for revenue-generating lines of business including commercial, middle market and specialty banking, treasury solutions, SBA, mortgage and private capital management.
SMBK

Hot Stocks

17:02 EDT SmartFinancial subsidiary to acquire operating assets of Chattanooga - Rains Insurance, a wholly owned subsidiary of SmartBank, announced that it has acquired the operating assets of Chattanooga, TN-based Sunbelt Group. The transaction is effective September 1 and marks the first acquisition of an independent insurance agency by Rains. Sunbelt, formed in 1984, is an independent, full-service insurance agency providing personal and commercial property and casualty insurance as well as life and health.
NATR

Hot Stocks

17:00 EDT Natures Sunshine Products CFO Joseph Baty to retire - Nature's Sunshine Products announced the retirement from the company of its Chief Financial Officer Joseph Baty, effective September 30, 2022. Nature's Sunshine has engaged a leading executive search firm to find its next CFO. Jonathan Lanoy, the company's Corporate Controller and Vice President of Finance, will serve as interim CFO, principal financial officer and principal accounting officer until a full-time CFO has been appointed. "On behalf of the entire management team, I thank Joe for his dedication and valuable contributions during his career at Nature's Sunshine," said CEO Terrence Moorehead. "Joe played an important role in developing a strong finance team and driving critical financial and operational improvements that have put Nature's Sunshine in a position to achieve its strategic goals. I am deeply appreciative of Joe's service and leadership and wish him all the best."
VBTX

Hot Stocks

17:00 EDT Veritex: StoneCastle Partners terminated pact for its StoneCastle Insured buy - Veritex Holdings announced that, on September 1, StoneCastle Partners unilaterally terminated the definitive agreement in respect of Veritex's previously announced proposed acquisition of StoneCastle Insured Sweep, from StoneCastle . Veritex had already received the approval of the Texas Department of Banking for the acquisition and was substantially progressed in pursuing the approval of the Federal Deposit Insurance Corporation for the acquisition when StoneCastle terminated the Agreement. Veritex believes all the other conditions precedent to closing under the Agreement were satisfied upon receipt of approval from the FDIC. Neither Veritex nor the other parties to such agreement will pay a termination fee in connection with the termination of the transaction. Veritex is considering all options in connection with the termination of the Agreement, including in respect of willful and material breaches of the Agreement by StoneCastle.
JELD

Hot Stocks

16:49 EDT Jeld-Wen director buys $199K in common stock - In a regulatory filing, Jeld-Wen disclosed that its director Steven Wynne bought 18K shares of common stock on September 2nd in a total transaction size of $199.2K.
RKLB

Hot Stocks

16:43 EDT Rocket Lab signs CRADA with U.S. TRANSCOM to explore Neutron, Electron rockets - Rocket Lab announced that it has signed a Cooperative Research and Development Agreement, or CRADA, with the United States Transportation Command, or U.S. TRANSCOM, to explore the possibility of using the company's Neutron and Electron launch vehicles to transport cargo around the world. The agreement will also see Rocket Lab explore using Photon spacecraft to establish on-orbit cargo depots and deliver re-entry capability. The CRADA enables the collaborative investigation between TRANSCOM and Rocket Lab to explore Neutron, Electron and Photon capabilities, informing the Rocket Cargo program led by the Air Force Research Laboratory, or AFRL, and the U.S. Space Force. Rocket Cargo is one of the Air Force's Vanguard programs designed to advance emerging systems and concepts through prototyping and experimentation to deliver remarkable new capabilities. The program seeks to explore the viability of space launch to deliver improvements in delivery cost and speed compared to existing air cargo operations.
LW

Hot Stocks

16:41 EDT Lamb Weston expands french fry processing capacity in Argentina - Lamb Weston announced an expansion of french fry processing capacity in Argentina with the planned construction of a new manufacturing facility in Mar del Plata, Buenos Aires. The company recently increased its stake in its South American joint venture, Lamb Weston Alimentos Modernos S.A. from 50% to 90%. The new french fry processing facility in Mar del Plata is expected to produce more than 200M pounds of frozen french fries and other potato products per year for the 2B pound South American market. Construction of the new line is expected to be completed by mid-calendar year 2024, and will add approximately 250 new jobs. The total investment is expected to be approximately $240M, subject to inflation and exchange rates at the time. This investment will add to the capacity produced at the joint venture's existing manufacturing facility in Munro, Buenos Aires.
EQT

Hot Stocks

16:38 EDT EQT to acquire assets from Tug Hill and Xcl Midstream for $5.2B - EQT announced that it has entered into a purchase agreement with THQ Appalachia I and THQ-XcL Holdings I, whereby to which EQT has agreed to acquire Tug Hill's upstream assets and XcL Midstream's gathering and processing assets, for total consideration of $5.2B. Tug Hill and XcL Midstream are backed by equity commitments from funds managed by Quantum Energy Partners. The transaction is expected to close in the Q4,with an effective date of July 1, 2022. Subject to the transaction close and EQT's regular board approval process, Wil VanLoh, Founder and CEO of Quantum Energy Partners, will join EQT's board of directors. Transaction highlights include: strategic bolt-on adds ~800 MMcfe/d in the core of southwest Appalachia; ~90,000 core net acres offsetting EQT's existing core leasehold in West Virginia, 96% operated working interest, 83% net revenue interest; ~300 remaining net risked locations, which compete favorably with EQT's adjacent assets and provide additional wet gas production optionality; 11 years of inventory at maintenance capital levels High-margin assets expected to generate free cash flow at average natural gas prices above ~$1.35 per MMBtu over the next 5 years. President and CEO Toby Z. Rice stated, "The acquisition of Tug Hill and XcL Midstream checks all the boxes of our guiding principles around M&A, including accretion on free cash flow per share, NAV per share, lowering our cost structure and reducing business risk, while maintaining an investment grade balance sheet. The valuation metrics are compelling and accretion from the deal should lower our NYMEX free cash flow breakeven price by approximately 15c per MMBtu, which gives us greater free cash flow durability through the cycle. As a result of even more confidence in the sustainability of our business, we are enhancing our shareholder returns framework by doubling our share repurchase authorization to $2.0Bbillion and increasing our year-end 2023 debt reduction goal from $2.5B to $4.0B." The total purchase price of the transaction is $5.2B, subject to customary adjustments, consisting of $2.6B in cash and approximately $2.6B in EQT common stock. EQT expects to fund the $2.6B of cash consideration with cash on hand, borrowings under its revolving credit facility and/or through one or more financing or debt capital markets transactions, subject to market conditions and other factors. Royal Bank of Canada, Mizuho Bank and PNC Bank, National Association, have jointly provided $2.5B of committed financing in connection with the transaction and EQT has access to $2.2B of liquidity under its unsecured credit facility. The stock consideration consists of 55M shares of EQT common stock representing $2.6B, based on the 15-day volume-weighted average price as of September 2. Post effective date purchase price adjustments will be split 50/50 against the cash and equity consideration and are expected to result in a total purchase price reduction of approximately $300M-$400M at closing. The transaction was unanimously approved by EQT's Board of Directors. RBC Capital Markets served as financial advisor to EQT, and Kirkland & Ellis is serving as EQT's legal counsel on the transaction. J.P. Morgan Securities and Wells Fargo Securities served as financial advisors to Tug Hill and XcL. Midstream and Vinson & Elkins is serving as legal counsel to Tug Hill and XcL Midstream.
RIOT

Hot Stocks

16:35 EDT Riot Blockchain announces 374 BTC produced in August, down 15 y/y - The company states: "In August 2022, Riot produced 374 BTC, a decrease of approximately 15% as compared to August 2021 production of 441 BTC, while significantly reducing overall power costs through effective employment of its proprietary power strategy. Riot earned an estimated $3.0M in power credits as a result of curtailment activity, to be credited against its power invoices; the $3.0M in power credits equates to approximately 136 BTC, computed by using the August 2022 average daily closing BTC price of $22,097. As of August 31, 2022, Riot held approximately 6,720 BTC, all produced by the Company's self-mining operations. In August 2022, Riot sold 350 BTC, generating net proceeds of approximately $7.7M."
SQZ

Hot Stocks

16:33 EDT SQZ Biotechnologies names Chief Scientific Officer Howard Bernstein to board - SQZ Biotechnologies "announced that Howard Bernstein, M.D., Ph.D., has been appointed to the company's board of directors, effective October 31, 2022. Dr. Bernstein has served as the company's Chief Scientific Officer since July 2015, a position that he will hold until his appointment to the board. The CSO responsibilities will be divided among current senior leaders at SQZ. Ipsita Roymoulik, Ph.D., Scott Loughhead, Ph.D., and Maisam Dadgar will lead chemistry, manufacturing, and controls; translational research; and engineering, respectively. Dr. Bernstein will continue to be available for operational consultation to the team to ensure a smooth transition of leadership and provide technical expertise as needed."
NDSN

Hot Stocks

16:32 EDT Nordson approves additional $500M for share repurchase program - Nordson announced that its Board of Directors has authorized the repurchase of up to an additional $500M of the Company's outstanding common shares, adding capacity to the $160M remaining from its 2018 Board authorization.
ASR

Hot Stocks

16:32 EDT Asur reports August traffic up 22.8% vs. 2019 - Asur announced that passenger traffic for August reached a total of 5.9M passengers, 22.8% above the levels reported in August 2019. Compared to August 2019, passenger traffic increased by 34.8% in Colombia, 21.5% in Mexico and 11.1% in Puerto Rico. All countries of operations reported increases in both domestic and international traffic. This announcement reflects comparisons between the periods August 1 through August 31, 2022, 2021 and 2019. Transit and general aviation passengers are excluded from traffic measures in Mexico and Colombia.
MTCR

Hot Stocks

16:30 EDT Metacrine trading resumes
GPI

Hot Stocks

16:28 EDT Group 1 Automotive acquires BMW/MINI franchises in the U.K. - Group 1 Automotive announced the expansion of its U.K. operations with the acquisition of a BMW/MINI dealership and a collision center in the town of Southend located east of London in the county of Essex. This location is contiguous with several other existing automotive dealerships currently owned and operated by Group 1 Automotive in the U.K and increases the Company's U.K. operations to 56 dealerships and 79 franchises. This acquisition is expected to generate $80M in annual revenues, bringing year-to-date total acquired revenues for Group 1 to $740M. Group 1's Chief Executive Officer Earl Hesterberg stated, "We are extremely pleased to further expand our operations in the U.K. and to increase our BMW/MINI footprint to 43 franchises in the U.S and U.K. Our strong relationship with BMW and our experience in this market area make this an ideal addition to our growing U.K. business."
RYTM

Hot Stocks

16:26 EDT Rhythm Pharmaceuticals announces expanded EC marketing authorization for Imcivre - Rhythm Pharmaceuticals announced that the European Commission, or EC, has expanded the marketing authorization for Imcivree to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome, or BBS, in adult and pediatric patients six years of age and older. Under the terms of the revenue interest financing agreement with HealthCare Royalty Partners announced on June 16, Rhythm is now eligible to receive an additional investment of $37.5M following EC marketing authorization for setmelanotide for BBS. Rhythm had received an initial investment amount of $37.5M from HealthCare Royalty as a result of the approval of setmelanotide by the FDA, and the company remains eligible for an additional investment amount of $25M, which would be payable upon the achievement of certain agreed sales milestones in 2023. Rhythm also announced today that Health Canada has granted Priority Review for Rhythm's new drug submission for setmelanotide, indicated in adult and pediatric patients six years of age and older with impairments in the MC4R pathway due to genetic diseases, for the treatment of obesity and control of hunger in BBS or biallelic pro-opiomelanocortin, proprotein convertase subtilisin/kexin type 1, or leptin receptor deficiency.
ELDN

Hot Stocks

16:23 EDT Eledon gets FDA clearance of IND application to evaluate tegoprubart in IgAN - Eledon Pharmaceuticals announced that the U.S. Food and Drug Administration has cleared the company's Investigational New Drug application to evaluate tegoprubart for the treatment of IgA Nephropathy or IgAN. Eledon plans to open U.S. sites under this IND as part of its ongoing global Phase 2a clinical trial evaluating tegoprubart for the treatment of IgAN. Including the U.S., the trial has now received regulatory clearances in 10 countries with plans to expand the study in up to 2 additional countries, including China. Multiple patients in the Phase 2a study have begun receiving treatment with tegoprubart. IgAN, the most common primary glomerulonephritis disease, affects approximately 150,000 Americans and is characterized by gradual, progressive kidney function deterioration which can potentially lead to End-Stage Renal Disease , dialysis, renal transplant, and death. Leakage of blood proteins into the urine, or proteinuria, is a clinical sign of IgAN, and the severity of proteinuria predicts the rate of progression to ESRD. In addition, reducing proteinuria has been shown to delay progression to ESRD. Current standard of care with ACEi/ARB therapies and budesonide are effective in a subset of patients with IgAN, but many patients on these therapies continue to have progressive disease and continue to be at risk of ESRD.
VAL

Hot Stocks

16:18 EDT Valaris announces receipt of $40M from ARO Drilling joint venture - Valaris "announced that it has received a payment of $40 million from its joint venture ARO Drilling, representing a partial early repayment of its shareholder notes receivable. Following this payment, Valaris has shareholder notes receivable totaling approximately $403M, with $225M due in October 2027 and approximately $178M due in October 2028."
KIII

Hot Stocks

16:17 EDT Kismet Acquisition Three receives noncompliance notification from Nasdaq - Kismet Acquisition Three announced that it received a notice from the Listing Qualifications Department of Nasdaq notifying the company that because it is delinquent in filing its Quarterly Report on Form 10-Q for the period ended June 30, it was not in compliance with Nasdaq Listing Rule 5250. The Listing Rule requires listed companies to timely file all required periodic financial reports with the Securities and Exchange Commission. The Notice stated that the company has sixty calendar days from the date of the notice to submit a plan to regain compliance with the Listing Rule. If Nasdaq accepts the company's plan, it has the discretion to grant the company an extension of up to 180 calendar days from the due date of the Form 10-Q to regain compliance. The notice has no immediate effect on the listing of the company's securities on Nasdaq.
FLT

Hot Stocks

16:16 EDT FleetCor acquires Plugsurfing, terms not stated - FLEETCOR "announced the acquisition of Plugsurfing, a leading European electric vehicle software and network provider to vehicle OEMs, charge point operators, and fleets. Plugsurfing has developed a proprietary EV charging network in Europe with over 300,000 charge points, or nearly 80% of all charge points in Europe. The Plugsurfing app provides access to comprehensive tariff information and facilitates payment for EV charging. This capability is an essential tool for EV drivers and is available directly and as a turnkey white-label solution to EV OEMs for distribution to their customers."
LAZY...

Hot Stocks

16:16 EDT Lazydays appoints John North as CEO - Lazydays (LAZY) Holdings announced that John North joined Lazydays as its CEO on September 6. North was also appointed to serve as a director on the Company's Board of Directors. Robert DeVincenzi, who has been acting as Interim CEO, will return to his role as Lead Independent Director on the board. In connection with the commencement of John North's service, Lazydays granted North a restricted stock unit award covering 105,308 shares of Lazydays common stock. This award was granted as an inducement material to North becoming a new employee of Lazydays in accordance with The Nasdaq Stock Market Listing Rule 5635. John most recently served as CFO of Copart (CPRT), a member of the S&P 500 and a leading provider of online auctions and vehicle remarketing services. Previously, he served as the Chief Financial Officer of Avis Budget Group (CAR), a global leader in car and truck rental and on-demand car sharing. Before joining Avis Budget Group, he spent 17 years in leadership roles with Lithia Motors (LAD), one of the largest automotive retailers in the United States, including as CFO and Chief Accounting Officer.
MARA...

Hot Stocks

16:16 EDT Marathon Digital produces 184 Bitcoin in August - Marathon Digital published unaudited bitcoin BTC production and miner installation updates for August. Operating mining fleet consists of approximately 34,000 active miners, producing approximately 3.2 EH/s, after approximately 25,000 miners are successfully energized in August. Approximately 65,000 additional miners are expected to be energized over the next 90 days. The company produced 184 bitcoin in August; year-to-date through August 31, produced 2,222 bitcoin, a 26% increase over the same time period in the prior year. Benefitted from a downward market price adjustment for the S19 XPs set to ship in September; benefits from price adjustments expected to continue as additional XPs are shipped in the October-December timeframe. Total bitcoin holdings increased to 10,311 BTC with a fair market value of $206.7M as of August 31. Unrestricted bitcoin holdings were approximately 6,483 BTC with a fair market value of approximately $130M. Unrestricted cash on hand was approximately $71.4M at August 31. Previously announced exit from Hardin, Montana facility along with the resales and/or redeployments of Hardin miners are expected to be completed by the end of September.
PCVX

Hot Stocks

16:13 EDT Vaxcyte completes enrollment of tolerability study of VAX-24 in adults 65 + - Vaxcyte announced the completion of enrollment in the Phase 2 study evaluating VAX-24 in healthy adults 65 years of age and older. VAX-24 is the Company's lead, 24-valent pneumococcal conjugate vaccine PCV candidate designed to prevent invasive pneumococcal disease IPD.This Phase 2 clinical study, which is now fully enrolled with approximately 200 participants, is a randomized, observer-blind, dose-finding study designed to evaluate the safety, tolerability and immunogenicity of VAX-24 in adults 65 years of age and older. Vaxcyte expects to announce topline safety, tolerability and immunogenicity results from this Phase 2 study in the first half of 2023. "Completing the enrollment of the VAX-24 study in adults 65 years and older is a significant step toward understanding the full clinical potential of our lead vaccine candidate in adults," said Grant Pickering, Chief Executive Officer and Co-founder of Vaxcyte. "We are very pleased with the progress made to advance the VAX-24 clinical program and we remain on track to announce the topline data from the VAX-24 Phase 1/2 study in adults 18-64 years of age in October or November of this year, as well as the topline data from the study in adults 65 and older in the first half of 2023."
COUP

Hot Stocks

16:12 EDT Coupa Software announces $100M share repurchase program - Coupa announced hat its Board of Directors authorized a share repurchase program of up to $100M of the Company's common stock. Under the program, Coupa may purchase shares from time to time through open market transactions in compliance with applicable securities laws. The program is currently set to expire on September 1, 2023.
FLT

Hot Stocks

16:10 EDT FleetCor completes acquisition and investment in European EV assets - FLEETCOR "announced the acquisition of Plugsurfing, a leading European electric vehicle (EV) software and network provider. FLEETCOR has also invested in Zap-Map, the UK's leading EV search and pay mapping service. Plugsurfing has developed a proprietary EV charging network in Europe with over 300,000 charge points, or nearly 80% of all charge points in Europe, along with a mobile app to access charge point locations, availability, and cost. Plugsurfing serves EV manufacturers, CPOs and fleets with its software and network solutions."
NWL

Hot Stocks

16:09 EDT Newell Brands CEO says experienced significantly greater than expected pullback - CEO Ravi Saligram said, "Although we remain enthusiastic about the back-to-school season and continue to see solid growth in the Commercial business, we have experienced a significantly greater than expected pullback in retailer orders and continued inflationary pressures on the consumer. As a result of these developments and our more cautious posture for the balance of the year, we are adjusting our expectations for the second half of 2022. We are taking decisive actions to mitigate the impact of these challenges by further tightening our belt on cash and cost management and adjusting our supply plan. I am confident that our team can effectively navigate through the softer macroeconomic environment and address the near-term hurdles, while positioning the company to come out stronger."
FBHS

Hot Stocks

16:07 EDT Fortune Brands names Ron Wilson chief supply chain officer - Fortune Brands Home & Security announced key organization and leadership changes, enabling the company to drive accelerated growth and productivity. "The upcoming separation of our company represents more than just the creation of two world-class, public companies; it also represents an opportunity for Fortune Brands to take the next steps in its evolution," said Nicholas Fink, Chief Executive Officer, Fortune Brands. "This organization redesign will position us to capture the many opportunities we see to drive accelerated growth and margin progression in the years ahead. We are transitioning from a decentralized structure with separate businesses to a more aligned operating model that will prioritize activities that are core to brand, innovation, and channel. Additionally, we are aligning all of our global supply chain resources under a chief supply chain officer to fully leverage the scale and execution excellence of our total business." The company's brand, innovation and channel organization will report to Cheri Phyfer in the newly created role of Group President, Fortune Brands. This change enables the Company to further build and leverage its best-in-class capabilities, as well as to better align and accelerate key growth priorities. In her time as President of Water Innovations, Phyfer was critical in driving the success of the platform as a multi-brand portfolio while delivering exceptional sales growth and margin progression. Additionally, Phyfer led the evolution of the Water Innovations segment toward an innovative, digitally enabled water technology company. Additionally, the company is unifying its global supply chain and manufacturing operations under Ron Wilson in the newly created role of Chief Supply Chain Officer, Fortune Brands. This change will drive the scale needed for critical strategic sourcing and planning initiatives, lean manufacturing, and increased efficiency to help unlock the full potential of the Fortune Brands Advantage. Wilson is an experienced supply chain and operations executive, who, prior to this role, led Water Innovations' global supply chain. In April 2022, Fortune Brands announced it would pursue a separation into two world-class companies via a tax-free spin-off of its Cabinets business. As the separation progresses ahead of schedule, the company is actively taking steps to prepare for sustained, accelerated value creation.
PHG

Hot Stocks

16:06 EDT Philips announces alert for users of CPAP or Bi-Level PAP therapy masks - Philips subsidiary Philips Respironics is alerting users of certain CPAP or Bi-Level PAP therapy masks with magnetic headgear clips or straps that these devices should not be used by or near patients and their household members, caregivers and bed partners who have metallic implanted devices or metallic objects in the body. The magnetic headgear clips are used to attach the headgear straps to the masks, which is a method that is commonly used in the sleep therapy devices industry. This is a voluntary notification to users of specific CPAP or Bi-Level PAP therapy masks containing such magnetic clips to inform them of the updated instructions and labeling. All users should read and follow Philips Respironics' voluntarily updated warning and added contraindication described below. This represents a new practice.
BSET

Hot Stocks

16:06 EDT Bassett Furniture purchases Noa Home for cash payments of C$2.M plus - Bassett Furniture Industries announced that it has acquired the capital stock of Noa Home , a mid-priced e-commerce furniture retailer headquartered in Montreal, Canada. Noa has operations in Canada, Australia, Singapore and the United Kingdom and had net revenues of approximately C$19.M for its most recent fiscal year. The purchase price included cash payments of C$2.0M paid to the co-founders of Noa and approximately C$5.7M for the repayment of existing debt. The Noa co-founders will also have the opportunity to receive additional annual cash payments of C$1.33M per year for the following three fiscal years based on established increases in net revenues and achieving certain internal EBITDA goals. "We are excited to add the digital commerce ability and the entrepreneurial spirit of the Noa Home management team to the Bassett portfolio," commented Rob Spilman, Bassett Chairman and CEO. "In less than six years, with a very lean staffing model, the Noa team has built an operational blueprint that can grow significantly beyond the C$19.1 million of revenue that they generated in their fiscal year ended February 28. The acquisition will provide Bassett with a greater online presence and will allow us to attract more digitally native consumers."
AMRX SNY

Hot Stocks

16:06 EDT Amneal names Gustavo Pesquin chief commercial officer - specialty - Amneal Pharmaceuticals (AMRX) announced it has appointed Gustavo Pesquin as Executive Vice President, Chief Commercial Officer - Specialty, effective September 6, 2022. Pesquin joins the company from Sanofi (SNY), a global pharmaceutical company, where he served leadership roles of increasing responsibility over his 11-year tenure, including most recently as North America Head for General Medicines. Amneal Co-Chief Executive Officers Chirag Patel and Chintu Patel said, "We are very pleased to welcome Gustavo as our Chief Commercial Officer for Specialty. Gustavo brings world-class experience in building and leading the rapid and sustained growth of various therapeutic divisions at leading healthcare companies including Sanofi, Abbott, and Pfizer. We believe his unique experience and breadth of knowledge in this area will help lead the Specialty business through its next phase of growth."
FIXX

Hot Stocks

16:04 EDT Homology CEO Arthur Tzianabos named chairperson, Albert Seymour to succeed - Homology Medicines announced the promotion of Albert Seymour to CEO, president and member of the board of directors. He is succeeding Arthur Tzianabos, who has been appointed as chairperson of Homology's board of directors. Tzianabos and Seymour joined Homology in 2016 as CEO and president and chief scientific officer, respectively, and they helped to build the company into a clinical-stage organization with programs spanning nuclease-free gene editing, gene therapy and gene therapy-delivered monoclonal antibodies.
EQ MTCR

Hot Stocks

16:03 EDT Equillium to acquire Metacrine in all-stock transaction - Equillium (EQ) and Metacrine (MTCR) announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33M in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024. The transaction has been approved by the boards of directors of both companies. The transaction consideration will be comprised entirely of stock, where Equillium will issue stock valued at a 25% premium over the net cash delivered at closing, which is estimated to be approximately $26M. Net cash is total cash, cash equivalents, and short-term investments, adjusted by certain factors including debt, which includes term debt with an outstanding principal of $15M, and other liabilities, as defined in the merger agreement. The stock value will be based on Equillium's 10-day volume weighted average closing price calculated ten trading days prior to closing, subject to a share price collar ranging from $2.70 to $4.50. In addition, Equillium has agreed to terms on an amended debt facility with Metacrine's current lender, K2 HealthVentures LLC, whereby Equillium would assume Metacrine's existing loan with an outstanding principal balance of $15M, along with potential access to an additional $10M of committed debt capital. Concurrent with the transaction closing, Equillium intends to retire its existing debt facility with Oxford Finance LLC and SVB, which currently has an outstanding principal balance of $10 million. After paying off its existing debt facility, Equillium expects to add an estimated $33 million of cash to its balance sheet at closing. Equillium is not planning to retain any current Metacrine employees and expects to assume minimal operating expenses while maintaining sole discretion over the timing and extent of advancing development of the Metacrine programs. The acquisition is anticipated to close late 2022 pending approval from both Equillium and Metacrine shareholders, Metacrine having minimum net cash of $23M, and other customary closing conditions.
BSY

Hot Stocks

16:02 EDT Bentley Systems names Michael Campbell as Chief Product Officer - Bentley Systems "announced that Michael Campbell has been appointed chief product officer and will lead more than 1,500 colleagues in the company's product advancement group. Campbell joins Bentley from product engineering software leader PTC Inc, where he has spent his whole career since earning his mechanical engineering degree from Boston University in 1995. He has had product leadership responsibility for PTC's mainstream design applications and for its IoT acquisitions, and most recently served as executive vice president and general manager for its augmented reality offerings. Campbell will be responsible for defining Bentley's product strategy and for managing product development to advance the company's leadership in infrastructure engineering software. He will report to Chief Operating Officer Nicholas Cumins."
SNBR

Hot Stocks

16:01 EDT Sleep Number announces three-year partnership renewal with L.A. Rams - Sleep Number announced a renewed three-year commitment with the Los Angeles Rams. Sleep Number will continue to be the "Official Sleep + Wellness Partner" for the LA Rams through the 2024 season. "The LA Rams take a holistic approach to training. They understand the impact that quality sleep has on improving their players' physical, mental and emotional health," said Kevin Brown, EVP and Chief Marketing Officer, Sleep Number. "Our 360 smart bed provides these Super Bowl Champion athletes with in-depth knowledge of how their sleep affects their performance and recovery, every night and over time. The science backed, data-driven approach to sleep and wellness that only Sleep Number can provide will continue to set this exceptional team up for ongoing success. We are proud to be part of the LA Rams' championship season last year and can't wait to see them do it again!"
EQ MTCR

Hot Stocks

16:02 EDT Equillium to acquire Metacrine fo $26M - Equillium (EQ) and Metacrine (MTCR) announced that the two companies have entered into a definitive merger agreement pursuant to which Equillium will acquire Metacrine in an all-stock transaction. The transaction is anticipated to add $33 million in cash to Equillium's balance sheet at closing, which is expected to extend the company's cash runway into 2024. The transaction has been approved by the boards of directors of both companies. The transaction consideration will be comprised entirely of stock, where Equillium will issue stock valued at a 25% premium over the net cash delivered at closing, which is estimated to be approximately $26 million. Net cash is total cash, cash equivalents, and short-term investments, adjusted by certain factors including debt, which includes term debt with an outstanding principal of $15 million, and other liabilities, as defined in the merger agreement. The stock value will be based on Equillium's 10-day volume weighted average closing price calculated ten trading days prior to closing, subject to a share price collar ranging from $2.70 to $4.50. In addition, Equillium has agreed to terms on an amended debt facility with Metacrine's current lender, K2 HealthVentures LLC, whereby Equillium would assume Metacrine's existing loan with an outstanding principal balance of $15 million, along with potential access to an additional $10 million of committed debt capital. Concurrent with the transaction closing, Equillium intends to retire its existing debt facility with Oxford Finance LLC and SVB, which currently has an outstanding principal balance of $10 million. After paying off its existing debt facility, Equillium expects to add an estimated $33 million of cash to its balance sheet at closing. Equillium is not planning to retain any current Metacrine employees and expects to assume minimal operating expenses while maintaining sole discretion over the timing and extent of advancing development of the Metacrine programs. The acquisition is anticipated to close late 2022 pending approval from both Equillium and Metacrine shareholders, Metacrine having minimum net cash of $23 million, and other customary closing conditions.
MTCR

Hot Stocks

16:01 EDT Metacrine trading halted, news dissemination
EQ MTCR

Hot Stocks

16:01 EDT Equillium to acquire Metacrine in all-stock transaction
DWAC

Hot Stocks

15:58 EDT Digital World Acquisition confirms special meeting adjourned to September 8 - Digital World Acquisition Corp. announced that the special meeting of stockholders, which was originally scheduled for September 6, is being adjourned to 12:00 p.m. Eastern Time on September 8. The special meeting is for stockholders to consider amending the company's amended and restated certificate of incorporation to extend the period of time for completing a business combination up to four times, each by an additional three months, for an aggregate of 12 additional months, or until September 8, 2023, or such earlier date as determined by the company's board. If the extension amendment is not approved by the stockholders by September 8, ARC Global Investments II, LLC, the company's sponsor, intends to contribute to the company's trust account an aggregate amount of $2,875,000, which is equal to 10c per share of Class A common stock issued in the company's initial public offering, to extend the time to consummate an initial business combination for a three-month period, until December 8, 2022. "Such contribution would be made as a loan that would not accrue interest and would either be paid upon earlier of consummation of an initial business combination or the company's liquidation, or, at the lender's discretion and subject to certain conditions, converted upon consummation of the initial business combination into additional into units, at a price of $10.00 per unit, identical to the units issued in the company's private placement that was consummated in connection with the company's initial public offering. The contribution will increase the pro rata portion of the funds available in the company's trust account in the event of the consummation of an initial business combination or liquidation from approximately $10.20 per share to approximately $10.30 per share," the company stated.
SPLK

Hot Stocks

14:07 EDT Splunk appoints Jason Lee as Chief Information Security Officer - Splunk announced that Jason Lee has been appointed as the Company's Chief Information Security Officer, or CISO, effective immediately. Lee will oversee all facets of global security to protect Splunk employees and customers, including cloud and application security, operations, threat management, penetration testing, risk, and customer trust. Most recently, he served as CISO of Zoom, where he was responsible for the security of the platform and its customers, the company stated.
PRMW

Hot Stocks

13:47 EDT Primo Water CEO Harrington buys 39K shares of company stock - The CEO of Primo Water Corp Thomas Harrington disclosed in a regulatory filing that he had purchased 39,000 shares of company stock at $13.07 per share on September 1, for a total transaction amount of $509,691.
SBNY

Hot Stocks

13:19 EDT Signature Bank: Spot loan growth about $2.39B quarter-to-date - Spot deposit balances are lower by approximately $1.64B as of September 2, and spot loan growth is nearly $2.39B quarter-to-date with growth coming from nearly all of its lending businesses, Signature Bank said in a mid-quarter financial update for its third quarter. The bank is well-positioned to meet target of combined loans and securities growth in the higher end of $1B-$3B range for Q3.
SBNY

Hot Stocks

13:18 EDT Signature Bank: Spot loan growth about $2.94B quarter-to-date - Spot deposit balances are lower by approximately $1.64B as of September 2, and spot loan growth is nearly $2.39B quarter-to-date with growth coming from nearly all of its lending businesses, Signature Bank said in a mid-quarter financial update for its third quarter. The bank is well-positioned to meet target of combined loans and securities growth in the higher end of $1B-$3B range for Q3.
MO

Hot Stocks

13:10 EDT Juul Labs reaches $438.5M settlement with states over marketing - Texas Attorney General Paxton announced he and peers have secured a $438.5M agreement in principle between JUUL Labs and 34 states and territories, resolving a two-year bipartisan investigation into the e-cigarette manufacturer's marketing and sales practices. The investigation, initially launched in 2020 by Attorney General Paxton, was led by his office, along with the Attorneys General of Connecticut and Oregon. Of the $438.5M, Texas will receive $42.8M. "The settlement will also force JUUL to comply with a series of strict injunctive terms severely limiting their marketing and sales practices," the AG reported. The states are in the process of finalizing and executing the settlement documents. The $438.5M would be paid out over a period of six to ten years, with the amounts paid increasing the longer the company takes to make the payments. If JUUL chooses to extend the payment period up to ten years, the final settlement would reach $476.6M, according to Paxton. Altria holds a stake in JUUL. Reference Link
AMTD

Hot Stocks

13:03 EDT SEC adds AMTD to list of companies facing possible U.S. delisting - The Securities and Exchange Commission added today MTD IDEA Group to the Holding Foreign Companies Accountable Act list. Under the HFCAA, the Public Company Accounting Oversight Board has the responsibility for determining that it is unable to inspect or investigate completely a registered public accounting firm or a branch or office of such a firm because of a position taken by an authority in a foreign jurisdiction.
META

Hot Stocks

12:45 EDT Meta to hold Connect conference on October 11 - Meta will hold its Connect conference virtually on October 11. The company says: "Meta Connect is a one-day virtual event that explores the building of the metaverse and the future of augmented and virtual reality. Industry leaders will share the latest technologies and developer sessions will cover how to use them. Our goal is to bring the world closer together and deepen human connection through new experiences." Reference Link
TRQ RIO

Hot Stocks

12:36 EDT Rio Tinto to acquire remaining 49% stake in Turquoise Hill for C$43 per share - Earlier, Turquoise Hill (TRQ) announced that, based on the unanimous recommendation of an independent special committee of its board of directors, it has entered into an arrangement agreement with Rio Tinto (RIO) and Rio Tinto International, a wholly-owned subsidiary of Rio Tinto, will acquire the approximately 49% of the issued and outstanding common shares of the company that Rio Tinto does not currently own for C$43.00 in cash per share, subject to approval by the Turquoise Hill minority shareholders and other customary closing conditions. "The announcement is the culmination of negotiations that took place following the September 1 public announcement of the term sheet entered into in connection with the transaction. The purchase price of C$43.00 per share reflects a 67% premium to Turquoise Hill's closing price of C$25.68 per share on the Toronto Stock Exchange on March 11, being the last trading day prior to Rio Tinto's initial public proposal to acquire Turquoise Hill, and a 19% premium to Turquoise Hill's closing price of C$36.12 on August 31, being the last trading day prior to the September 1 announcement of the term sheet. The special committee was established by the Turquoise Hill board of directors to consider the initial proposal, as well as other alternatives available to the company and, if it deemed advisable, negotiate with Rio Tinto. Following an evaluation of the initial proposal and extensive negotiations between the special committee and Rio Tinto on price and other terms of the transaction, including amendments to the financing heads of agreement between the company and Rio Tinto dated May 18 to address the company's near-term liquidity while the transaction is pending, the special committee unanimously recommended that the board approve the transaction. The board, having received the unanimous recommendation of the special committee, unanimously determined that the transaction is in the best interests of Turquoise Hill and fair to the shareholders of Turquoise Hill other than Rio Tinto and its affiliates and recommends that minority shareholders vote in favor of the transaction at the special meeting of shareholders to be held to approve the transaction," the company announced. Completion of the transaction is not subject to any financing condition. The company expects to hold the special meeting of shareholders to consider and to vote on the transaction as early as possible in the fourth quarter. If approved at the meeting, the transaction is expected to close in the fourth quarter, subject to court approvals and other customary closing conditions. Further details regarding the terms and conditions of the transaction are set out in the arrangement agreement, which will be publicly filed by the company under its profiles. Additional information regarding the terms of the arrangement agreement, the background of the transaction and the independent valuation and fairness opinions will be provided in the information circular for the special meeting of shareholders.
AAPL

Hot Stocks

12:17 EDT OWC acquires Apple trade-in company SellYourMac.com - OWC announced the acquisition of SellYourMac.com, an Apple trade-in company. "Being a part of the OWC family helps us work towards achieving our vision of being the #1 most trusted and known Apple trade in company in the world," said Brian Burke, Chief Mac Man at SellYourMac.com. "I've long admired OWC as a growing and successful company within the Apple ecosystem and we are beyond excited to take SellYourMac.com onward and upwards together as part of OWC."
TGODF

Hot Stocks

12:05 EDT Green Organic Dutchman closes sale of HemPoland subsidiary - The Green Organic Dutchman Holding is pleased to announce that it has closed the sale of its Polish subsidiary, HemPoland. Under the terms of a share purchase agreement, TGOD sold its full interest in HemPoland to RAMM Pharma Corporation for $1.2 million on closing after customary closing adjustments, in addition to a $0.15 million non-refundable deposit provided in July that was used for operating expenses in HemPoland. In conjunction with closing, the loan payable to HemPoland by TGOD, of $4M plus accrued interest, was forgiven.
OPTN

Hot Stocks

12:02 EDT Optinose reports ReOpen1 abstract selected for presentation at ARS meeting - Optinose announced that data from its ReOpen1 phase 3 clinical trial will be presented at the American Rhinologic Society 68th Annual Meeting in Philadelphia, Pennsylvania on September 9, 2022. ReOpen1 was the first of two phase 3 clinical trials in its ReOpen Program which evaluated XHANCE, also referred to as the Exhalation Delivery System with fluticasone, as a potential treatment for chronic sinusitis. The ReOpen program comprises two global, randomized, double-blind, placebo-controlled Phase 3 trials that evaluated the efficacy and safety of one or two sprays of XHANCE in each nostril twice daily, over 24 weeks, in patients suffering from chronic sinusitis. In ReOpen1, the first of the two trials, 332 patients were treated who had CS with or without nasal polyps. In ReOpen2, the second of the two trials, 222 patients were treated who had CS without nasal polyps. The co-primary endpoints were change from baseline in symptoms, as measured by a composite score of patient-reported symptoms at the end of week 4, and objective change in inflammation inside the sinus cavities, as measured by the change in average of percentages of volume occupied by disease across the ethmoid and maxillary sinuses as measured by CT scan.
GLT

Hot Stocks

12:00 EDT Glatfelter falls -14.9% - Glatfelter is down -14.9%, or -73c to $4.21.
CMCM

Hot Stocks

12:00 EDT Cheetah Mobile falls -16.2% - Cheetah Mobile is down -16.2%, or -60c to $3.10.
TUP

Hot Stocks

12:00 EDT Tupperware Brands falls -20.7% - Tupperware Brands is down -20.7%, or -$2.28 to $8.74.
ZVIA

Hot Stocks

12:00 EDT Zevia rises 14.7% - Zevia is up 14.7%, or 59c to $4.61.
GROV

Hot Stocks

12:00 EDT Grove Collaborative rises 21.2% - Grove Collaborative is up 21.2%, or $1.04 to $5.94.
ECOM

Hot Stocks

12:00 EDT ChannelAdvisor rises 54.9% - ChannelAdvisor is up 54.9%, or $8.07 to $22.77.
UBSFY TCEHY

Hot Stocks

11:53 EDT Ubisoft board authorizes Tencent to boost stake to 9.99% from 4.5% - Ubisoft (UBSFY) announced that Tencent (TCEHY) has acquired a minority stake in Guillemot Brothers Limited and has entered into the concert with the company's founders. "The expansion of the concert with Tencent further reinforces Ubisoft's core shareholding around its founders and provides the company with the stability essential for its long-term development." said Yves Guillemot, CEO and Co-Founder, Ubisoft. Tencent acquired a 49.9% economic stake with 5% voting rights in Guillemot Brothers Limited. Tencent's investment in Guillemot Brothers Limited amounts to EUR 300M at an implied valuation for Ubisoft of 80 EUR per share. In addition, Tencent is providing Guillemot Brothers with a long-term unsecured loan to refinance its debt and provide additional financial resources that can be used to acquire equity in Ubisoft. Guillemot Brothers Limited remains exclusively controlled by the Guillemot family. Tencent will not be represented on its board and will not obtain any consent or veto rights over the business. The Guillemot family concert with respect to Ubisoft is extended to include Tencent. The expanded concert may increase its stake to 29.9% of Ubisoft's capital or voting rights. Additionally, Ubisoft's board has authorized Tencent to increase its direct stake in Ubisoft from 4.5% to 9.99% of the capital or voting rights. Tencent will not be able to sell its shares in Ubisoft for a period of five years and will not be able to increase its stake in Ubisoft beyond 9.99% of Ubisoft's capital and voting rights for a period of eight years.
WORX

Hot Stocks

11:09 EDT SCWorx signs two new hospital customers - SCWorx announced that it has launched a new product offering for healthcare providers along with the signing of two new mid-Atlantic hospitals for the product. The new product offering enables hospitals of all sizes to quickly and easily benefit from the SCWorx data platform. SCWorx offers a technically advanced solution which has proven to be beneficial to large hospitals with challenging technical and data management issues. To expand the Company's target demographic SCWorx has modified its product deliverables and pricing structure to more effectively meet the needs of hospitals of all sizes
GVP PCG

Hot Stocks

10:58 EDT GSE Systems 'pleased' with extension of Diablo Canyon nuclear facility - GSE Systems announced its pleasure that California lawmakers have overwhelmingly approved an operational extension for its sole nuclear facility, Diablo Canyon. The legislation will keep the facility open until 2030, or an additional five years. The legislation also includes a $1.4B loan from the state to Pacific Gas & Electric, the utility operating the nuclear reactor, to cover necessary capital expenditures required to keep the facility open, which has been signed into law by Governor Newsom.
CFVI

Hot Stocks

10:51 EDT Rumble CEO hints at potential partnership with Joe Rogan - Rumble CEO Chris Pavlovski hinted at a potential partnership with Joe Rogan on Twitter. Reference Link
IHG

Hot Stocks

10:48 EDT InterContinental reports unauthorized access to technology systems - InterContinental Hotels Group PLC reports that parts of the company's technology systems have been subject to unauthorized activity. "IHG's booking channels and other applications have been significantly disrupted since yesterday, and this is ongoing. IHG has implemented its response plans, is notifying relevant regulatory authorities and is working closely with its technology suppliers. External specialists have also been engaged to investigate the incident. IHG is working to fully restore all systems as soon as possible and to assess the nature, extent and impact of the incident. We will be supporting hotel owners and operators as part of our response to the ongoing service disruption. IHG's hotels are still able to operate and to take reservations directly. A further update will be provided as and when appropriate," the company stated in a notice to the London Stock Exchange.
ACN

Hot Stocks

10:46 EDT Accenture to acquire supply chain specialist firm Inspirage - Accenture announced it has agreed to acquire Inspirage, an integrated supply chain specialist firm focused on Oracle technology. "The acquisition will further enhance Accenture's Oracle Cloud capabilities, helping it accelerate innovation for clients through emerging technologies, such as touchless supply chain and digital twins," the company stated. Inspirage is headquartered in Bellevue, WA with offices across North America, Europe and Asia and once the acquisition is completed, its 710 employees will join the Accenture Oracle Business Group. Terms of the transaction were not disclosed.
BFRI

Hot Stocks

10:33 EDT Biofrontera Inc. announces notice of allowance for nanoemulsion patent - Biofrontera Inc. announced that the United States Patent and Trademark Office has granted a notice of allowance to Biofrontera Bioscience GmbH for patent application No. 12/520,759, titled "Nanoemulsion Formulation with Improved Stability and Cell Penetration." Biofrontera Inc. has an exclusive license to market and sell Ameluz, an FDA-approved drug utilizing the technology covered by the patent, in the U.S. The '759 patent relates to the compositions of Biofrontera's nanoemulsions and an active agent and the preparation of the nanoemulsions or compositions, and describes its use in the treatment of dermatological, virus-associated and cell proliferation diseases, as well as in cosmetics. Biofrontera's compositions of nanoemulsions overcome the disadvantages of other nanoemulsion formulations through a reduced particle size that contributes to improved stability, better penetration into cells and tissues and lower production costs. "This new patent will further protect Biofrontera's growing position in the dermatology market and our continued investment in the market. Compound-of-matter patents provide the strongest protection of all patent types. Our license agreement covers all combinations of the patented nanoemulsion technology with aminolevulinic acid, the active ingredient in Ameluz. Together with Biofrontera Bioscience we are now even more strongly positioned to broaden the use of photodynamic therapy in dermatology," stated Hermann Lubbert, Executive Chairman of Biofrontera Inc.
GP

Hot Stocks

10:24 EDT GreenPower Motor, West Virginia launch all-electric school bus pilot project - GreenPower Motor announced the launch of its West Virginia state pilot project to demonstrate all-electric school buses in school transportation operations across West Virginia starting with Cabell, Kanawha and Mercer Counties. The first buses in each County will be deployed this week bringing school children safely to their school without contamination from NOx emissions. Through the pilot project done in cooperation with Governor Jim Justice, the West Virignia Department of Economic Development and the West Virginia Department of Education, three all-electric GreenPower Type D BEAST school buses will be deployed the week of September 5th in the first three counties - Cabell, Kanawha and Mercer - along with the required charging infrastructure. In the coming weeks, a fourth pilot bus using the Type A Nano BEAST with ADA capabilities will be deployed in Clay County.
PHIL

Hot Stocks

10:23 EDT PHI Group, Tin Thanh Group sign strategic agreement with PVMS - PHI Group announced that its partner Tin Thanh Group and the Company have signed an agreement to strategically cooperate with PetroVietnam Marine Shipyard JSC in order to increase marine and general building activities. According to the agreement, PetroVietnam Marine Shipyard will increase charter capital to allow Tin Thanh Group and Philux Global Group to become its strategic and majority shareholders. The companies will deploy their collective resources to expand PVMS's scope of business and undertake major offshore and onshore, domestic and international projects that may be substantially beneficial for all parties, including but not limited to ship-building, yacht-building, drilling rigs, refineries and petrochemical plants, power plants, wind farms, ship dismantlement, Tin Thanh Group's waste-to-energy plants and multiple processing facilities as well as Philux Global Group's Asia Diamond Exchange project, industrial logistic zone and multi-commodities center in Vietnam.
CNTY

Hot Stocks

10:21 EDT Century Casinos' partner bet365 launches internet sports betting in Colorado - Century Casinos announced that bet365 went live with its internet and mobile sports betting application using one of the Company's master licenses with the State of Colorado. The online sportsbook operations agreement with bet365 is a 10-year agreement that includes a minimum annual revenue guarantee and a percentage share of net gaming revenue payable to the Company each year, with an advance fee, which was paid at contract signing in May 2020.
GSK

Hot Stocks

10:15 EDT GSK plc says FDA to convene advisory committee to review daprodustat NDA - GSK plc announced that the U.S. Food and Drug Administration will convene a meeting of the Cardiovascular and Renal Drugs Advisory Committee to review the New Drug Application, or NDA, for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor under regulatory review for the potential treatment of anaemia due to chronic kidney disease, or CKD, in adult patients on dialysis and not on dialysis. "GSK is committed to working closely with the US FDA to bring daprodustat to appropriate patients with anaemia of CKD. A date for the Advisory Committee meeting is set for 26 October 2022," the company stated. Chris Corsico, Senior Vice President, Development, GSK said: "We believe daprodustat and the results demonstrated in the ASCEND clinical trial programme have significant potential for patients living with anaemia of CKD who currently do not have an oral treatment option. We look forward to participating in the upcoming Advisory Committee meeting and working with the US FDA to complete its assessment of daprodustat, with the goal of bringing this innovative new treatment to appropriate patients in the US."
OIG

Hot Stocks

10:03 EDT Orbital Infrastructure Group awarded multi-year electric distribution project - Orbital Infrastructure Group announced that its subsidiary, Orbital Power, has been awarded a multi-year electric distribution project for an Investor-Owned Utility customer in Texas. The scope of work includes a reconductor and pole replacement program on approximately a 20 mile overhead and underground electric distribution circuit and related maintenance on feeder and service lines in conjunction with the system upgrade. The project will take approximately two years to complete.
LOB JKHY

Hot Stocks

10:03 EDT Live Oak Ventures exits Payrailz investment - Live Oak Ventures has exited its investment in Payrailz, LLC, a digital payments platform, recently acquired by Jack Henry & Associates (JKHY). Live Oak anticipates an estimated pre-tax gain of approximately $28M, subject to final adjustments. "This is the third investment by Live Oak that has had a greater than 9x return. We are proud of the success we are seeing in our investment strategy - partnering with industry veterans to address challenges in banking, and particularly in small business banking," said Stephanie Mann, Live Oak's Chief Strategy Officer. Live Oak Ventures is a wholly owned subsidiary of Live Oak Bancshares.
WWE

Hot Stocks

10:02 EDT WWE appoints Paul 'Triple H' Levesque to CCO - WWE announced that Paul "Triple H" Levesque has been elevated to Chief Content Officer. Additionally, the company has promoted Frank Riddick III to President & CFO. As Chief Content Officer, Levesque will oversee Creative Writing, Talent Relations, Live Events, Talent Development and Creative Services. The role will report to WWE co-CEO Nick Khan. Riddick joined WWE as Chief Financial Officer last year, after serving on the company's Board of Directors for more than 13 years and previously holding the role of interim CFO.
GRN

Hot Stocks

10:00 EDT General Re Corporation falls -8.5% - General Re Corporation is down -8.5%, or -$2.59 to $27.91.
CMCM

Hot Stocks

10:00 EDT Cheetah Mobile falls -13.1% - Cheetah Mobile is down -13.1%, or -48c to $3.21.
GLT

Hot Stocks

10:00 EDT Glatfelter falls -17.8% - Glatfelter is down -17.8%, or -88c to $4.06.
SES

Hot Stocks

10:00 EDT SES rises 14.1% - SES is up 14.1%, or 66c to $5.34.
CTV

Hot Stocks

10:00 EDT Innovid rises 17.5% - Innovid is up 17.5%, or 63c to $4.22.
ECOM

Hot Stocks

10:00 EDT ChannelAdvisor rises 54.6% - ChannelAdvisor is up 54.6%, or $8.02 to $22.72.
GRN

Hot Stocks

09:47 EDT General Re Corporation falls -8.4% - General Re Corporation is down -8.4%, or -$2.55 to $27.95.
CMCM

Hot Stocks

09:47 EDT Cheetah Mobile falls -8.8% - Cheetah Mobile is down -8.8%, or -32c to $3.38.
GLT

Hot Stocks

09:47 EDT Glatfelter falls -17.2% - Glatfelter is down -17.2%, or -85c to $4.09.
KOLD

Hot Stocks

09:47 EDT ProShares UltraShort Bloomberg Natural Gas rises 10.7% - ProShares UltraShort Bloomberg Natural Gas is up 10.7%, or $1.20 to $12.38.
ADT

Hot Stocks

09:47 EDT ADT Inc. rises 11.9% - ADT Inc. is up 11.9%, or 85c to $8.06.
ECOM

Hot Stocks

09:47 EDT ChannelAdvisor rises 54.8% - ChannelAdvisor is up 54.8%, or $8.05 to $22.75.
ATXG

Hot Stocks

09:43 EDT Addentax Group Corp trading resumes
SHPH

Hot Stocks

09:41 EDT Shuttle Pharmaceuticals Inc trading resumes
ZFOX

Hot Stocks

09:41 EDT L&F Acquisition Corp trading resumes
BBBY

Hot Stocks

09:40 EDT Bed Bath & Beyond names CAO Laura Crossen Interim CFO - Bed Bath & Beyond disclosed that effective September 5, Laura Crossen, the company's Senior Vice President of Finance and Chief Accounting Officer, was appointed Interim Chief Financial Officer. Crossen will be the company's principal financial officer on an interim basis and will continue as its principal accounting officer, Bed Bath & Beyond said in a regulatory filing following the death of its Chief Financial Officer Gustavo Arnal.
EIGR

Hot Stocks

09:40 EDT Eiger BioPharmaceuticals trading resumes
ATXG

Hot Stocks

09:38 EDT Addentax Group Corp trading halted, volatility trading pause
SHPH

Hot Stocks

09:36 EDT Shuttle Pharmaceuticals Inc trading halted, volatility trading pause
ZFOX

Hot Stocks

09:36 EDT L&F Acquisition Corp trading halted, volatility trading pause
ASTI

Hot Stocks

09:35 EDT Ascent Solar Technologies, Inc. trading resumes
KTTA

Hot Stocks

09:34 EDT Investor Group commences process of calling Pasithea Special Meeting - Camac Partners and Leonite Capital, who together are one of the largest stockholders of Pasithea Therapeutics, announced that the Investor Group has received sufficient support from its fellow stockholders to request the call of a Special Meeting of Stockholders. Accordingly, the Investor Group has formally commenced the process of calling the Special Meeting and issued the following statement: "We are very pleased that our fellow stockholders agree that change is needed at Pasithea and support our call for the Special Meeting. We firmly believe that removing all sitting directors will position Pasithea to enhance its corporate governance, improve capital allocation and unlock significant value for all stockholders. We expect Pasithea to move expeditiously to call the Special Meeting, as required by its organizational documents, and not to use any delay tactics to try to prevent stockholders' voices from being heard." At the Special Meeting, the Investor Group plans to seek the removal of all of Pasithea's sitting directors. Delaware law provides a clear mechanism whereby stockholders can petition the Delaware Court of Chancery to hold an election if all directors are removed or if the remaining directors constitute less than a majority of the total directorships. If necessary, the Investor Group is prepared to make such a petition.
EIGR

Hot Stocks

09:30 EDT Eiger BioPharmaceuticals trading halted, volatility trading pause
ASTI

Hot Stocks

09:30 EDT Ascent Solar Technologies, Inc. trading halted, volatility trading pause
NXTTF

Hot Stocks

09:25 EDT Lifeist says CannMart introduces second new product category shatter - Lifeist Wellness announced that its Canadian cannabis business unit compromised of CannMart Inc. and CannMart Labs has successfully brought a second new product category to market, namely shatter, produced through Labs' state-of-the-art BHO extraction facility. The first new product in the new category, in-house branded Roilty Wedding Shatter, has shipped to retailers in Saskatchewan and is a key part of CannMart's focus on higher margin revenue streams with the goal to improve profitability. CannMart continues to execute on its growth strategies and is launching a third product category this September 2022, live resin vapes, with first product Roilty Purple Berry also receiving purchase orders in Saskatchewan. Labs' fourth product category, THCa diamonds, is executing its R&D phase, with purchase orders from provincial buyers anticipated in the fiscal fourth quarter of 2022. THCa diamonds are sought after within the cannabis concentrates segment, as being the purest form of THC capable of achieving a 99.9% potency. The first product category for Labs was live resin and was introduced to market in the fiscal fourth quarter of 2021.
TBPMF

Hot Stocks

09:22 EDT Tetra Bio Pharma collaborates with Cellvera for co-development of ARDS-003 - Tetra Bio-Pharma announced they signed an agreement with Cellvera Global Holdings, for the co-development of ARDS-003 as a combination product, with Qifenda 400MG, a commercial-stage broad-spectrum antiviral drug. Cellvera owns the rights to the brand originator Favipiravir, which has a long and verified history of safety and efficacy and was initially developed by FujiFilm Toyama Chemical Co and approved in Japan to treat pandemic influenza. Favipiravir is a selective inhibitor of viral RNA-dependent RNA polymerase with potent antiviral activity against single-stranded RNA viruses, including coronaviruses. As novel strains of the SARS-CoV-2 virus continue to emerge, preliminary studies on SARS-COV-2 Variants, Omicron and Delta, have shown that Favipiravir maintains its antiviral activity, demonstrating viruses' inability to resist Favipiravir even with prolonged exposure of virus-infected cells to the drug. "The ongoing complexities of COVID-19 require multiple treatment options. By joining forces with Tetra, we hope to offer this additional treatment option to patients." Stated Mary O'Brien, CEO of Cellvera. "This collaboration with Tetra supports our partnership strategy and the development of further combination therapies involving Qifenda. We share a passion with Tetra to deliver innovative medicines to address this pandemic. We look forward to working with Guy and his team to investigate the potential of ARDS-003 and Qfienda. By joining the Prepaire partner platform, we connect with like-minded experts from across industry, academia, and the government sector, we are better equipped to lead the way towards transforming drug discovery and development through the application of machine learning".
AXS

Hot Stocks

09:20 EDT Axis Capital promotes Dan Draper to chief underwriting officer - Axis Capital announced that the company has promoted Dan Draper to the role of group chief underwriting officer. Draper, who is based in London and had previously served as group head of underwriting, will report to president and CEO Albert Benchimol and join the company's executive committee.
ATH

Hot Stocks

09:19 EDT Athene Holding announces any-and-all tender offers by Athene Global - Athene Holding announced that Athene Global Funding with respect to Series 2022-6, has commenced its offer to purchase $500,000,000 aggregate principal amount of its Series 2022-6 3.205% senior secured medium term notes due 2027 and with respect to Series 2020-5, has commenced its offer to purchase $650,000,000 aggregate principal amount of its Series 2020-5 2.450% senior secured medium term notes due 2027. The Series 2022-6 Offer and the Series 2020-5 Offer are two separate offers. The procedures for tendering the Series 2022-6 Notes in the Series 2022-6 Offer and tendering the Series 2020-5 Notes in the Series 2020-5 Offer are separate. These Offers are made upon the terms and subject to the conditions set forth in separate offers to purchase, each dated September 6, 2022 and their accompanying notices of guaranteed delivery. Capitalized terms used but not defined in this announcement have the meanings given to them in the Offers to Purchase.
CORZ...

Hot Stocks

09:18 EDT Core Scientific produces 1,334 bitcoins in August - Core Scientific announced production and operational updates for August. As of month end, the company operated 225,451 ASIC servers for both colocation and self-mining, representing a total of 21.54 EH/s. The company's Georgia, Kentucky, North Carolina, and North Dakota data center facilities continue to operate at capacity. The company is continuing to build additional capacity in Texas. Core Scientific's self-mining operations produced 1,334 bitcoins in August. Self-mining bitcoin production benefited from the deployment of approximately 17,000 new servers during the month. Increased curtailment activity across multiple data centers limited production advances. The company expanded its fleet of self-mining servers during the month to 127,716, increasing hashrate to 12.69 EH/s. The company expects to deploy approximately 43,000 additional self-mining ASIC servers before the end of 2022. As of August month end, self-mining accounted for approximately 59% of the Company's total hashrate.
TNET

Hot Stocks

09:17 EDT TriNet announces acquisition of Clarus R+D Solutions - TriNet announced that it has acquired Clarus R+D Solutions LLC, an industry-leading, service and expertise driven, fintech solutions company that simplifies the R&D tax credit process for SMBs. Terms of the deal were not disclosed. Clarus R+D helps SMBs take advantage of the research and development tax credit, one of the largest tax incentives available to US businesses. "With our acquisition of Clarus R+D, TriNet takes another important step towards powering the success of small and medium-sized businesses," said Burton M. Goldfield TriNet's President and Chief Executive Officer. "Many of our PEO and HCM customers qualify for R&D tax credits and do not have the time or expertise to successfully apply for them. With the addition of Clarus R+D, TriNet expands its offering to better serve these customers. I look forward to leveraging Clarus R+D to put money back in the hands of our hard-working SMB clients."
KALU

Hot Stocks

09:16 EDT Kaiser Aluminum lifts force majeure declared at Warrick Rolling Mill - Kaiser Aluminum announced that it has lifted force majeure declared on July 7 at its Warrick Rolling Mill, due to limited availability of magnesium utilized in the production of certain of its aluminum beverage and food packaging products, reducing its ability to produce those products at that time. As the Company has previously disclosed, US Magnesium, Kaiser Warrick's largest supplier of magnesium, declared force majeure on September 29, 2021 and had continued to supply approximately 50% of its contractual commitment until June 2022, at which time deliveries abruptly stopped. US Mag is not currently supplying any magnesium to Kaiser Warrick and no further shipments of magnesium are expected through the December 31, 2022 expiration of its supplier agreement. The Company has now successfully secured and qualified magnesium from alternative sources to meet its requirements for the remainder of 2022, and is currently finalizing its supplier agreements for 2023 and beyond. With security of supply and its capacity fully restored, Kaiser Warrick is currently working with its customers to return to full production.
SKYT

Hot Stocks

09:16 EDT SkyWater to expand its packaging facility operations in FLorida after grant - SkyWater Technology announced that $50.8M has been awarded to Osceola County Board of County Commissioners for building Central Florida's Semiconductor Cluster for Broad-Based Prosperity, as part of the U.S. Department of Commerce Economic Development Administration's, EDA's, Build Back Better Regional Challenge. The Osceola County-led Prosperity Coalition Proposal will build upon the initial success of NeoCity, by investing in infrastructure, workforce development and community reinvestment that leverages new, high-demand production processes to propel Central Florida as a leader for semiconductor research, development and manufacturing. EDA funds will be allocated among six component projects, two of which include $36.5M in federal funding for enhancements to SkyWater's advanced packaging operations at the Center for Neovation: expansion and facilitization of the clean room and purchase and installation of tools and machinery. Pursuant to the award, SkyWater will provide a 20% "matching share" of the project costs associated with the facility. Coalition partners include the Orlando Economic Partnership, the University of Central Florida, BRIDG, SkyWater, the Florida High Tech Corridor and Valencia College. The Osceola County coalition was one of 21 winners out of over 500 submissions and the only recipient from the semiconductor industry.
OPXS

Hot Stocks

09:15 EDT Optex Systems announces $1.1M order for optical assemblies - Optex Systems Holdings announced it has been awarded a $1.1M order as part of a multi-year strategic supplier agreement with a domestic commercial manufacturer of premium optical devices. The products will be manufactured at the Applied Optics Center Division of Optex Systems, Inc.
MBOT

Hot Stocks

09:15 EDT Microbot Medical awarded two patents in Europe adding to Liberty portfolio - Microbot Medical continues to execute its objective of expanding its global intellectual property, or IP, portfolio for the LIBERTY Robotic System as a grant for two Design Patent Applications was issued by the European Patent Office, or EPO, covering the LIBERTY Robotic System's Robotic Drive and Remote Controller.
CPSS

Hot Stocks

09:13 EDT Consumer Portfolio chooses Informed.IQ to streamline auto lending - Consumer Portfolio Services partnered with Informed.IQ to automatically calculate income, collect and clear credit stipulations and dealer docs, creating a better dealer and consumer experience throughout the auto lending process. Informed is the leader in AI-based software used by the nation's largest financial institutions to automate loan verifications. "Our whole business is based on artificial intelligence and machine learning, from credit to servicing," said Mike Lavin, Chief Operating Officer with CPS. "Adding Informed.IQ to the equation enables us to handle larger origination volume, increase no-touch processing, more easily identify loan document defects and ultimately better support our customers to fund faster."
NVEI

Hot Stocks

09:13 EDT Nuvei partners with Air Transat - Nuvei announces that it has partnered with Air Transat. The partnership offers Air Transat customers an intuitive payment experience while providing revenue accelerating approval rate optimization and fraud management capability to the airline. Based in Montreal, Air Transat is Canada's third largest airline with hubs in Toronto and Montreal. Through its partnership with Nuvei, Air Transat has secured card acquiring capabilities with enhanced payment processing in 39 markets globally.
RAVE

Hot Stocks

09:12 EDT Pizza Inn announces reimagined store design, logo - Pizza Inn is rolling out a fresh new look including a new store design, logo and legendary mascot, Jojo. The first Pizza Inn location to feature the refreshed design will be unveiled in Asheboro, N.C. later this year. The buffet has and will continue to be the 'hero' of the restaurant design. Families will enjoy a party room tailor-made for birthdays and sports gatherings with an Instagrammable 'say cheese' accent wall, game room and other fun elements. An outside patio complements the design.
ADIL

Hot Stocks

09:11 EDT Adial announces Purnovate achieved positive in-vivo data from its study - Adial Pharmaceuticals announced that Purnovate, a subsidiary of Adial focused on developing novel molecules targeting the adenosine receptors for the treatment of major unmet medical needs, achieved positive in-vivo data from its study with mice treated with Purnovate's PNV-6005 as a potential treatment for inflammatory bowel diseases. PNV-6005 is a selective adenosine 2A receptor agonist designed to have anti-inflammatory properties and protective effects against colitis and other inflammatory bowel diseases. In the study, PNV-6005 demonstrated statistically significant effect against both primary study endpoints, which are pre-clinical endpoints expected to indicate potential efficacy against ulcerative colitis in humans.
AVGO

Hot Stocks

09:10 EDT Broadcom ships Trident 4C security switch - Broadcom announced delivery of the Trident 4C Ethernet switch ASIC, a 12.8 terabits/second security switch capable of analyzing all traffic at line rate. Trident 4C detects flow anomalies in real time as part of a rapid cyber-threat defense.
TLRY

Hot Stocks

09:09 EDT Tilray begins policy roundtable with German regulators on cannabis legalization - Tilray Brands announced that the Company has initiated a policy roundtable with German regulators on adult-use cannabis legalization in Germany. In this meeting, the German Drug Commissioner, Burkhard Blienert, presented the plan for adult-use cannabis legalization and repeated the German government's announcement that a first draft of the bill would be presented in the coming months. With this event, Tilray reaffirms its leading role as a trusted partner to government regulators and contributes to German legalization efforts by sharing its long-standing expertise and experience in cannabis research, product quality and safety, supply management, patient and consumer protection, and cannabis education.
WGO

Hot Stocks

09:09 EDT Winnebago appoints Ray Posadas as VP, investor relations, market intelligence - Winnebago Industries announced the appointment of Ray Posadas as Vice President, Investor Relations and Market Intelligence, effective September 6, 2022. Posadas succeeds Steve Stuber, who was appointed CFO of Grand Design RV in April 2022.Prior to joining Winnebago Industries, Posadas served as Managing Director of Investor Relations for Allison Transmission.
ACN

Hot Stocks

09:08 EDT Accenture subsidiary AFS appoints Ron Ash COO - Accenture Federal Services, AFS, a subsidiary of Accenture , announces new roles for two executives following the retirement of Chief Operating Officer, Kenny Mitchell. Ron Ash will serve as the new Chief Operating Officer and Elaine Beeman will assume the responsibilities of Chief Leadership Officer.
ACN

Hot Stocks

09:08 EDT Correction: Accenture subsidiary appoints Ron Ash COO - Accenture Federal Services, AFS, a subsidiary of Accenture , announces new roles for two executives following the retirement of Chief Operating Officer, Kenny Mitchell. Ron Ash will serve as the new Chief Operating Officer and Elaine Beeman will assume the responsibilities of Chief Leadership Officer.
PTRA

Hot Stocks

09:08 EDT Proterra and ElDorado announce collaboration - Proterra and ElDorado National, or ENC, a subsidiary of REV Group, an industry leader in heavy-duty transit, airport and university buses and emissions-free technology, announced a new collaboration to power ENC's second-generation electric transit buses with Proterra's industry-leading battery technology. Under a new, multi-year supply agreement, Proterra will supply its S-Series battery system to power ENC's Axess Battery Electric Bus that will be available to transit agencies in 32-foot, 35-foot, and 40-foot models. Delivery of the first Proterra Powered ENC Axess EVO-BEs is expected to begin in 2023.
CLAR

Hot Stocks

09:08 EDT Clarus says Caption's beneficial ownership of 17.1% violates rights agreement - Clarus Corporation released a statement regarding Caption Management, LLC's recently filed Schedule 13G and its acquisition of beneficial ownership of Clarus common stock in violation of its Rights Agreement. The statement provided by the Company is as follows: "Caption Management, LLC and its affiliates recently filed a Schedule 13G with the Securities and Exchange Commission disclosing that it has ceased to be the beneficial owner of more than 5% of Clarus common stock. Caption has acknowledged to Clarus that the Company's press release dated September 1, 2022 caused Caption to evaluate its beneficial ownership in Clarus's common stock and determined that since July 2022, Caption failed to timely comply with the beneficial ownership reporting provisions of Section 13 of the Securities Exchange Act of 1934, as amended, after acquiring more than triple the position that triggers a filing requirement. Caption's failure to comply with applicable SEC rules undermined the market transparency intended by such rules. Caption's acquisition of in excess of 5% beneficial ownership in Clarus' outstanding common stock without the approval of Clarus' Board of Directors is a violation of its Rights Agreement dated February 7, 2008. The Rights Agreement is intended to preserve, amongst other things, the Company's valuable net operating losses by limiting the number of 5% or more beneficial owners and therefore reducing the risk of a possible change of ownership under Section 382 of the Internal Revenue Code of 1986, as amended. Caption has confirmed ownership of in excess of 10% of Clarus stock on more than one occasion, calling into question whether they have violated the short swing profits rule under Section 16(b) of the Securities Exchange Act of 1934, as amended. Clarus is evaluating Caption's transactions in Clarus stock and will seek disgorgement of any profits as applicable under the securities laws. The Company's Board of Directors will pursue any and all remedies available against Caption, including, without limitation, taking action to trigger the remedies under the rights agreement which would result in material dilution in the economic value of Caption's ownership in Clarus' common stock.The Company has contacted the enforcement division of Nasdaq regarding Caption and its trading activity in its common stock and continues to actively investigate and seek to contact regulators regarding the trading in its common stock as well as related derivatives by other entities. Clarus will pursue appropriate civil, regulatory and all other action available against Caption and Parallax Volatility Advisers, L.P., as well as any other person or group, that is engaging in any manipulative trading activities and/or that acquires 4.9% or more beneficial ownership in Clarus' common stock without the approval of its Board of Directors in violation of the Rights Agreement."
CHDN

Hot Stocks

09:06 EDT Churchill Downs completes purchase of Chasers Poker Room - Churchill Downs, or CDI, announced that the Company has completed its previously-announced purchase of Chasers Poker Room in Salem, New Hampshire. The purchase of Chasers follows the approval of the transaction by the New Hampshire Lottery Commission. Chasers is located approximately 30 minutes from downtown Boston and is the leading New Hampshire charitable gaming operator, offering poker and a variety of table games. CDI plans to construct an expanded charitable gaming facility in Salem, with up to 800 gaming positions including historical racing machines and table games. CDI expects the total investment in Salem, inclusive of the purchase price, to be approximately $150M.
ACN

Hot Stocks

09:06 EDT Accenture appoints Ron Ash COO, Elaine Beeman Chief Leadership Officer - Accenture Federal Services, AFS, a subsidiary of Accenture , announces new roles for two executives following the retirement of Chief Operating Officer, Kenny Mitchell. Ron Ash will serve as the new Chief Operating Officer and Elaine Beeman will assume the responsibilities of Chief Leadership Officer.
CMLS

Hot Stocks

09:05 EDT Cumulus Media adds 325 popular podcasts from Cumulus Podcast Network to Tuneln - Cumulus Media announce that they have renewed and expanded their existing content partnership in a new agreement that adds 325 popular podcasts from the Cumulus Podcast Network to the TuneIn platform, which reaches an audience of over 75 million active users each month. In addition to the podcasts, TuneIn will continue to make Cumulus Media's high-quality local sports, news, talk and entertainment programming across 405 owned-and-operated radio stations in 86 U.S. markets available to TuneIn listeners. Under the terms of the deal, audio streams of Cumulus Media stations and podcasts across the country will be available 24/7 through TuneIn, with 325 popular podcasts now available through TuneIn.
MCBI

Hot Stocks

09:05 EDT Mountain Commerce Bancorp plans grand opening of first Nashville area location - Mountain Commerce Bank, a subsidiary of Mountain Commerce Bancorp, is already officially open for business in the greater Nashville market with a full-service branch-its first in the Nashville market-located at 5205 Maryland Way in Brentwood. The branch opened its doors on June 30 and plans are underway for a grand opening and ribbon cutting on Monday, September 19. "We are still relatively new to the Nashville market," said Bill Edwards, MCB's president and chief executive officer, "but Mountain Commerce Bank and its predecessors have operated in Tennessee for over a century. And we are committed to building our characteristic Responsive Relationship Banking brand here in the greater Nashville area just as we have across all our locations."
DK C

Hot Stocks

09:04 EDT Delek US expands leadership team, adds Hobbs as EVP, Corporate Development - Delek US (DK) announced that Mark Hobbs will join Delek in the upcoming weeks to fill the role of Executive Vice President, EVP, Corporate Development. In his new role, Hobbs will work closely with Delek's management team to lead the Company's corporate development functions. Hobbs joins Delek US from Citigroup (C), where he spent the past 11-years as a Managing Director.
CW

Hot Stocks

09:04 EDT Curtiss-Wright awarded contracts valued at $120M for U.S. Navy submarines - Curtiss-Wright announced that it has been awarded contracts valued at approximately $120M when fully funded to provide generators for the U.S. Navy's next-generation Columbia-class submarine. "We are very proud to have been chosen by Northrop Grumman to provide generators for this significant U.S. nuclear naval defense platform," said Lynn M. Bamford, President and CEO of Curtiss-Wright Corporation. "The Columbia-class ballistic missile submarine, SSBN, program is the U.S. Navy's top priority to maintain the nation's force structure, and Curtiss-Wright's selection for this award reflects our long-standing commitment to and our ongoing support of the U.S. Navy's most critical platforms." The Columbia-class submarine will replace the fleet of Ohio-class ballistic missile submarines. The lead ship is scheduled to be delivered to the Navy in 2027. Curtiss-Wright is performing this work at its Cheswick, Pennsylvania facility within the Company's Naval & Power Segment.
PHG

Hot Stocks

09:03 EDT Philips announces Miami Cardiac & Vascular Institute started using Verisight Pro - Royal Philips announced that Baptist Health's Miami Cardiac & Vascular Institute, Florida, has successfully started treating patients with Verisight Pro, Philips' real-time 3D Intracardiac Echocardiography, or ICE, catheter, during minimally-invasive image-guided procedures for structural heart disease. Offering superior 2D and 3D live imaging, VeriSight Pro allows interventionalists to navigate procedures with ease, provide superior care, and optimize performance of the interventional suite to benefit more heart patients. With Philips' intracardiac echocardiography, or ICE, catheter VeriSight Pro, additional groups of patients can now be treated, such as those who are not suitable for transesophageal echocardiography, which typically requires heavy sedation or general anesthesia.
DTGI MEOA

Hot Stocks

09:03 EDT Digerati Technologies, Minority Equality enter business combination agreement - Digerati Technologies (DTGI) announced its signing of a definitive business combination agreement with Minority Equality Opportunities Acquisition Inc. (MEOA), which is the first Minority led special purpose acquisition company to list on NASDAQ with the mission of executing a business combination with a minority owned, led or founded business. Highlights of the transaction include: Transaction to result in Digerati becoming a listed company on NASDAQ and delisting from OTC Markets. Combined company to have an initial equity value of approximately $228 million translating into an enterprise value of approximately $145 million, assuming no redemptions by MEOA stockholders. MEOA currently has approximately $129.9 million cash in trust as of September 2, 2022. New capital and being a NASDAQ listed company is expected to provide Digerati with flexibility for additional strategic and accretive acquisitions in the UCaaS sector. The current Digerati management team will continue to operate the business. The current Digerati Board of Directors will remain with one additional director to be appointed by the Company and Shawn D. Rochester, CEO of MEOA, joining the Company's Board of Directors at the closing of the transaction. All existing Digerati shareholders will receive 100% of their equity in the pro forma company. The combined company is expected to have a total pro forma equity value of approximately $228 million translating into an enterprise value of approximately $145 million, with the proposed business combination to provide access to capital of up to approximately $121 million from the cash held in trust by MEOA, assuming no redemptions from MEOA stockholders. All references to available cash from the trust account and retained transaction proceeds are subject to any redemptions by the public stockholders of MEOA and payment of transaction fees and expenses. As part of the transaction, all Digerati shares owned by Digerati's existing equity holders will be converted to common stock of the pro forma company. The transaction, which has been approved by the Boards of Directors of both of Digerati and MEOA, is expected to close in the fourth quarter of CY 2022. The transaction remains subject to NASDAQ approving MEOA's initial listing application in connection with the merger, approval by both MEOA and Digerati shareholders, as well as other customary closing conditions.
CFVI

Hot Stocks

09:03 EDT Rumble signs exclusive partnership deal with David Freiheit - Rumble announced an exclusive partnership with David Freiheit, an accomplished attorney and successful content creator on YouTube. The partnership will include exclusive livestreams on Rumble an average of four times per week, including VivaFrei's popular Sunday show. "Viva was one of the first major creators on Rumble due to a viral video hit he created many years ago, which had nothing to do with politics or law," said Rumble CEO Chris Pavlovski. "Viva can now continue to create content that remains authentic, insightful, and honest without having to worry about capricious or politically motivated censorship. This move will allow him to create even more compelling and impactful content, and I'm personally excited to see how his audience grows." The company announced in December 2021 the execution of a definitive business combination agreement with CF Acquisition Corp. VI.
SHPH

Hot Stocks

09:02 EDT Shuttle Pharmaceuticals announces closing of initial public offering - Shuttle Pharmaceuticals Holdings announced the closing of its initial public offering of 1,225,888 units of common stock and warrants at a public offering price of $8.125 per unit, for aggregate proceeds of $9,960,340, before deducting underwriting discounts and estimated offering expenses. Each unit consisted of one share of common stock and a warrant to purchase one share of common stock. Each of the warrants were exercised simultaneously with closing at an exercise price of $0.01 per share.
VZ

Hot Stocks

09:02 EDT Verizon increases dividend 1.25c to 62.25c - The Board of Directors at Verizon Communications declared a quarterly dividend of 65.25c per outstanding share, an increase of 1.25c per share from the previous quarter. The quarterly dividend is payable on November 1, to Verizon shareholders of record at the close of business on October 7. This is the 16th consecutive year Verizon's Board has approved a quarterly dividend increase.
RVPH

Hot Stocks

08:52 EDT Reviva Pharmaceuticals announces $8.5M registered direct offering - Reviva Pharmaceuticals Holdings announced that it has entered into definitive agreements with a single healthcare-focused institutional investor, in a registered direct offering priced at-the-market under Nasdaq rules, and two affiliates of a member of the Company's Board of Directors, each in a private placement, for the purchase and sale of an aggregate of 3,359,684 shares of its common stock at a purchase price per share of $2.53 for gross proceeds of approximately $8.5 million before deducting placement agent fees and other estimated offering expenses. The Company has also agreed to issue to each investor, in an additional concurrent private placement, unregistered warrants to purchase up to 3,359,684 shares of the Company's common stock. The warrants will have an exercise price of $2.40 per share, will be exercisable immediately following the date of issuance and will expire five years from the initial exercise date. The closing of the registered direct offering and the concurrent private placements is expected to occur on or about September 8, 2022, subject to the satisfaction of customary closing conditions. Reviva intends to use the net proceeds from the offering to continue the clinical development of brilaroxazine for the treatment of acute and maintenance schizophrenia, and for working capital and other general corporate purposes. A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.
LVRLF

Hot Stocks

08:51 EDT CordovaCann says Star Buds stores generated $1.36M revenue in August - CordovaCann provides an update on its Star Buds Cannabis Co. retail operations in Canada. The company said, "Star Buds Cannabis Co. continues to achieve strong performance to close out the summer. The stores continue to benefit from market share gains despite a difficult economic environment. Gross margin is expanding due to menu optimization and management continues to focus on increasing store profitability with strong cost controls. The Star Buds Cannabis Co. stores posted a record month of revenues in August, following the very strong month of July. In August, the store chain generated revenues of $1.26 million with a gross margin of 25.5%. This equates to a revenue run rate of $15.1 million annually. Six of the fourteen Star Buds Cannabis Co. stores posted record monthly revenues, and eleven of the fourteen stores increased revenues over July. Management expects Star Buds Cannabis Co. to continue to benefit from closures of competing stores, industry consolidation, and increased customer awareness due to greater availability of third-party delivery. Recent performance and new initiatives give the Company increased confidence in our retail strategy, and management continues to work on expanding the Star Buds Cannabis Co. footprint across Canada through both organic store growth and acquisitions."
ZEN

Hot Stocks

08:49 EDT Zendesk believes Hellman & Friedman led consortium deal provides superior value - Zendesk released an investor presentation that provides significant additional information to stockholders in connection with the proposed transaction with the consortium led by Hellman & Friedman and Permira. The company stated: "Our Board believes that the acquisition by the Consortium is the best path forward for Zendesk and our stockholders. It is important for stockholders to understand the challenges facing the Zendesk business, including the significant deceleration of key leading indicators and measures of Zendesk's business performance. To ensure full transparency and help investors make an informed decision, we disclosed certain recent monthly performance metrics so that Zendesk stockholders are able to understand that the standalone alternative, under any structure, carries material risk for Zendesk stockholders given Zendesk-specific performance challenges, as well as a challenging market and macroeconomic environment. The Board conducted a thorough and extensive strategic review process before determining to enter into the Consortium transaction, which the Board believes offers immediate and certain value that is superior to the standalone alternatives, including the recapitalization proposal from Light Street Capital." The company is continuing to advance toward completing the transaction with the Consortium, subject to customary closing conditions. A special meeting of Zendesk stockholders to vote on the transaction will be held on September 19. The board unanimously recommends that stockholders vote for the consortium transaction.
CWK

Hot Stocks

08:48 EDT Finacity, ING Belgium facilitate increase of ARS program for Cushman & Wakefield - Finacity Corporation and announce that they have facilitated an increase from $125 million to $200 million of the commitment capacity for the Accounts Receivables Securitization Program for Cushman & Wakefield.
MBRX

Hot Stocks

08:46 EDT Moleculin Biotech receives FDA ODD of WP112 for treatment of GBM - Moleculin Biotech announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation, ODD, of WP1122 for the treatment of Glioblastoma Multiforme, GBM. "The receipt of Orphan Drug Designation represents an important milestone for our promising WP1122 development program," commented Walter Klemp, Chairman and Chief Executive Officer of Moleculin. "Given the progress of our Phase 1 clinical trial in healthy volunteers, the strong preclinical data supporting GBM as one of many potential indications and the recent clearance by the FDA of IND status for WP1122 in GBM, we believe this designation further supports the potential of WP1122 and is another step forward in further validating our deep pipeline."
NIOBF

Hot Stocks

08:45 EDT NioCorp demonstration plant begins testing process improvements - NioCorp Developments announces that its demonstration-scale processing plant in Quebec, Canada is now processing ore samples from the Company's Elk Creek Critical Minerals Project. The demonstration plant project is intended to demonstrate that the Company can extract and separate rare earth elements from ore that NioCorp expects to mine from the Project site, subject to receipt of necessary project financing, and that its simplified process for potentially producing niobium, scandium, and titanium is technically and economically feasible. The demonstration plant will process Elk Creek ore samples in three phases. Testing is expected to be completed over the next several weeks. NioCorp expects to publicly disclose testing results after each operational phase concludes. Phase 1 is designed to demonstrate a new approach to the initial processing of the ore that NioCorp expects to mine from the Project site, subject to receipt of necessary project funding, including calcination, initial leaching, and rare earth extraction. Phase 2 is designed to demonstrate an improved process for the second stage of leaching along with Niobium and Titanium separation. Phase 3 is designed to demonstrate the technical viability of separating high-purity versions of several target magnetic rare earth products from Elk Creek ore samples, as well as confirming previously achieved high recovery rates for high-purity Scandium trioxide.
RHP

Hot Stocks

08:44 EDT Ryman Hospitality announces new 10c interim dividend - Ryman Hospitality Properties announced that the Company has declared a quarterly cash dividend of 10c per common share, to be paid on October 17, to stockholders of record as of September 30. The Company's new interim dividend policy is a minimum dividend of 100% of REIT taxable income annually, subject to the Board of Directors' future determinations as to the amount of quarterly distributions and the timing thereof. The Company today is also providing a business update on recent operating trends and supplemental information. The supplement can be located on the Company's website.
POWW

Hot Stocks

08:43 EDT AMMO places Urvan, Lokey on administrative leave, forms special committee - AMMO announced that Steven Urvan, Chief Strategy Officer, and Susan Lokey, Chief Financial Officer of SpeedLight I, LLC d/b/a GunBroker.com, have been placed on administrative leave with immediate effect. The company said, "The Company has reason to believe that these individuals may have misappropriated the Company's data and digital assets and transmitted that data to a third party controlled by Mr. Urvan and with which Ms. Lokey is associated. The Company commenced an internal investigation into the alleged misconduct several weeks ago. During the pendency of the investigation, these individuals will remain suspended from their duties. The Company's board of directors has formed a special committee in connection with the conduct of Mr. Urvan. The Special Committee issued the following statement: "We are deeply concerned by the preliminary results of our investigation to date. We are committed to ensuring that all aspects of the Company's business are conducted with integrity, transparency and oversight. The Company seeks to protect its data and digital assets against all forms of misappropriation. Mr. Urvan was aware of our concerns and our prior attempts to investigate and discern more information. We believe that his recently announced proxy contest to replace the entire Board may be, at least in part, an attempt by Mr. Urvan to thwart our investigation and driven by his desire to avoid accountability. Nevertheless, we will continue our thorough investigation into the alleged misconduct. We will conduct this investigation with the urgency and diligence it deserves, and we will take responsive or preventative actions that the Special Committee determines to be appropriate. In the meantime, to protect the Company and its customers, stockholders and other stakeholders, the Special Committee has determined to place these individuals on administrative leave. It is untenable to allow these individuals continued access to the Company's systems, data, property or employees while the investigation is underway and until we fully understand the nature and scope of their prior actions. In the meantime, we remain committed to delivering exceptional and innovative products and experiences for outdoor sporting enthusiasts that drive value for our shareholders and other stakeholders. The Company currently does not expect the investigation to yield any findings that impact the financial results, balance sheet or business prospects of the Company."
PECO

Hot Stocks

08:42 EDT Phillips Edison increases monthly distribution 3.7% to 9.33c - Phillips Edison & Company announced that its Board of Directors approved a 3.7% increase to the monthly distributions payable October 3 and November 1 to stockholders of record at the close of business on September 16 and October 17 respectively. The Board approved the distribution at a rate of 9.33c per share of the Company's common stock and per operating partnership unit. When annualized, this is equal to a rate of $1.12 per share, representing an increase of 3.7% over the previous annualized rate of $1.08 per share.
FLUX

Hot Stocks

08:41 EDT Flux Power announce combined purchase orders worth $64M - Flux Power announced combined purchase orders from new and existing customers in excess of $64M in the FY22, which was more than 82% over the order volume for fiscal year June 30. While not an exact measure, we estimate that purchase orders indicate future revenue potential from new customers in fiscal year 2022 was 26% of revenue, with the remaining 74% from repeat customers. Our strategy reflects a "relationship," not transactional, business with our customers that provides ongoing new purchase needs and service requirements.
GPRE

Hot Stocks

08:40 EDT Green Plains, Tallgrass and PNNL awarded funding from DOE - Green Plains, Tallgrass, and Pacific Northwest National Laboratory, or PNNL, announced they have been awarded funding from the U.S. Department of Energy, or DOE, to advance sustainable aviation fuel, or SAF, technology as part of the federal agency's effort to support the development of valuable biofuels and bioproducts for the clean energy economy. The DOE award will support Green Plains and Tallgrass in funding the demonstration of an innovative process developed by PNNL to convert ethanol to SAF via ketone intermediates, a critical step in proving the scalability of the technology. Green Plains and Tallgrass currently hold the option to exclusively license the PNNL SAF technology globally. They will jointly pursue the production of SAF from cellulosic and corn ethanol and intend to commercialize PNNL's production process upon successful completion of the pilot project.
MEG

Hot Stocks

08:40 EDT Montrose Environmental acquires AirKinetics, terms undisclosed - Montrose Environmental announced the acquisition of AirKinetics. AirKinetics' leadership team, including founder and president Tony Wong, will join Montrose's Measurement and Analysis segment. The terms of the transaction were not disclosed. AirKinetics has been a provider of emissions testing services to industry and government partners since 1995. The company is recognized as a top environmental testing firm in Southern California, with domain expertise in compliance and regulatory testing, CEMS testing, engineering and diagnostics testing and ambient air monitoring. AirKinetics' expertise is primarily in California, Hawaii, Nevada, Arizona, Oklahoma, Oregon and Washington.
RMAX

Hot Stocks

08:40 EDT RE/MAX Holdings announces 180 new franchise agreements, 215 renewals - RE/MAX announced over 180 new franchise agreements and over 215 renewals were signed worldwide between April and June 2022. This news comes on the heels of recently announced strategic growth initiatives at both RE/MAX and RE/MAX Holdings. Peter Luft, RE/MAX Vice President of Franchise Sales, is excited about the new brokerages that have recently joined the RE/MAX network. He is looking forward to meeting other entrepreneurs who are drawn to the balloon as new state-of-the-art technology and resources roll out. "RE/MAX has a long-established reputation for delivering results, and our most recent announcements are proofpoints that this legacy is alive and well. The newest offering of MAX/TechSM powered by kvCORE consists of incredible technology that will help affiliates market themselves, generate leads, and automate many aspects of their business. We pride ourselves in helping entrepreneurs be extraordinary at what they do." RE/MAX has a presence in more countries and territories than any other real estate brand. From a single office that opened in 1973 in Denver, Colorado, RE/MAX has grown into a global real estate network with more than 140,000 sales associates in almost 9,000 offices and a presence in more than 110 countries and territories.
BHAT

Hot Stocks

08:39 EDT Blue Hat Interactive enters agreement with TravelerNetwork - Blue Hat Interactive Entertainment Technology announced that the Company has reached an agreement with a leading game distributor Xiamen Traveler Network Technology to distribute Blue Hat's proprietary games "cute monopoly" and "cute game box" worldwide. The Company and TravelerNetwork signed a joint operating agreement.
HUGE

Hot Stocks

08:39 EDT FSD Pharma receives study may proceed letter for FSD201 IND - FSD Pharma announced that it received "Study May Proceed" letter for the investigational new drug, or IND, application from the FDA and "Notice of Authorization" from Health Canada for its Phase 2 clinical trial of FSD201. The corresponding study protocol is titled "A Randomized, Double-Blind Placebo Controlled Parallel Group Study of Safety and Efficacy of FSD201 in Patients with Chronic Widespread Musculoskeletal Nociplastic Pain Associated with Idiopathic Mast Cell Activation Syndrome (Disorder)".
ADT...

Hot Stocks

08:38 EDT State Farm to make $1.2B equity investment in ADT - ADT (ADT) announced that State Farm will make a $1.2B equity investment in ADT, resulting in State Farm owning approximately 15% of ADT after the equity investment and the tender offer close. Additionally, ADT plans to partner with State Farm, and build upon its existing relationship with Google (GOOG), with the aim to expand opportunities to combine next-generation security, innovative smart home technology and reimagined risk-mitigation capabilities to monitor, detect, prevent and optimize against homeownership risks. State Farm will commit up to $300M to fund product and technology innovation, customer growth and marketing. In addition, Google has separately agreed to commit an incremental $150M, subject to the achievement of certain milestones, to advance opportunities created by this type of innovation, raising its total success fund commitment to $300M. With their investment, State Farm will obtain a seat on ADT's Board of Directors and intends to designate Paul Smith, Executive Vice President and Chief Operating Officer of State Farm. State Farm's equity investment, which is subject to customary closing conditions, is expected to close early in the Q4. In connection with State Farm's equity investment, ADT will be commencing a self-tender offer for up to 133.3 million shares of its outstanding common stock and Class B common stock at $9 per share, to be funded by the proceeds from the State Farm equity investment. The tender offer is expected to eliminate any dilution from State Farm's equity investment. Funds managed by affiliates of Apollo Global Management. Citi and Evercore were the financial advisors to ADT, and Cravath, Swaine & Moore acted as legal advisor. Morgan Stanley & Co. was the financial advisor to State Farm, and Sidley Austin acted as legal advisor.
MDGS

Hot Stocks

08:38 EDT Medigus says Eventer reports 1H revenue of $1.4M vs. $0.45M last year - Medigus announced today that its 46.21% owned subsidiary, Eventer Technologies achieved record high financial results for the first six months of 2022. Eventer's first half of 2022 highlights: Eventer's overall turnover from ticket sales for the first half of 2022 amounted to approx. $35 million, compared to approx. $8.6 million in the first half of 2021, an increase of approx. 307% and an increase of approx. 35% compared to the entire year of 2021; Over 1 million tickets were sold using Eventer's online platform during the first half of 2022; Eventer retained its commission rate through the first six months of 2022 at approx. 5%, equal to the first six months of 2021; Eventer's revenues for the first half of 2022 totaled at approx. $1.4 million, an increase of approx. 211% compared to approx. $0.45 million in the first half of 2021; Eventer's gross profit for the first half of 2022 amounted to approx. $1.17 million, an increase of approx. 350% compared to approx. $0.26 million in the first half of 2021 and an increase of approx. 45% compared to the entire year of 2021.
SRPT

Hot Stocks

08:36 EDT Sarepta says FDA lifts clinical hold on SRP-5051 for treatment of DMD - Sarepta Therapeutics announced that the U.S. Food and Drug Administration has removed the clinical hold on SRP-5051, the Company's investigational, next-generation peptide-conjugated phosphorodiamidate morpholino oligomer to treat patients with Duchenne muscular dystrophy who are amenable to exon 51 skipping. After discussions with FDA and as part of the lift, Sarepta will adjust the global trial protocol to include expanded monitoring of urine biomarkers. The hold in Part B of Study 5051-201, also known as MOMENTUM, followed a serious adverse event of hypomagnesemia. Information was provided by the Company to FDA to assess the adequacy of the risk mitigation and safety monitoring plan. "We would like to thank FDA for working closely with us to expeditiously resolve this clinical hold. We will implement the changes in the protocol to resume dosing in the U.S. as quickly as possible," said Louise Rodino-Klapac, Ph.D., executive vice president and CSO, Sarepta Therapeutics. "Our monitoring plan is designed to mitigate the risks of hypomagnesemia. MOMENTUM has continued enrolling participants outside the U.S., and we remain on track to complete enrollment by the end of 2022. Sarepta is committed to the SRP-5051 program and excited about the PPMO platform as a next-generation exon-skipping approach for the treatment of Duchenne."
DAVE

Hot Stocks

08:35 EDT Dave appoints Chou as new Chief Technology Officer - Dave announced that Chien-Liang Chou has been named Chief Technology Officer, effective immediately. Chou previously served as Executive Vice President of Engineering at Dave, a position he held since 2020. In this role, he led the engineering, data, infrastructure, security and information technology teams, spearheading various data initiatives resulting in greater efficiencies and a better member experience.
CSCW

Hot Stocks

08:35 EDT Color Star Technology, Global Digital Club forms strategic partnership - Color Star Technology has recently signed an official strategic partnership agreement with Global Digital Club, GDC. From now on, the focus of this partnership will be on the metaverse digital economy, and both parties will jointly develop a series of related digital businesses in Color World_Metaverse. CEO of Color Star, Farhan Qadir said: "Color Star has always viewed smart intelligence as its technical core, and while we continue to develop the entertainment metaverse, we expect to further develop more industrial content, the digital economy and artificial intelligence since they will certainly be profitable developments for the company. The partnership with GDC will not only allow us to progress further with our digital economy, but also allow Color Star to attract more partners, which is a very good thing. Next, we will partner with more corporate organizations, which suggests that the future developments of Color Star will be more diversified and comprehensive, bringing our partners and investors more guaranteed revenue."
PWFL

Hot Stocks

08:34 EDT PowerFleet telematics solutions selected by ST Engineering - PowerFleet announced that ST Engineering has selected its industrial telematics solutions for the Maintenance Repair Operations, or MRO, at its airframe facility in San Antonio. ST Engineering, also known as Singapore Technologies Engineering, is a global technology, defense and engineering group and one of the largest airframe MRO solutions providers in the world. ST Engineering's San Antonio facility will utilize PowerFleet's telematics solutions to improve overall equipment visibility into its aerospace MRO operations, as well as an API tool to integrate data from their vehicles into the necessary systems to improve performance.
NAT

Hot Stocks

08:34 EDT Nordic American Tankers says reduced fleet to about 20 vessels - The company said, "The situation associated with the war between Russia and Ukraine is difficult to assess in detail. However, it is a general experience that uncertain times are good for Nordic American Tankers. Our suezmaxes are well placed to benefit from the situation. We have reduced our fleet to about 20 vessels. We are now in an upward trend and over the next year, two or three, we expect to increase our fleet. Our strong links with the Far East are continuing. This above all relate to Japan, China, Korea and India. Over the years we have long experience from these areas. The main advantage for Nordic American Tankers is that we have good ships, good people and access to finance. Being listed in the US, we have to comply with strict and detailed rules. Over the years we have learned to live with that situation. Going forward, we prioritize to distribute dividend. In a stronger market that we now see, the dividend can be expected to increase."
CRTD

Hot Stocks

08:34 EDT Creatd appoints Maury to board of directors, Frommer as chairman, CEO - Creatd announces a new appointment to its board of directors, Justin Maury, Creatd COO and co-founder, as well as the appointment of current Executive Chairman, Jeremy Frommer to the position of Chairman and CEO.
BCOV

Hot Stocks

08:33 EDT Brightcove and Evergent expand partnership - Evergent announced an expanded partnership with Brightcove. The new integration will see the introduction of Evergent's monetization solution to Brightcove Beacon for over-the-top video streaming, making it possible for Brightcove customers to test and implement flexible monetization approaches within the platform. Integrated into the Brightcove Beacon offering, Evergent's solution, which will be available in the Brightcove Marketplace, will power complex user and payment management scenarios for Brightcove's global customer base.
ONVO

Hot Stocks

08:32 EDT Organovo announces postponement of annual meeting - Organovo Holdings announced that its 2022 Annual Meeting of Stockholders that was scheduled to be held at 9:00AM on Wednesday, September 7, 2022 has been postponed to October 12, 2022 at 9:00AM, a date determined by the Company's board of directors. The Company's board of directors also established a new record date for the 2022 Annual Meeting, and based on this record date, the Company will deliver a new notice of the 2022 Annual Meeting to stockholders entitled to receive notice of such meeting. The new record date for the 2022 Annual Meeting is September 7, 2022. To date, the Company has received proxies from less than thirty-five percent as of the prior July 15, 2022 record date and has therefore postponed the 2022 Annual Meeting in an effort to allow its stockholders additional time to consider the matters to be presented at the 2022 Annual Meeting, to encourage greater stockholder participation and to give the Company's Board of Directors additional time to further address and consider stockholder input. The Company plans to promptly file with the Securities and Exchange Commission and mail an amended definitive proxy statement, which will include a new notice of the 2022 Annual Meeting and contain additional information about the 2022 Annual Meeting.
BLDP

Hot Stocks

08:31 EDT Ballard Power to power India's first hydrogen trains - Ballard Power Systems announced a fuel cell module order from Medha Servo Drives, a leading rail system integrator, who has been contracted by Indian Railways to develop India's first hydrogen powered trains. The two retrofitted diesel-electric commuter trains will integrate 8 units of 100 kW FCmoveTM-HD+, Ballard's latest fuel cell technology, which offers improved efficiency and power density than previous module generations. The contract to provide the hydrogen-powered trains was awarded to Medha as a first step in Indian Railways' path to achieve their net zero ambitions. The fuel cell modules are expected to be shipped in 2023, with trains scheduled to go into service in 2024, with potential for additional retrofits following the initial deployment. "Our progress in decarbonizing the rail market is just beginning, as we work with leading rolling stock manufacturers, integrators and operators globally. This announcement with Medha exemplifies the growing need and progress being made to decarbonize global mobility. We are excited to grow our fuel cell business in India, and to power the first hydrogen powered, zero emission passenger trains in the Indian market," said David Mucciacciaro, Ballard Chief Commercial Officer.
ALCO

Hot Stocks

08:31 EDT Alico appoints Perry Del Vecchio as CFO - Alico announced the hiring and appointment of Perry G. Del Vecchio as the Company's CFO, effective as of September 6. Del Vecchio will be responsible for all corporate finance, treasury and accounting functions of the Company and will report directly to John Kiernan, the Company's President and CEO. Del Vecchio most recently served as a Vice President and the Controller for Lexyl Travel Technologies in West Palm Beach, Florida. He spent the majority of his career in financial management positions within the Hertz organization. He earned his MBA degree from Montclair State University and earned CPA credentials while an auditor with Deloitte & Touche.
ALHC

Hot Stocks

08:31 EDT Alignment Healthcare completes debt refinancing - Alignment Healthcare announced the close of a $250 million senior secured term loan facility with Oxford Finance LLC, of which $165 million was funded upon closing of the transaction, net of certain expenses. The Company used these funds to repay in full the outstanding principal and accrued interest under its existing term loan facility with CRG Servicing LLC. The new credit facility provides for a delayed draw term loan commitment of $85 million, which is available at the Company's option, subject to certain conditions specified in the loan agreement.
SPRO

Hot Stocks

08:30 EDT Spero Therapeutics provides update on its tebipenem HBr program - Spero Therapeutics provided an update on its tebipenem HBr program following the receipt of minutes from a recent Type A meeting with the FDA, discussing steps required for resubmission of the New Drug Application, or NDA, for tebipenem HBr for the treatment of complicated urinary tract infection, or cUTI, including pyelonephritis. During the Type A meeting, the FDA indicated that positive results from a single additional Phase 3 clinical trial supported by confirmatory nonclinical evidence of efficacy could be sufficient to support the approval of tebipenem HBr for the treatment of cUTI, including pyelonephritis for a limited use indication. Spero and the FDA also achieved alignment on key components of the proposed pivotal Phase 3 trial design which may be the subject of a Special Protocol Assessment (SPA) request, to be confirmed once the clinical protocol is finalized.
BBKCF

Hot Stocks

08:26 EDT Bigg Digital Assets' Netcoins announces U.S. expansion plans - BIGG Digital Assets announced initial launch plans for Netcoins US operations. Netcoins is proud to announce its plans to launch in the United States during Q4 2022.Netcoins USA Inc, based in the state of Wyoming, will begin its operations in the fourth quarter of this year and will launch its trading platform starting in four states: California, Pennsylvania, Michigan and Virginia. With significant growth aspirations, Netcoins plans to launch additional states in Q1 2023 pending approvals. During the last 6 months, the Netcoins team has been diligently working to enhance its proposition, now with over 30 coins and a renewed focus on the user experience and customer journeys within the platform. In addition, Netcoins has been working on a number of leading FinTech integrations to bolster its ecosystem and create a strong foundation for its North American business. Netcoins will comply with US regulations and will continue to operate as a compliance-first crypto platform that is focused on regulatory adherence and customer safety. Netcoins will launch in the US with a Mobile only proposition that will be available on iOS and Android. Prior to going live, Netcoins will allow US customers to sign up for a mailing list on a new Netcoins US website to get updates on state-specific launch dates, waitlists and exciting contests.
SDC

Hot Stocks

08:26 EDT SmileDirectClub completes transition to new manufacturing technology - SmileDirectClub announced the complete transition of its second-generation retainer manufacturing technology in the Company's FDA-registered Smile Labs based in Antioch, Tennessee. The Company's upgraded retainer manufacturing lines feature the patented laser technology and automations that are leveraged to produce SmileDirectClub's Comfort Sense aligners. The laser technology results in precision-cut retainers that fit more comfortably while helping to maintain proper tooth alignment and healthy positioning, and the manufacturing automations continue to increase the Company's efficiency and productivity. Thanks to this advanced technology, the Smile Labs can now produce twice as many aligners and retainers with approximately 1/3 of the manpower, effectively increasing productivity by 225%.
CGAU

Hot Stocks

08:25 EDT Centerra Gold appoints Paul Wright as interim CEO - Centerra Gold announced that Paul Wright has replaced Scott Perry as President and CEO of Centerra. Wright, a director of Centerra, will act as interim President and CEO to manage the Company through a leadership transition period, as the Board works with an executive search firm to select Centerra's long-term CEO. In connection with this leadership transition, Perry also resigned as a director of Centerra and will not be nominated for election to the Board at the Company's upcoming Annual Meeting of Shareholders to be held on September 22. The Board has determined to reduce the number of directors from 9 to 8 and the 8 other directors identified in Centerra's management information circular dated August 19, 2022 will stand for election at the upcoming Annual Meeting of Shareholders.
TCBI TFC

Hot Stocks

08:25 EDT Texas Capital sells BankDirect Capital Finance to AFCO Credit for $3.1B - Texas Capital Bancshares announced that it entered into a definitive agreement to sell BankDirect Capital Finance, its insurance premium finance subsidiary, to AFCO Credit Corporation, an indirect wholly-owned subsidiary of Truist Financial Corp.(TFC). The sale of BankDirect includes its business operations and loan portfolio of approximately $3.1 billion as of June 30, 2022. AFCO is purchasing BankDirect from Texas Capital in an all-cash transaction for a purchase price of approximately $3.4 billion, representing an 8.5% asset premium compared to the value of the purchased loan portfolio as of June 30, 2022. The purchase price is subject to customary adjustments, including for the net asset value of the loan portfolio, as set forth in the Purchase Agreement. This transaction represents the divestiture of the entire business unit including the equity interests of BankDirect and the associated loan balances held by Texas Capital Bank and no parent funding, deposits or capital will be transferred. The transaction is expected to increase Texas Capital's capital levels. Relative to June 30, 2022, Common Equity Tier 1 ratio expected to increase 199 basis points and Tangible Book Value per Share accretion is estimated to be 6.5%. Additionally, the divestiture will improve Texas Capital's liquidity position as the Loan to Deposit ratio is expected to decline and the Liquidity Assets to Assets ratio is expected to rise, before giving effect for future redeployment actions. Additionally, given the expected growth in the core business strategy, Texas Capital is reaffirming forward guidance of delivering year-over-year quarterly operating leverage by year-end. The sale is expected to close in the fourth quarter of 2022, subject to various customary closing conditions.
CISO

Hot Stocks

08:23 EDT Cerberus Cyber completes acquisition of NLT Secure - Cerberus Cyber Sentinel announced that it has completed the acquisition of NLT Secure, a cybersecurity company with headquarters in Providencia, Chile, and U.S. offices in Tampa, Florida. Under the terms of the agreement, NLT Secure became a wholly owned subsidiary of Cerberus Sentinel. NLT Secure provides a broad range of security solutions and managed services to organizations throughout South America. Lorenzo Espinoza, founder and chairman, NLT Secure, will continue to manage the company's team of professionals and will work closely with the leadership team in Latin America. NLT Secure will continue to be based in Chile and Tampa, Florida.
CHCI

Hot Stocks

08:23 EDT Comstock Holding acquires property in Reston - Comstock Holding announced the acquisition of 1891 Metro Center Drive in Reston, Virginia on behalf of Comstock Partners, an affiliated, privately-held company. This acquisition adds 2.67 acres with frontage on the Dulles Toll Road to Comstock's expansive Reston Station development. Comstock plans to incorporate the property into its development plans for the west end of the Reston Station neighborhood, temporarily utilizing the existing 58,260 square foot building as swing space for its existing tenancy. The property is adjacent to Reston Station's Metro Plaza District, which provides immediate access to the Wiehle-Reston East Metro Station where Comstock has completed more than 1.3 million square feet of development, including three Trophy-Class office towers, the BLVD residential tower, and retail spaces for Starbucks, CVS, Founding Farmers, Matchbox, Big Buns, Sweet Leaf, and Davio's Northern Italian Steakhouse. Comstock recently announced a separate acquisition by CP of eight acres on Wiehle Avenue between Sunset Hills Road and the Dulles Toll Road, expanding the Reston Station neighborhood eastward.
IMMP

Hot Stocks

08:22 EDT Immutep announces investigator-initiated Phase II trial of efti - Immutep announced it has signed a Material Transfer Agreement with the Maria Skodowska-Curie National Research Institute of Oncology in Warsaw, Poland to enable an investigator-initiated open label Phase II clinical trial. The trial will evaluate Immutep's lead product candidate efti in combination with pembrolizumab and radiotherapy in the neoadjuvant setting in up to 40 patients with select soft tissue sarcoma. Subject to the necessary approvals from the Polish State Institute for Drug Control and ethics committee, the dosing of the first patient is anticipated in the first half of calendar year 2023, with initial interim data expected in the fourth quarter of CY 2024. Under the Agreement, the Maria Skodowska-Curie National Research Institute of Oncology will primarily fund the study with an approved grant from the Polish government of EUR 1.5M awarded by the Polish Medical Research Agency program. Immutep will provide efti at no cost to the Maria Skodowska-Curie National Research Institute of Oncology and will technically support the trial. The trial will be led by Principal Investigators, Dr. Katarzyna Kozak, M.D. PhD., and Pawe Sobczuk, M.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at the Maria Skodowska-Curie National Research Institute of Oncology.
HOTH

Hot Stocks

08:22 EDT Hoth Therapeutics announces development updates for HT-004 - Hoth Therapeutics announced development updates for its novel asthma and allergy maintenance therapeutic, HT-004. Hoth's innovative approach employs a chemically-stable antisense oligonucleotide to eliminate cell surface high-affinity IgE receptor expression and function on mast cells and basophils, rendering mast cells unresponsive to IgE-mediated activation that occurs during asthma and allergy disorders. Through a sponsored scientific research agreement with North Carolina State University, the team used the HT-004 FceRI mRNA frame-shifting approach to reduce lung inflammation induced by OVA in mice. OVA-induced inflammation mice treated with HT-004 via inhalation showed significantly reduced inflammatory cell recruitment in the bronchioles compared to vehicle control and oligonucleotide control OVA-induced mice; the reduction in bronchiolar inflammation in HT-004-treated mice was near the non-OVA stimulated mice. The results of these studies support the use of HT-004 as a novel inhalation maintenance therapy for asthma and allergic disorders. The results of these studies are a continuation of the 2016 publication by Hoth Scientific Advisory Board member Dr. Glenn Cruse, "Exon skipping of FceRIbeta eliminates expression of the high-affinity IgE receptor in mast cells with therapeutic potential for allergy." Hoth has filed several patent applications to protect this IP throughout the world.
POST

Hot Stocks

08:21 EDT Post Holdings approves new $300M share repurchase program - Post Holdings announced its Board of Directors has approved a new $300M share repurchase authorization, with share repurchases under the new authorization beginning on September 3. As of September 2, Post had repurchased approximately $354M under its previous $400M share repurchase authorization, which was approved on November 17, 2021, became effective on November 20, 2021 and was cancelled effective September 2.
LAIX

Hot Stocks

08:20 EDT Laix set record date for dissemination of transaction statement, plan of merger - LAIX announced that it has set September 6, 2022 as the record date for the dissemination of Rule 13e-3 Transaction Statement on Schedule 13E-3 and the executed plan of merger in connection with a previously announced "going private" transaction contemplated under an Agreement and Plan of Merger the Company entered into with Laix Infinite, an exempted company incorporated with limited liability under the laws of the Cayman Islands, and Prilingo Merger Limited, an exempted company incorporated with limited liability under the laws of the Cayman Islands and a wholly-owned subsidiary of Parent, on June 17, 2022. Holders of record of ordinary shares of the Company as of the close of business on September 6, 2022 will each receive a copy of the Schedule 13E-3 and a copy of the Plan of Merger. Holders of the Company's American depositary shares as of the close of business on September 6, 2022 will each receive a copy of the Schedule 13E-3. The merger is currently expected to close in October 2022 and is subject to the terms and conditions set forth in the Merger Agreement. If completed, the merger will result in the Company becoming a privately held company, and its ADSs will no longer be quoted on the OTC Market, and the Company's ADS program will be terminated.
PETQ

Hot Stocks

08:19 EDT PetIQ approves $30M stock repurchase program - PetIQ announced that its Board of Directors has authorized a stock repurchase program, which will enable the Company to repurchase up to $30M in aggregate of the Company's outstanding shares of common stock. Cord Christensen, PetIQ's Chairman and CEO, commented, "We have confidence in PetIQ's business model, financial strength, and future growth opportunities which we believe are undervalued in the Company's current share price. We will use our cash on hand and free cash flow to repurchase stock and pay down debt while continuing to maintain the flexibility to pursue all strategic initiatives as part of our plan to create long-term shareholder value."
TKLF

Hot Stocks

08:19 EDT Yoshitsu announces opening of physical retail store in Hong Kong - Yoshitsu announced the grand opening of its physical retail store in Hong Kong on August 30, 2022. The Store is located at No. 118, 1/F, Nina Tower 1, No. 8 Yeung Uk Road, Tsuen Wan, New Territories, Hong Kong, an iconic shopping destination. The opening hours are from 11 a.m. to 8 p.m. on Monday - Thursday, and 12 p.m. to 9 p.m. on Friday - Sunday. The opening of the Store is a part of the Company's long-term expansion plan to expand its footprint in Hong Kong. The Store features an extensive product assortment, including cosmetics, skincare, fragrances, cosmetic applicators and body care products. Customers will not only have a large selection of exclusive Japanese brands, but also receive personalized beauty assistance with finding new and trending products.
TTI CCLP

Hot Stocks

08:18 EDT Tetra Technologies announecs changes, addition to senior management - TETRA Technologies (TTI) announced changes in its senior management with the promotion of Matt Sanderson, to Executive Vice President and Chief Commercial Officer and the addition of Roy McNiven, who will be joining TETRA as Senior Vice President, Energy Services Operations. In his new role, Sanderson will be responsible for leading the business development, technology, marketing, and corporate development functions of the company to develop and execute on the key company growth strategies. Since December 2016, Sanderson served as TETRA's Senior Vice President responsible for its Water and Flowback Services and its Completion Fluids and Products divisions. McNiven previously served as Senior Vice President of Operations and Manufacturing at CSI Compressco (CCLP).
LUXA

Hot Stocks

08:18 EDT Lux Health Tech Acquisition enters LOI to combine with life sciences company - Lux Health Tech Acquisition announced that it has entered into a non-binding letter of intent, or LOI, for a business combination with a life sciences company addressing unmet needs in healthcare. The target has an experienced executive and scientific leadership team that has built an extensive technology platform with multiple programs in development, and is backed by leading private and public market investors. The company expects that it can offer the target its resources, experience and network of relationships to support the target's growth and access to public markets, making this an attractive potential business combination for the company's stockholders. Under the terms of the LOI, the company and target would become a combined entity, with the Target's existing equityholders rolling 100% of their equity into the combined public company. The company expects to announce additional details regarding the proposed business combination when a definitive agreement is executed, which is expected in the second half of 2022. No assurances can be made that the parties will successfully negotiate and enter into a definitive agreement, or that the proposed transaction will be consummated on the terms or timeframe currently contemplated, or at all. Any transaction would be subject to board and equityholder approval of both companies, regulatory approvals and other customary conditions.
ALBO

Hot Stocks

08:18 EDT Albireo Pharma announces approval of reimbursed access to Bylvay in Italy - Albireo Pharma announced that the Italian Medicines Agency, also known as Agenzia Italiana del Farmaco, or AIFA, has enabled reimbursed access to Bylvay, or odevixibat, for the treatment of all types of progressive familial intrahepatic cholestasis, PFIC, patients in Italy. A potent, oral, once-daily, non-systemic ileal bile acid transport inhibitor, Bylvay has minimal systemic exposure and acts locally in the small intestine as a treatment for PFIC, a rare and devastating disorder that causes progressive, liver disease. Patients with PFIC have impaired bile flow, or cholestasis, and the resulting bile build-up in liver cells causes life-threatening liver disease and symptoms, such as intense itching, poor sleep, delayed growth, and diminished quality of life.
TNYA

Hot Stocks

08:16 EDT Tenaya Therapeutics announces FDA clearance of IND for TN-301 - Tenaya Therapeutics announced clearance of its Investigational New Drug application to begin clinical testing of TN-301 by the U.S. Food and Drug Administration. TN-301 is Tenaya's highly selective small molecule inhibitor of histone deacetylase 6, initially being developed for the potential treatment of heart failure with preserved ejection fraction. Tenaya has initiated its first-in-human Phase 1 clinical trial of TN-301 in healthy adult participants. HFpEF is a complex syndrome with many contributing causal factors and is estimated to affect more than three million people in the U.S. alone.1 It is a disease that involves systemic inflammation, left ventricular hypertrophy, fibrosis, and diastolic dysfunction, resulting in high morbidity and mortality. In preclinical studies, Tenaya's proprietary HDAC6 inhibitors have shown evidence of improvements in multiple parameters of HFpEF, including reducing inflammation, normalizing metabolic dysfunction and improving diastolic dysfunction2, all of which have been linked to the pathogenesis of the disease. The IND clearance was based on preclinical studies that characterized the safety and mechanistic profile of TN-301. Tenaya's Phase 1 randomized, double-blind, placebo-controlled clinical study is designed to evaluate the safety and tolerability of escalating oral doses of TN-301. Secondary objectives of the study will be to assess pharmacokinetics and pharmacodynamics measures. The Phase 1 trial will enroll healthy adult participants in two stages. In Stage 1, participants will receive single ascending doses of either TN-301 or placebo. Based on emerging data from the SAD portion of the study, including PD evidence of target engagement, participants in Stage 2 will receive multiple ascending doses of TN-301 at dose levels of interest to help guide dosing in future studies.
LSEA

Hot Stocks

08:16 EDT Landsea Homes closes on 136 acres of land - Landsea Homes announced that it has closed on approximately 136 acres of land made up of 461 homesites for a new community called Wildera in Pinal County, Arizona. "As our growth continues in Arizona, we are excited about extending our presence into the San Tan Valley area of Pinal County where Landsea Homes will offer high quality, attainably priced homes with great community amenities," said Kaylee Smith, Arizona Division President, Landsea Homes. "Wildera will be Landsea Homes' first master planned community in this region, with robust recreational and cultural opportunities. We know home buyers will experience a great overall quality of life and we look forward to providing them with an opportunity to 'Live in their Element' in the near future." Development is expected to begin immediately, with the grand opening slated for December 2023.
LCFY

Hot Stocks

08:15 EDT Locafy acquires Jimmy Kelley Digital - Locafy announced that it has acquired Jimmy Kelley Digital, a marketing firm led by SEO and e-commerce specialist Jimmy Kelley. In conjunction with the acquisition, Kelley will join Locafy as its new Global Head of Search Technology, effective immediately. Kelley is a highly regarded SEO traffic expert who specializes in organic search innovation on several data platforms. An industry thought leader, Kelley brings to Locafy over 20 years of experience in highly competitive internet markets, including eight years spent developing e-commerce marketing strategies. Jimmy Kelley Digital, headquartered in Austin, TX, has a proven track record of positive impact for its clients.
SPG

Hot Stocks

08:14 EDT Clip collaborates with Simon Property for ClipDrops network - Clip Money announced a strategic collaboration with Simon. Under the agreement, Clip has set up a network of ClipDrops, which are free-standing, secure, self-service boxes located in malls and at large retailers where retail customers can quickly and safely deposit cash and coin. Clip is currently located in 130 Simon centers, with additional units to be installed this year, including premier properties such as King of Prussia, Sawgrass Mills, Del Amo Fashion Center, The Galleria and Roosevelt Field.
RAAS

Hot Stocks

08:14 EDT Cloopen announces substantial completion of Independent Internal Investigation - Cloopen Group Holding announced that the independent special committee of the Company's Board of Directors has substantially completed its independent internal investigation into the issues disclosed in the press release issued by the Company on May 3, 2022. As previously announced, the Company's Board of Directors formed the Special Committee to oversee the Independent Investigation of the employee misconduct and transaction irregularities that were raised to the Board's attention by KPMG Huazhen LLP, the Company's previous independent registered public accounting firm, during its audit of the Company's consolidated financial statements for the fiscal year ended December 31, 2021. The Independent Investigation generally covers the fiscal year 2021. For certain large customer accounts, relevant evidence in the fiscal years 2018 to 2020 was also reviewed. Based on the assessment from the Independent Investigation, the Special Committee has found that, as a result of the uncovered employee misconduct and transaction irregularities, the Company's reported revenues were inflated by approximately RMB11.6 million in the second quarter of the fiscal year 2021 and by approximately RMB17.8 million in the third quarter of the fiscal year 2021, representing approximately 4% and 6% of its reported total revenues in the same period, respectively. The Company's reported costs and expenses were inflated by approximately RMB9.2 million in the second quarter of the fiscal year 2021 and by approximately RMB1.8 million in the third quarter of the fiscal year 2021. The Company would also fall significantly below its previously announced revenue guidance on the fourth quarter of the fiscal year 2021. The financial impact and the affected historical financial statements remain subject to the review by the Company's incumbent auditors. The Independent Investigation did not uncover any evidence indicating that the Company's chief executive officer or chief financial officer had participated in the employee misconduct and transaction irregularities. The Company has taken significant remedial measures, including, among others, discontinuing certain implicated business department, and terminating, requesting the resignation of, or giving disciplinary warnings to relevant employees.
NGM

Hot Stocks

08:14 EDT NGM reports preliminary findings from Phase 1a study of NGM120 drug candidate - NGM Biopharmaceuticals announced that updated preliminary findings from its open-label Phase 1a dose escalation study of NGM120, a novel GFRAL antagonist antibody drug candidate, in a subset of patients with advanced prostate cancer will be presented at the European Society for Medical Oncology, or ESMO, Annual Congress on Sunday, September 11. These results demonstrate that treatment with NGM120 was well tolerated to date in the study with no dose-limiting toxicities and provide encouraging signals of anti-cancer activity in patients with advanced prostate cancer. The poster titled "Initial Results of a Cohort of Advanced Prostate Cancer Patients in a Phase 1a Study of NGM120, a First-in-class Anti-GDNF Family Receptor Alpha Like antibody" is available to conference attendees for the duration of the ESMO Annual Congress and will be archived on the 'Presentations and Publications' page of NGM Bio's website.
NXPL

Hot Stocks

08:13 EDT NextPlat, Progressive Care complete strategic transaction - Progressive Care announced that it has successfully completed a recapitalization of its debt and a strategic investment by NextPlat. Dawson James Securities served as the placement agent for this transaction. Under the agreement, Progressive Care received an aggregate gross proceeds of $6 million from NextPlat in exchange for the issuance to NextPlat of 3,000 units of Series B Preferred Stock as well as warrants to purchase up to 3,000 shares of Series B Preferred Stock at an exercise price of $2,000 per share. In addition, NextPlat, NextPlat's Executive Chairman and CEO, Charles M. Fernandez, board member, Rodney Barreto, and certain other investors purchased approximately $2.8 million of outstanding convertible debt in Progressive Care. Progressive Care and the other purchasers of the debt agreed to modify the debt so as to fix the conversion price of the debt at $0.02 per share, to reduce the interest rate from 10% to 5% per annum, and to extend the maturity date to August 31, 2027. In addition, Charles Fernandez, NextPlat's CEO and Chairman of the Board, will be appointed as the Chairman of Progressive Care's Board of Directors joined by Rodney Barreto, Director of NextPlat, as Co-Vice-Chairman. Alan Jay Weisberg, CEO, and Chairman of the Board of Progressive Care, will assume the position of Co-Vice-Chairman of the Board while continuing to serve as the CEO of the company.
TCON RWAY

Hot Stocks

08:12 EDT Tracon Pharmaceuticals announces $35M debt financing - TRACON Pharmaceuticals announced entry into a $35 million non-dilutive long-term debt facility with Runway Growth Capital, a leading provider of loans to venture and non-venture backed companies seeking non-dilutive capital. $10 million of the $35 million loan was funded upon closing. The additional $25 million available under the facility may be funded upon achievement of certain clinical milestones and at Runway's discretion. The loan has a 24-month interest-only period followed by 24 monthly payments of principal and interest. In connection with the debt financing, TRACON issued Runway warrants to purchase up to 150,753 of its common stock at an exercise price of $1.99 per share Proceeds from the facility will be used to support the ongoing pivotal ENVASARC trial and for general corporate purposes.
EIGR

Hot Stocks

08:11 EDT Eiger provides update on planned EUA application for peginterferon lambda - Eiger BioPharmaceuticals provided an update on the status of its planned request for emergency use authorization, EUA, of peginterferon lambda for the treatment of patients with mild-to-moderate COVID-19 based on its most recent communications with the U.S. Food and Drug Administration, FDA. Following a cooperative and extensive pre-EUA information exchange with FDA regarding the Phase 3 TOGETHER study of peginterferon lambda for COVID-19, the agency has indicated that it is not yet able to determine whether the criteria for the submission of an application and issuance of an EUA are likely to be met. FDA has indicated that it will consider any new information and data from the TOGETHER study to support an EUA as well as the company's plans for the further development of peginterferon lambda for COVID-19. Eiger remains in active dialogue with FDA and will provide additional information to the agency that the company believes could be supportive of an EUA. "We appreciate the active dialogue with FDA and remain committed to continued engagement with the agency to obtain the necessary alignment to submit our EUA application for peginterferon lambda," said David Cory, President and CEO, Eiger. "Given its unique mechanism of action and the ongoing need for effective COVID-19 therapeutics, making peginterferon lambda available for patients remains a priority for Eiger."
ENPH

Hot Stocks

08:11 EDT Enphase Energy expands global relationship with BayWa - Enphase Energy announced that Enphase has expanded its global relationship with renewable energy company BayWa, a leading global developer and solar photovoltaic, or PV, distributor, to distribute Enphase's IQ7 family of microinverters and IQ Batteries in Germany and Benelux. IQ7, IQ7+, and IQ7A Microinverters leverage Enphase's software-defined architecture and semiconductor integration for excellent reliability and economies of scale.
BKR

Hot Stocks

08:10 EDT Baker Hughes simplifies organization, expects $150M in cost reductions - Baker Hughes Company has announced it is restructuring and simplifying its organization and accelerating its strategic transformation. These changes will simplify operations, enhance profitability, and drive growth, meeting customer needs and producing solutions in the rapidly evolving energy and industrial markets. Baker Hughes is restructuring its four product companies to focus on two reporting business segments and streamlining its corporate structure, which is expected to deliver at least $150 million in cost savings and form the baseline for further margin improvement. Effective October 1, the Company will be formally restructured into two reporting business segments: Oilfield Services & Equipment integrates the current Oilfield Services and Oilfield Equipment product companies. Industrial & Energy Technology integrates the current Turbomachinery & Process Solutions and Digital Solutions product companies. After identifying OFSE and IET as the two broad business areas in 2021, Baker Hughes has carefully evaluated all aspects of the Company's long-term strategy, its corporate performance, organizational structure, and the market outlook across its businesses. This transformation is the next step in the Company's journey to create the pre-eminent energy technology company, positioning for the changes unfolding across the energy landscape. Baker Hughes will also be making changes to its management team reporting to Lorenzo Simonelli. Effective October 1: Maria Claudia Borras is executive vice president of OFSE. Borras previously served as EVP of OFS since 2017. Rod Christie is EVP of IET. Christie previously served as EVP of TPS since 2017. Jim Apostolides is senior vice president (SVP) of enterprise operational excellence, a newly-created role to drive better coordination and alignment of key operational areas. Apostolides will oversee the Company's consolidated Supply Chain Centers of Excellence; Health, Safety, Environment, and Quality and Environmental, Social, and Governance functions. He previously served as SVP of enterprise excellence and has been with the Company for 23 years.
BTOG

Hot Stocks

08:09 EDT Bit Origin appoints Lianfei Du as Exceutive Vice President - Bit Origin announced that the Company's board of directors has appointed Lianfei Du as the Executive Vice President, effective on September 1, to further support its growth strategy and accelerate its business development from perspectives of finance and operations. Du became the second female member of management at Bit Origin, furthering the Company's proactive gender equality initiatives.Du has rich experience in equity/debt investments, financial advisory, and fund operating management. Du joined the Company in December 2021 as Head of Corporate Finance and Operation. From January 2018 to December 2021, Du served as the Vice President in TCC Capital, a Hong Kong-based boutique private equity fund backed by an HK family office with assets under management of hundreds of million US dollars. As the VP at TCC Capital, Du led multiple venture capital and growth capital investment projects across various industries, including biotech, new material, fintech, and real estate.
OVV PEG

Hot Stocks

08:08 EDT Ovintiv appoints Izzo to board of directors - Ovintiv (OVV) announced that Ralph Izzo has been named as an independent member of its Board of Directors, effective September 6, 2022, and that Bruce Waterman will retire from the Board of Directors effective December 31, 2022. Izzo currently serves as the Executive Chair of Public Service Enterprise Group Incorporated (PEG), having recently retired as their Chair, President and CEO.
CEMI

Hot Stocks

08:08 EDT Chembio Diagnostics awarded $3.2M contract from CDC - Chembio Diagnostics announced it was awarded a $3.2M contract from the Centers for Disease Control and Prevention, or CDC, for the development and clinical validation of a rapid point-of-care, or POC, diagnostic test for syphilis. Chembio will undertake to develop a syphilis test and confirm assay based on its Dual Path Platform (DPP) technology and proprietary DPP Micro Reader II. The assay will be intended to simultaneously and separately detect treponemal and nontreponemal IgM and IgG antibodies. The test should require only 10 microL of fingerstick blood, serum, or plasma and produce results in under 20 minutes. Serologic tests are currently available in clinical laboratories for the detection of active syphilis, which require shipping samples to perform tests of moderate or high complexity. There is no rapid point-of-care test currently available to accomplish both screening and confirmation of active syphilis. The development of such a test should allow for rapid diagnosis of an active infection and timely patient treatment, thus reducing the overall burden of syphilis in the U.S.
TFC TCBI

Hot Stocks

08:07 EDT Truist Financial announces acquisition of BankDirect Capital Financal - Truist Insurance Holdings, a subsidiary of Truist Financial Corporation (TFC), announced that it has signed a definitive agreement to acquire BankDirect Capital Finance from Texas Capital Bancshares (TCBI). After the closing, BankDirect will operate as a division of AFCO Credit Corporation, Truist Insurance Holdings' existing premium finance operation in the U.S. The transaction will add over $3B in loans to Truist Insurance Holdings' premium finance business-which also includes CAFO Inc., its Canadian operation-while broadening its business into the life insurance arena. The transaction is expected to close in the fourth quarter of 2022, subject to satisfaction of customary closing conditions. "This strategic investment increases the breadth of our insurance capabilities and demonstrates our continued commitment to the growth of Truist Insurance Holdings," said Truist Chairman and CEO Bill Rogers. "The addition of BankDirect expands our team, further diversifies the risk management solutions we can provide our clients and creates new opportunities to fulfill our purpose to inspire and build better lives and communities."
OSPN

Hot Stocks

08:07 EDT OneSpan appoints Jorge Garcia Martell CFO - OneSpan announced that Jorge Garcia Martell has been appointed as the Company's Chief Financial Officer, effective September 6. Mr. Martell replaces Jan Kees van Gaalen, who concluded his role as the Company's Interim Chief Financial Officer concurrently with Mr. Martell's appointment.
TSE

Hot Stocks

08:06 EDT Trinseo announces $200M share repurchase program - Trinseo announced that its board of directors authorized a new share repurchase program of up to $200M of its ordinary shares, subject to certain parameters defined by the board of directors. This new authorization, which expires in 18 months, follows the repurchase of the full $200M authorization from December 2021. All repurchases will be carried out by way of redemption in accordance with Irish law and the company's constitutional documents.
ENLV

Hot Stocks

08:06 EDT Enlivex Therapeutics receives notice of allowance for patent related to Alocetra - Enlivex Therapeutics announced that the U.S. Patent and Trademark Office issued a Notice of Allowance for patent application number 15/551,284. Once issued, the resulting patent will provide Enlivex with added intellectual property protection through at least 2036 with claims covering methods of using Allocetra to inhibit or reduce cytokine release syndrome in patients undergoing chimeric antigen receptor, or CAR, T-cell therapy. The Company expects that this new patent will be issued in the United States by the end of the Q1 of 2023. CAR T cells are T cells that have been genetically engineered to include a receptor that allows them to specifically target and destroy cancerous cells. While several CAR T cell treatments were recently approved by the FDA in several cancer indications, such treatments have been associated, in many patients, with a side effect named cytokine release syndrome, which describes a collection of potentially severe or life-threatening symptoms that stem from over-activation of immune pathways.
ICNAF

Hot Stocks

08:05 EDT Icanic Brands appoints Micah Anderson as CEO - Icanic Brands Company announces the appointment of Micah Anderson to the position of CEO of the Company. Mr. Anderson founded and is the CEO of LEEF Holdings Inc. which was acquired by Icanic on April 21, 2022. In conjunction with Mr. Anderson's appointment, Brandon Kou, the Company's current CEO has resigned from his position.
STR MNRL

Hot Stocks

08:04 EDT Sitio Royalties, Brigham Minerals to combine in $4.8B all-stock merger - Sitio Royalties (STR) and Brigham Minerals (MNRL) announced that they have entered into a definitive agreement to combine in an all-stock merger, with an aggregate enterprise value of approximately $4.8B based on the closing share prices of STR and MNRL on Friday, September 2. Under the terms of the definitive merger agreement, Brigham shareholders will receive a fixed exchange ratio of 1.133 shares of common stock in the combined company for each share of Brigham common stock owned on the closing date, and Sitio's shareholders will receive one share of common stock in the combined company for each share of Sitio common stock owned on the closing date. Brigham's and Sitio's Class A shareholders will receive shares of Class A common stock in the combined company, and Brigham's Class B and Sitio's Class C shareholders will receive shares of Class C common stock in the combined company as merger consideration. Based on the exchange ratio and the closing price of Sitio's Class A common stock on September 2, the combined company would have an aggregate enterprise value of $4.8B. Upon completion of the transaction, Sitio shareholders will own approximately 54% and Brigham shareholders will own approximately 46% of the combined entity on a fully diluted basis. The transaction has been unanimously approved by the boards of directors of both companies. Funds managed by Kimmeridge, Blackstone and Oaktree, which own 43.5%, 24.8% and 15.4% of the outstanding shares of Sitio, respectively, have entered into support agreements to vote in favor of the transaction. The closing of the merger, which is expected to occur in the first quarter of 2023, is subject to customary closing conditions, including regulatory clearance and approvals by the shareholders of Sitio and Brigham. Sitio intends to continue paying its quarterly cash dividend and Brigham intends to pay both its fixed and variable quarterly dividend through closing of the transaction. Following the completion of the merger, the combined company's board of directors will consist of nine members, including five members nominated by Sitio and four members nominated by Brigham. Noam Lockshin, the current chairman of Sitio's Board, will serve as chairman of the board of directors of the combined company. The combined company, which will operate under the name Sitio Royalties Corp, will be led by Sitio's current executive leadership team and be headquartered in Denver, Colorado.
CRNX

Hot Stocks

08:04 EDT Crinetics presents long-term safety, efficacy data on paltusotine - Crinetics Pharmaceuticals announced that Monica R. Gadelha, MD, PhD, professor of endocrinology at the Medical School of the Universidade Federal do Rio de Janeiro and a principal investigator in the Phase 2 ACROBAT program, presented new data from the planned two-year interim analysis of the ACROBAT Advance open label extension study at the 35th Brazilian Congress of Endocrinology and Metabolism. These results show that paltusotine, an investigational compound, lowered and maintained insulin-like growth factor-1 at levels comparable to prior injected SRL therapy for up to 103 weeks in participants living with acromegaly. This was seen in all subsets of participants representing a range of baseline disease control. Paltusotine was well tolerated with a safety profile similar to that of injected SRLs, including when used in combination with adjunctive therapy. Following the conclusion of the Evolve and Edge studies, 88% of the eligible participants opted to continue into the Advance OLE study. In addition, 89% of participants who had completed 52 weeks of treatment or had discontinued treatment selected once-daily oral paltusotine as their preferred treatment option over injected SRLs.
BF.A BF.B

Hot Stocks

08:04 EDT Brown-Forman to purchase the Gin Mare brands, no terms - Brown-Forman announced it has reached an agreement to purchase the Gin Mare brands from Vantguard and MG Destilerias. Upon completion of the transaction, Brown-Forman will add Gin Mare and Gin Mare Capri to its growing portfolio. Gin Mare, the world's No. 1 ultra-premium gin, is a Spanish gin with a Mediterranean-inspired recipe of botanicals, including Arbequina olives, thyme, rosemary, and basil. Gin Mare Capri, introduced last year, is made with Italian bergamot and lemons, along with Gin Mare's four principal botanicals. "Gin Mare and Gin Mare Capri are unique gin brands with impressive sales growth and strong distribution in important European markets. They are excellent complements to Brown-Forman's super-premium portfolio," said Lawson Whiting, President and CEO, Brown-Forman Corporation. "We believe this exciting acquisition enhances our capacity to deliver meaningful global growth for the long term." Gin Mare was founded in 2010 by the Giro Family of MG Destilerias and Alfonso Morodo and Antonio Pardo of Vantguard. Today, it is sold in more than 70 countries and is the largest ultra-premium gin brand in the world according to IWSR.
GEG

Hot Stocks

08:03 EDT Great Elm Group appoints Nichole Milz as COO - Great Elm Group announced Nichole Milz has joined the Company as COO, responsible for managing the operations of the Company and its portfolio companies. Milz' responsibilities include developing and overseeing an institutional quality operations department at Great Elm to support the growth of its investment management business. Milz joins Great Elm Group with over 20 years of experience in the asset management industry. Most recently, Milz spent 16 years at Magnetar Capital where she worked in various senior operations, finance and strategy roles. At Magnetar, she served as Deputy COO and ESG Officer of the Energy and Infrastructure Group as well as a member of the Energy & Infrastructure management committee. Milz also served as Treasurer of Star Peak Energy Transition Corp. and Star Peak Corp. II, two alternative energy-focused Special Purpose Acquisition Corporations.
STR MNRL

Hot Stocks

08:02 EDT Sitio Royalties, Brigham Minerals to combine in all-stock merger valued at $4.8B
TCRT

Hot Stocks

08:02 EDT Alaunos Therapeutics announces early findings from TCR-T Library Phase 1/2 trial - Alaunos Therapeutics announced early clinical findings from its ongoing TCR-T Library Phase 1/2 trial. The TCR-T Library Phase 1/2 trial is an open label, dose escalation study being conducted at The University of Texas MD Anderson Cancer Center. The trial is enrolling patients with non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers that have a matching human leukocyte antigen, or HLA, and hotspot mutation pairing in Alaunos' TCR library. The first patient dosed was diagnosed with non-small cell lung cancer with a KRAS G12D mutation, matching one of the ten TCRs within the Company's TCR library. The patient received TCR-T cells, which were produced using Sleeping Beauty at the Company's in house cGMP manufacturing facility. The patient had a confirmed objective partial response. The Company has dosed a second patient in the study, diagnosed with colon cancer, who has been treated at the second dose level and has cleared the 28-day safety window. Data is scheduled to be presented during a proffered talk at CICON, which is being held in New York, NY from September 28 - October 1.
GSK

Hot Stocks

07:54 EDT GSK plc announces WHO grants prequalification to Mosquirix malaria vaccine - GSK plc announced that the World Health Organization, or WHO, has awarded prequalification to Mosquirix, GSK's malaria vaccine. "This is the first prequalification for a malaria vaccine and is an important step in rolling out the vaccine in countries with moderate to high P. falciparum malaria transmission. The WHO prequalification decision is a mandatory prerequisite for United Nations agencies, such as UNICEF, to procure the vaccine in partnership with Gavi, the Vaccine Alliance, and eligible countries. Pre-qualification for Mosquirix is the result of a rigorous regulatory process with the assessment of clinical, safety and technical data ensuring that the vaccine meets standards of quality, safety and efficacy, and is suitable for the target population," the company stated.
CAMT

Hot Stocks

07:53 EDT Camtek receives 9 systems orders from tier-1 customers for delivery in 2023 - Camtek announced that it has received orders for 9 systems from a Tier-1 OSAT and 8 systems for Heterogenous Integration applications from two Tier-1 players. In total, Camtek received orders for 35 new systems since the beginning of August. Most of the orders will be delivered in the first half of 2023. Rafi Amit, Chief Executive Officer, commented, "I am very happy with these orders, which demonstrate a continuous order momentum into the first half of 2023. Most of them are repeat orders, showing a vote of confidence from our customers. The systems will mainly be used for the inspection and metrology of Advanced Packaging and Heterogenous Integration applications supporting the technology advancements and change in our industry."
AEHA OCEA

Hot Stocks

07:51 EDT Aesther Healthcare, Ocean Biomedical announce discovery of bispecific antibodies - Ocean Biomedical and Aesther Healthcare Acquisition announced the discovery of bispecific antibodies that target Chitinase 3-like-1 and immune checkpoint inhibitors, killing glioblastoma cells and melanoma cells, and blocking the metastasis of malignant melanoma cells to the lung by over 90%. Glioblastoma multiforme is a deadly type of brain tumor and 5-year survival is just 8% for those aged 45-54. About 25% of GBM patients are not actively treated due to rapid disease progression. Malignant melanoma, the most serious skin cancer, can metastasize to other organs. Once it has spread to other organs it is difficult to treat. Metastatic melanoma has 22.5% five year survival. Non-small cell lung cancer is a major unmet medical need that accounts for 85% of pulmonary malignancies and effects approximately 450,000 individuals. In greater than 50% of affected patients the tumors are diagnosed at advanced stages with metastatic spread that precludes curative surgical resection. The companies said, "Recent studies from our laboratory have demonstrated that CHI3L1 is a critical regulator of a number of key cancer-causing pathways. We have highlighted its ability to inhibit tumor cell death, its inhibition of the expression of the tumor suppressors P53 and PTEN and its stimulation of the B-RAF protooncogene. Most recently we have discovered that CHI3L1 is a "master regulator" of ICPI including key elements of the PD-1 and CTLA4 pathways. In accord with the importance of these pathways we have also generated antibodies: a monoclonal antibody against CHI3L1, and bispecific antibodies that simultaneously target CHI3L1 and PD-1 or CTLA4. The impressive ability of our bispecific antibodies to control primary and metastatic lung cancer in murine experimental modeling systems is discussed below. We generated bispecific antibodies that simultaneously target CHI3L1 and PD-1 or CTLA4. We then compared their effects in experimental models in which T cells and tumor cells are cultured together and in a murine model of lung metastasis. In all cases we compared the effects of the bispecific antibody to control antibodies, and to individual monospecific antibodies against CHI3L1, PD-1 or CTLA4, alone or in combination and the results are shown in the figures below. In the coculture system, critical immune regulating cells called T cells were placed in culture with cancer cells. The ability of the antibodies to induce T cell differentiation and kill of the tumor cells were then evaluated. As can be seen in Figure 1 below, tumor cell death was not induced by isotype control antibodies, and modest degrees of tumor cell apoptosis were seen in cultures with monospecific antiCHI3L1, antiPD-1 or antiCTLA4 individually. Additive tumor cell death was seen when antiCHI3L1 was administered in combination with antiPD-1 or and CTLA4 alone. Most importantly, highly impressive synergistic tumor cell death was seen when the cocultures were treated with the bispecific antibodies. In all cases the cell death that was induced was due to T cell differentiation into CD8+ cytotoxic T cells. In the murine metastasis model we administered malignant melanoma cells into the murine circulation and evaluated their spread to the lungs and pleural surface by counting the number of black staining pleural metastasis. Tumor metastasis were readily appreciated in lungs from mice treated with isotype control antibodies, and modest decreases in metastasis were seen in lungs from mice treated with monospecific antiCHI3L1, antiPD-1 or antiCTLA4 individually. Additive inhibition of tumor spread was seen when antiCHI3L1 was administered in combination with antiPD-1 or and CTLA4. Most importantly, highly impressive synergistic inhibition of tumor metastasis was seen in lungs from mice treated with the bispecific antibodies."
IMO APD

Hot Stocks

07:47 EDT Imperial Oil announces long-term contract with Air Products - Imperial (IMO) announced a long-term contract with Air Products (APD) to supply low-carbon hydrogen for Imperial's proposed renewable diesel complex at its Strathcona refinery near Edmonton, Alberta. Air Products will provide pipeline supply from its hydrogen plant under construction in Edmonton. Imperial will use Air Products' low-carbon hydrogen to produce renewable diesel at Strathcona that substantially reduces greenhouse gas emissions relative to conventional production. The hydrogen and biofeedstock will be combined with a proprietary catalyst to produce premium low-carbon diesel fuel. Air Products is increasing overall investment in its Edmonton hydrogen facility to CAD $1.6B to support the Imperial contract. The additional investment by Air Products will be used to facilitate integration with Imperial's proposed project that is expected to enable further significant emissions reductions at Air Products' overall complex. Air Products will supply Strathcona with approximately 50% of the low-carbon hydrogen output from the 165M standard cubic feet per day hydrogen production complex.
IMO APD

Hot Stocks

07:47 EDT Imperial Oil awards hydrogen contract to Air Products - Imperial (IMO) announced a long-term contract with Air Products (APD) to supply low-carbon hydrogen for Imperial's proposed renewable diesel complex at its Strathcona refinery near Edmonton, Alberta. Air Products will provide pipeline supply from its hydrogen plant under construction in Edmonton. "Our agreement with Air Products is an important milestone as we progress plans to build the largest renewable diesel manufacturing facility in Canada," said Jon Wetmore, Imperial's vice president of downstream. "This project highlights Imperial's commitment to investing in a lower carbon future. We continue to progress discussions with our business partners and governments as we work toward a final investment decision in the months ahead." Imperial will use Air Products' low-carbon hydrogen to produce renewable diesel at Strathcona that substantially reduces greenhouse gas emissions relative to conventional production. The hydrogen and biofeedstock will be combined with a proprietary catalyst to produce premium low-carbon diesel fuel.
SAWLF

Hot Stocks

07:41 EDT Shawcor sells Lake Superior Consulting business for C$8M in gross proceeds - Shawcor announced that it has sold its Lake Superior Consulting operating unit to a private investment group, including members of LSC management, in a transaction generating approximately C$8 million in gross proceeds. The LSC business, reported within the Company's Pipeline and Pipe Services segment, offers engineering, consulting and field inspection services to the US onshore pipeline and broader energy infrastructure markets. It generated revenue of approximately C$59 million with neutral adjusted EBITDA during the full year of 2021 and generated revenue of approximately C$26 million with an adjusted EBITDA loss of C$1 million during the first half of 2022. Proceeds from the sale will be used to reduce the Company's existing indebtedness. With the completion of this transaction, the Company's PPS reporting segment now consists of two operating units: the Pipeline Performance Group business, which provides pipeline coating solutions; and the Integrity Management business, which provides non-destructive testing solutions to the US onshore and global offshore markets.
SKE

Hot Stocks

07:40 EDT Skeena Resources reports results from exploration programs at Eskay Creek - Skeena Resources announced the first drilling results from the 2022 regional and near mine exploration programs at the Eskay Creek gold-silver Project located in the Golden Triangle of British Columbia. Analytical results from the recently completed drill holes are detailed in this release. New 2022 Exploration Program Highlights include 1.66 g/t Au, 1.7 g/t Ag over 31.30 m; 2.97 g/t Au, 3.0 g/t Ag over 17.66 m; 2.27 g/t Au, 2.3 g/t Ag over 21.00 m. Expanding upon the in-pit mineralization discovered in 2021 by drill hole SK-21-997 which intersected high-tenor gold mineralization averaging 8.78 g/t Au, 13 g/t Ag over 34.00 m, the Company reports that 2022 drill hole SK-22-1093 has predictably lengthened the Rhyolite-hosted 21A West Zone with a new high-grade interval averaging 47.50 g/t Au, 73.4 g/t Ag over 12.12 m. Occurring entirely within the intended open-pit, 75 metres north of SK-21-997 at a vertical depth of only 50 metres below surface, this area of the Resource was never populated by previous drilling and as such was modelled as barren waste rock. Analytical results for three other 2022 drillholes within this 75-metre gap are pending. The Rhyolite-hosted mineralization within 21AW is not characterized by elevated concentrations of the epithermal suite of elements as is the case with the Contact Mudstone hosted mineralization. The limited drilling to date in 21AW indicates that precious metal grades typically increase vertically up stratigraphy with closer proximity to the Contact Mudstone. "The new results from the Rhyolite-hosted synvolcanic feeders clearly validate the predictability and robustness of our geological thesis", notes Paul Geddes, the Company's Senior Vice President of Exploration and Resource Development.
TITUF

Hot Stocks

07:39 EDT CVW Cleantech appoints Akshay Dubey as CEO - CVW CleanTech announced the appointment of Akshay Dubey as CEO effective September 14, 2022. Mr. Dubey will relocate to Calgary from November 1, 2022 and lead the Company into the next phase of its evolution, as it focuses on commercializing its patented oil sands reprocessing technologies and applying a unique financial structure to a rapidly growing clean tech industry. In addition, Mr. Dubey will be appointed to the Board of Directors .Mr. Dubey, previously reported directly to the Board of Directors of BaseCore Metals which he led since its inception and was recently sold for $525M.
CPE

Hot Stocks

07:38 EDT Callon Petroleum publishes 2021 Sustainability Report - Callon Petroleum announced the publication of the Company's 2021 Sustainability Report, titled Shaping Our Future. This report is the Company's third report and provides a comprehensive overview of Callon's continued progress on its sustainability initiatives as well as its partnership with the communities where it operates. Achievements and highlights from Callon's 2021 Sustainability Report include: 2021 Achievements: 11% Reduction in GHG emissions intensity for legacy Callon; 2% reduction in overall GHG emissions intensity, including initial impact of acquired Delaware Basin assets; 49% reduction in flare rate; 24% reduction in total fluid spill rate; 19% reduction in hydrocarbon spills to the environment; 65% of new hires identified as female, racially or ethnically diverse, or both; 83% participation rate in new Employee Development Plan; 21% increase in percent of women in above-field workforce
SPNS

Hot Stocks

07:37 EDT Sapiens selected by AEGIS to automate, modernize reinsurance process - Sapiens International announced that AEGIS, a leading mutual insurance company, has selected Sapiens ReinsurancePro to enhance their internal controls processes, automated calculations and reporting. Sapiens ReinsurancePro replaces AEGIS' complex combination of disparate custom applications and spreadsheets to streamline and optimize processes. "We are very pleased to empower AEGIS in their quest for full financial control of the reinsurance processes and to enable them to increase efficiency by streamlining the process," said Jamie Yoder, Sapiens North America President & General Manager. "Our platform enables AEGIS to take ownership of their data and proactively conduct analysis on that data instead of relying on IT or external parties, so they can better serve their customers."
DCFC

Hot Stocks

07:37 EDT Tritium enters $150M debt facility, $75M commited equity facility - Tritium DCFC announced entry into a $150 million debt facility, provided by a consortium of investors, in addition to a committed equity facility established with B. Riley Principal Capital II, LLC, for up to $75 million. This capital injection will be used to fund working capital, product development, and operational support and expansion. The working capital will position the Company to accelerate production and satisfy the large number of orders on hand from the Company's diversified blue-chip customer base. In addition to tremendous EV industry growth over the past year backed by government incentives and carbon reduction targets, Tritium continues to see high demand from new and existing customers across the globe as the Company continues its growth trajectory and expansion in the Americas, Europe, and Asia. The $150 million senior debt facility will refinance the existing $90 million facility and provide a net injection of $60 million. The facility has a three-year term and 8.5% cash coupon supplemented with the issuance to the lenders or their affiliates of warrants for the purchase of ordinary shares of the Company. The consortium providing the facility comprises long-term supporter Cigna Investments, the investment arm of Cigna Corporation, a U.S.-based global health services company, in addition to Barings LLC, a leading global financial services firm and subsidiary of MassMutual, a U.S.-based mutual insurance company, and Riverstone Energy Limited.
VHIBF

Hot Stocks

07:36 EDT Vitalhub subsidiary signs licensing agreement with West London NHS Trust - VitalHub reports that subsidiary, S12 Solutions, has signed a multi-year licensing agreement with West London NHS Trust, resulting in all nine London Trusts having now commissioned S12 Solutions. West London NHS Trust has signed a multi-year contract with S12 Solutions to help the Trust move towards its goal to digitally transform paper-based processes. The license features the S12 Solution platform, notably including the electronic statutory Mental Health Act forms. Local authorities also involved in the project include: Ealing Council, Hammersmith and Fulham Council, Hounslow Borough Council. With this contract, all nine London Mental Health Trusts have now commissioned the use of S12 Solutions.
SNGX

Hot Stocks

07:36 EDT Soligenix announces US FDA awarded OPD grant for study of HyBryte - Soligenix announced that the U.S. Food and Drug Administration, FDA, has awarded an Orphan Products Development, OPD, grant to support the evaluation of HyBryte for expanded treatment in patients with early-stage CTCL. The grant, totaling $2.6M over 4 years, was awarded to a prestigious academic institution that was a leading enroller in the recently published positive Phase 3 FLASH study in the treatment of early stage cutaneous T-cell lymphoma, CTCL. "We are pleased the FDA is supporting the HyBryte program and giving patients an opportunity to access the therapy in an open-label setting," stated Christopher Schaber, President and CEO of Soligenix, Inc. "CTCL is an incredibly difficult to treat orphan disease and remains an area of unmet medical need with a very limited number of safe and effective treatment options. The Phase 3 results provide the basis for our upcoming marketing application and this study will serve to embark on potential home-use of the therapy, augment the safety database as well as provide further real-world evidence into the practical use of HyBryte once commercially available." The clinical study RW-HPN-MF-01, "Assessment of Treatment with Visible Light Activated Synthetic Hypericin Ointment in Mycosis Fungoides Patients" is designed as an open-label, multicenter clinical trial enrolling approximately 50 patients at up to six of the highest enrolling clinical centers that participated in the Phase 3 FLASH study. Patients have the potential to be treated for up to 12 months with twice a week dosing. The primary endpoint for the study will be evaluating the number of treatment successes defined as greater than or equal to50% reduction in the cumulative CAILS score from baseline to end of the treatment. Study initiation is planned for the fourth quarter of 2022.
RVLGF

Hot Stocks

07:35 EDT Revival Gold provides update of prefeasibility study for Beartrack-Arnett - Revival Gold provided an update on the status of work on a Prefeasibility Study, or PFS, for the Beartrack-Arnett Gold Project located in Lemhi County, Idaho, USA. Revival Gold has appointed Kappes Cassiday Associates, or KCA, as the lead PFS consultant focused on metallurgy, infrastructure design and overall study economic analysis with Independent Mining Consultants engaged on mineral resources and to develop PFS-level open pit designs and mine plans. KCA and IMC are US-based experts in gold heap leach mine design and operations. Technical studies in support of the PFS are progressing on track; however, with the shift in overall project management and mine planning from the Company's previous engineering consultants to KCA and IMC, respectively, completion of the PFS will be deferred to 2023. This will, however, provide time for Revival Gold to incorporate 2022's drilling into the PFS which should improve results. PFS completion is expected mid-2023. Comprehensive metallurgical work has been completed on nine 180-day column leach tests by SGS Lakefield with results indicating average gold recoveries of 82% relative to the cyanide soluble gold assay for Beartrack and 92% relative to total fire assay gold for Arnett. All column testing was completed on 38 mm crush size material. Together with existing data, these results provide further confidence in Beartrack-Arnett heap leach recovery assumptions going into the PFS. Two PFS-level geotechnical characterization studies have been completed by Wood. The open pit geotechnical study provides pit slope design criteria and identifies opportunities to further steepen pit slopes with enhanced blasting practices, while the infrastructure geotechnical study characterizes the foundation conditions for the heap leach pad, waste rock dumps, haul roads and other surface infrastructure.
ILMN

Hot Stocks

07:35 EDT Illumina intends to appeal EC's decision in GRAIL deal - Illumina received a decision from the European Commission, EC, prohibiting the company's acquisition of GRAIL. The company is reviewing the Commission's order and intends to appeal the decision. The EC decision follows last week's ruling by US Federal Trade Commission judge in favor of Illumina's acquisition of GRAIL. "We are disappointed with the European Commission's decision prohibiting us from acquiring GRAIL back to Illumina," said Charles Dadswell, General Counsel of Illumina. "Illumina can make GRAIL's life-saving multi-cancer early detection test more available, more affordable, and more accessible - saving lives and lowering healthcare costs. As we continue to believe, this merger is pro-competitive and will accelerate innovation. Last week the Chief Judge of the US Federal Trade Commission issued a decision supporting Illumina acquiring GRAIL." In addition, to prepare for the anticipated divestment order from the European Commission in the coming months, the company will begin reviewing strategic alternatives for GRAIL in the event the divestiture is not stayed pending Illumina's appeal. The merger of Illumina and GRAIL would usher in a transformational phase in the detection and treatment of cancer by facilitating equal and affordable access to the life-saving early cancer detection Galleri test. Illumina would accelerate GRAIL's commercial entry into the EU at scale by at least five years, saving tens of thousands of lives in the EU and billions of euros in healthcare costs. Illumina is separately appealing a July 2022 decision by the General Court of the European Union regarding the European Commission's jurisdiction to challenge the GRAIL deal.
ECOM

Hot Stocks

07:33 EDT CommerceHub to acquire ChannelAdvisor for $23.10 per share - CommerceHub and ChannelAdvisor announced they have entered into a definitive agreement for CommerceHub to acquire the outstanding shares of ChannelAdvisor in a transaction led by global software investor and current shareholder of CommerceHub, Insight Partners. Under the terms of the agreement, ChannelAdvisor stockholders will receive $23.10 per share in cash, representing a premium of approximately 57% over the company's closing stock price on September 2, 2022, the last full trading day prior to this announcement. The boards of directors of both companies have unanimously approved the transaction. The complementary combination of CommerceHub and ChannelAdvisor expands capabilities for brands and retailers: Brands will be able to manage their public and private marketplaces alongside their retailer connections with a single vendor; Retailers will be able to access an even larger pool of brands; Companies across the network will be able to save on delivery costs and improve delivery experiences with Delivery Suite. The proposed transaction is not subject to a financing condition and is expected to close in 2022. Upon completion of the transaction, ChannelAdvisor will become a privately held company and shares of ChannelAdvisor common stock will no longer be listed on any public market.
GLUE

Hot Stocks

07:32 EDT Monte Rosa Therapeutics announces FDA cleared IND for MRT-2359 - Monte Rosa Therapeutics announced that the FDA has cleared the company's investigational new drug application, or IND, for MRT-2359, a potent and selective GSPT1-directed MGD. The company is on track with initiating a Phase 1/2 clinical trial of MRT-2359 in patients with MYC-driven solid tumors, including lung cancer, and expects to dose the first patient in the Q4.
ABML

Hot Stocks

07:32 EDT American Battery Metals appoints Bret Meich as general counsel - American Battery Technology is pleased to announce the addition of Bret Meich as General Counsel to the company, joining as a member of the company's executive team and reporting to ABTC CEO Ryan Melsert. Prior to joining ABTC, Meich was most recently a partner at the law firm Downey Brand LLP.
THR IFF

Hot Stocks

07:28 EDT Thermon Group appoints Angela Strzelecki to board of directors - Thermon Group Holdings (THR) announced the appointment of Dr. Angela Strzelecki, President of the Pharmaceutical Solutions Division of International Flavors & Fragrances (IFF), to its board of directors. With the addition of Dr. Strzelecki, the Thermon board of directors now is composed of seven independent directors and one management director.
BUR RITM

Hot Stocks

07:26 EDT Burford Capital appoints Jordan Licht as CFO - Burford Capital (BUR) announces that Jordan Licht has been appointed as its CFO. Licht was previously the COO of both Caliber Home Loans and Newrez LLC, which recently combined under the Rithm banner (RITM). Mr Licht replaces Ken Brause, who becomes a Senior Advisor to Burford and will assist in the CFO transition and continue to contribute his experience and insight to the business. Jim Kilman, Mr Brause's predecessor as CFO, continues in his role as a Senior Adviser.
OSIIF

Hot Stocks

07:24 EDT Osino Resources announces PFS results for Twin Hills Gold Project - Osino Resources pleased to announce the results of the pre-feasibility study for Osino's Twin Hills Gold Project, which is located in central Namibia and is rapidly being advanced through accelerated exploration drilling and fast-tracked development studies. The PFS was prepared by Lycopodium Minerals Canada in accordance with National Instrument 43-101-Standards of Disclosure for Mineral Projectsand contemplates a low-risk, technically simple open-pit mine utilizing contract mining and feeding a conventional carbon-in-leach metallurgical plant processing 5 million tonnes of mineralized material per annum. Heye Daun, Osino's co-founder, President & CEO commented: "We are very pleased with the results of this PFS which demonstrates that Twin Hills is what we always said it would be, namely a long-life, low-cost and economically robust open pit gold project with significant upside. It is geologically consistent, metallurgically simple and technically low risk with a low capital intensity and significant future upside. We are proud to have been able to deliver this PFS within 3 years of discovery and our vision for the next year is to optimize and improve the project further and to continue to advance Twin Hills to the construction stage. We expect imminent, significant progress on the permitting & project financing side which will assist in continuing to fast-track the project".
HYRE

Hot Stocks

07:22 EDT HyreCar announces $100M revolving line of credit - HyreCar announced an agreement with a premier global investment bank and Medalist Partners for a $100 million warehousing line of credit. The global investment bank will provide primary financing with Medalist Partners providing $20 million of additional financing. Under the agreement, HyreCar's fleet operator partner, AmeriDrive Holdings, LLC, will use this facility to purchase vehicles for exclusive listing on the HyreCar platform through a bankruptcy-remote joint venture. Through this initial warehousing line, HyreCar expects AmeriDrive to add an additional 6,000 to 7,000 vehicles over the next 12 to 18 months to the HyreCar platform. These vehicle assets will serve as collateral under the facility. As previously indicated, the company expects this line to begin a broader facility expansion into white-labeling vehicle financing for HyreCar's fleet operators.
KC

Hot Stocks

07:22 EDT Kingsoft Cloud intends to enter enter repurchase agreement no more than $30M - Henry He, CFO of Kingsoft Cloud, added, "Our total revenues amounted to RMB1,906.5 million in the second quarter of 2022. Among which, revenues from public cloud services amounted to RMB1,289.1 million in the second quarter of 2022. As we continued to proactively scale down our CDN services, its gross billing decreased by 30% year-over-year, while computing and storage services' gross billing increased by 5% year-over-year. Revenues from enterprise cloud services amounted to RMB616.6 million, largely stable year-over-year, as we navigated through challenging operating environment which slowed down bidding and project deployment process during the second quarter. Meanwhile, to drive efficiency, we have executed cost control measures and successfully saved RMB252.6 million in total costs on a sequential basis. Despite the challenges, we remain confident about our long-term prospect and value. We are pleased to announce that we intend to enter into a repurchase agreement with potential size no more than $30 million during a 90 days window, subject to agreements to be finalized with repurchase agent. This action is pursuant to and part of the $100 million repurchase program authorized by the board and announced back in March 2022. As usual, the timing, structure and dollar amount of the repurchase will be subject to, among others, the market conditions, terms to be agreed with the relevant repurchase agent, the trading prices of ADSs, and the relevant securities rules and regulations."
CHD

Hot Stocks

07:19 EDT Church & Dwight to acquire Hero Mighty Patch for $630M - Church & Dwight has signed a definitive agreement to acquire the Hero Mighty Patch brand and other acne treatment products for $630M, consisting of cash and Church & Dwight restricted stock. The transaction, which is subject to customary closing conditions, is expected to close in the fourth quarter. Hero's net sales for the trailing twelve months through June 30 were approximately $115M. The acne patch is the fastest growing treatment form in acne. The products are currently only marketed in the U.S. Hero's trailing twelve months EBITDA as of June 30 was approximately $45M, with a 40% EBITDA margin. Church & Dwight expects to expand Mighty Patch's limited distribution by leveraging its U.S. retailer relationships and international footprint.
CME

Hot Stocks

07:19 EDT CME Group proposes to convert Eurodollar futures, options contracts - CME Group announced that based on initial client feedback, it is proposing to convert Eurodollar futures and options open interest into corresponding SOFR contracts on April 14, 2023, under the company's previously adopted fallbacks plan. Eurodollar futures and options contracts that expire before June 30, 2023 are excluded from this proposal and will continue to trade until their expiry. "Our proposed conversion date will help our clients complete their operational work as early as possible in the transition process, while closely aligning with the recently published industry timelines for over-the-counter interest rate swaps," said Agha Mirza, CME Group Global Head of Rates and OTC Products. "SOFR futures and options are now the leading liquidity pool, as open interest has reached 19 million contracts and volume has significantly outpaced Eurodollars. Based on this growth, today's announcement provides a practical timeline by which clients can bring remaining Eurodollar contracts into the SOFR market." In addition, CME Group plans to add SOFR options to its portfolio margining solution for cleared products in December 2022, subject to regulatory approval.
GILT

Hot Stocks

07:18 EDT Gilat Satellite announces orders from SES to expand SATCOM business - Gilat Satellite Networks announced that the Company was awarded multimillion-dollar orders from SES as the companies extend global strategic cooperation. SES, in cooperation with Gilat, is expanding its SATCOM business reach utilizing Gilat's SkyEdge IV multi-orbit, multi-service capabilities. These activities represent follow-on orders stemming from the strategic partnership formed with the selection of Gilat's SkyEdge IV platform for SES's second-generation medium earth orbit satellite system, O3b mPOWER, and for SES's geostationary very high throughput satellite, SES-17. SkyEdge IV is a key enabler to such business as it operates simultaneously on both GEO and the MEO constellation.
MTAL

Hot Stocks

07:18 EDT Australian FIRB approves Metals Acquisition's purchase of CSA from Glencore - Metals Acquisition is pleased to announce that it has received approval from the Australian Foreign Investment Review Board of its proposed acquisition of the CSA Copper Mine, subject to customary tax and reporting obligations No Objection from FIRB approval is a Condition Precedent to the acquisition of CSA from Glencore as announced by MAC on March 17.Mick McMullen, MAC CEO, said: "We are pleased to have satisfied this Condition Precedent under the CSA acquisition agreement as we work towards obtaining shareholder approval and finalizing the transaction. MAC's status as a foreign investor under Australian law, together with the nature of the assets being acquired from Glencore, necessitated the acquisition of CSA being subject to regulatory review in accordance with the Australian Foreign Acquisitions and Takeovers Act 1975 . The Treasurer of the Commonwealth of Australia, acting through the Australian government's FIRB organization, has confirmed that there is No Objections to the transfer of CSA and associated land so that it will be under the control and ownership of MAC. Conditions attached to the No Objection are standard and involve post-Closing tax and reporting obligations.
ENCUF

Hot Stocks

07:18 EDT enCore completes baseline wells installation, drilling at Rosita Extension - enCore Energy announced the completion and installation of all baseline wells within the uranium mineralization at the 100%-owned, fully licensed Rosita Extension Project Production Authorization Area, PAA, wellfield. In addition to establishing baseline conditions in the production area, the wells returned excellent uranium values with Grade Thicknesse ranging from 0.932 to 5.139. The Company also reports it has commenced installation of production well patterns at the Rosita Extension PAA, South Texas as the initial source of uranium feed for the Rosita Central In-Situ Recovery Uranium Processing Plant.
BCRX

Hot Stocks

07:17 EDT BioCryst reports inducement grants under Nasdaq listing rule - BioCryst Pharmaceuticals announced that the compensation committee of BioCryst's board of directors granted 17 newly-hired employees stock options to purchase an aggregate of 161,500 shares, and restricted stock units covering an aggregate of 64,250 shares, of BioCryst common stock. The options and RSUs were granted as of August 31, 2022 as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $13.90 per share, which is equal to the closing price of BioCryst common stock on the grant date. The options and RSUs vest in four equal annual installments beginning on the one-year anniversary of the grant date, in each case subject to the new employee's continued service with the company. Each stock option has a 10-year term. The options and RSUs are subject to the terms and conditions of BioCryst's Inducement Equity Incentive Plan and a stock option agreement or restricted stock unit agreement, as applicable, covering the grant.
EVAX

Hot Stocks

07:16 EDT Evaxion Biotech and UMass Chan receive grant from NIH - Evaxion Biotech announced that the Company, in collaboration with UMass Chan Medical School, has received a grant from the U.S. National Institutes of Health, or NIH, for the development of a gonorrhea lead vaccine candidate. Evaxion recently announced a new discovery project with the aim of developing a gonorrhea vaccine based on the Company's artificial intelligence platform EDEN. Chief Scientific Officer at Evaxion, Birgitte Rono, states that the scientific collaboration with UMass Chan and the grant from NIH substantiate Evaxion's capabilities within AI-based vaccine design and allow the Company to fast-track the development of a gonorrhea vaccine candidate. Evaxion's AI platform, EDEN, was used to identify novel, highly efficacious B-cell antigens to be included in the vaccine. In preclinical studies, the vaccine candidate has demonstrated protection against infection, holding great promise for future development and the patients in need.
GPL

Hot Stocks

07:16 EDT Great Panther to file a notice of intention to make proposal under Canada's BIA - Great Panther Mining reports that, with the authorization and approval of its Board of Directors, it has determined to file a notice of intention to make a proposal under Canada's Bankruptcy and Insolvency Act, BIA, today, which will provide creditor protection while the Company seeks to restructure its affairs. The decision to seek creditor protection was taken after careful consideration of available alternatives, the Company's cash position, forecasted revenue and expenses, and scheduled debt payments. The Company expects that it is likely to default on several material debtor agreements due to liquidity constraints stemming from the operational challenges previously disclosed, inflationary pressures significantly impacting costs, unforeseen but necessary capital expenditures, and contractor mobilization delays because of equipment availability issues. Following consultation with its legal and financial advisors, the Board of Directors determined that it was in the best interests of the Company and its stakeholders to file the NOI and obtain creditor protection. The Board of Directors also authorized management to seek the conversion of the BIA proceedings into proceedings under the Companies' Creditors Arrangement Act should management determine that CCAA proceedings would be more appropriate. The effect of the NOI is an immediate stay of proceedings for 30 days, which may be extended by subsequent court order. Filing the NOI will allow the Company to pursue available options to maximize the Company's value for stakeholders. Importantly, the Company will continue to operate and will remain in control of its business. While the Company is exploring strategic and financial alternatives to maximize stakeholder value in the proposed proceedings, the failure of the Company to achieve its restructuring goals through an approved proposal would result in the Company being deemed to have made an assignment into bankruptcy. Due to the above-mentioned liquidity constraints, the Company's Brazilian subsidiary, Mina Tucano, intends to enter a temporary care and maintenance period while the Company explores alternatives to maximize value for all stakeholders.
ISO

Hot Stocks

07:15 EDT IsoPlexis partners with MediMergent, CCBD for study of AZD7442 - IsoPlexis announced a partnership with MediMergent, LLC, and The Center for Cancer and Blood Disorders to leverage IsoPlexis' single-cell proteomics in a large multi-site study of immuno-compromised cancer patients. The study entitled "Real World Evaluation of the Effectiveness of AZD7442 for Prevention of COVID-19 Infection in Immuno-Suppressed Cancer Patients", will focus on immune cells' functionality and their role in prevention of COVID-19 breakthrough infections in immuno-compromised patients, following administration of AZD7442 IM or IV. IsoPlexis' platform uniquely reveals highly active cells capable of secreting multiple cytokines simultaneously. The company's single-cell proteomics technology enables researchers to identify these highly powerful single cells which correlate with immune response, therapeutic persistence, and disease outcomes. In partnership with MediMergent, which designs and deploys programs to collect Real-World Evidence used for regulatory submission and product commercialization, and CCBD, a leading community oncology practice with locations in Bethesda and Germantown, Maryland, IsoPlexis will enable researchers to uncover T cell activity and mechanisms associated with COVID-19 breakthrough infections in immuno-compromised cancer patients.
LABP...

Hot Stocks

07:14 EDT Landos Biopharma appoints Fabio Cataldi as Chief Medical Officer - Landos Biopharma (LABP) announced the appointment of Fabio Cataldi, as the Company's Chief Medical Officer, effective September 5. Cataldi has over twenty years of diverse and extensive experience in medicine and drug development in the US and Italy. He most recently served as Vice President and Therapeutic Area Head of Gastroenterology at Arena Pharmaceuticals, where he led the development of etrasimod in inflammatory bowel disease and other gastrointestinal indications and expanded the immunology portfolio. Prior to joining Arena Pharmaceuticals, Cataldi served as Team Lead of Gastroenterology and Immunology in Global Pharmaceutical Research and Development at AbbVie (ABBV). Previously, Cataldi worked at Shire as Vice President of Clinical Development in Internal Medicine/Gastroenterology, where he led the expansion of the IBD portfolio with the out licensing of the anti-MAdCAM antibody from Pfizer (PFE).
HTHIY

Hot Stocks

07:13 EDT Hitachi announces acquisition of Flexware Innovation - Hitachi announced that on August 31, 2022 it acquired Flexware Innovation, which has been a leading manufacturing Systems Integrator since 1996. Flexware Innovation was a strategic acquisition for Hitachi due to its focus on the TOTAL SEAMLESS SOLUTION that links "shop floor" and "top floor" with data and digital technology. "With this acquisition of Flexware Innovation, Hitachi will strengthen and enhance its business in the domain of MES, SCADA, Software Development, Business Intelligence, and ERP implementation capabilities in North America, and accelerate the digitalization with JR Automation which engages in the robotic SI & automation," the company said. Further, through cooperation with Hitachi Vantara which has expertise in building and deploying Enterprise and Cloud applications, Hitachi will be able to provide TOTAL SEAMLESS SOLUTION from robotic SI & automation, MES, SCADA, BI, and ERP and help manufacturing leaders increase corporate value.
FEAM

Hot Stocks

07:13 EDT 5E Advanced Metals announces inclusion in S&P/ASX 300 Index - 5E Advanced Materials announced that the Company's 5EA stock has been selected for inclusion in the S&P/ASX 300 Index by S&P Dow Jones effective before the ASX market opens on September 19, 2022.
IRWD

Hot Stocks

07:13 EDT Ironwood announces LINZESS trial met primary, secondary endpoints - Ironwood announced topline data from a Phase III clinical trial evaluating LINZESS 72 mcg in pediatric patients aged 6-17 with functional constipation, or FC. The trial met its primary and secondary endpoints, demonstrating that linaclotide improved frequency of spontaneous bowl movements, or SBM, and stool consistency. Linaclotide was generally well-tolerated, and the safety profile is consistent with previously reported studies with linaclotide in FC and irritable bowel syndrome, or IBS, in pediatric patients. In this study, a total of 330 patients were randomized in a 1:1 ratio between linaclotide or placebo. Topline data indicate that linaclotide showed a statistically significant and clinically meaningful improvement compared to placebo in 12-week SBM frequency rate, the primary endpoint. Linaclotide-treated patients demonstrated a greater than two-fold least squares mean change from baseline in SBMs/week compared to placebo. Stool consistency, as assessed by Bristol Stool Form Scale, or BSFS, scores, which was the secondary endpoint, also showed an improvement at weeks 12 with linaclotide compared to placebo. The least squares mean change from baseline at week 12 was 1.108 and 0.685 points, respectively. The BSFS is a 7-point scale ranging from 1 to 7. Overall, linaclotide was well tolerated. The most frequently reported treatment-emergent adverse event was diarrhea, which occurred in 4.3% of linaclotide-treated participants versus 1.8% in the placebo group. These data are from the FC cohort of the Phase III, multicenter, randomized, double-blind, parallel-group, safety, and efficacy study of linaclotide vs. placebo in children ages 6-17 years with FC. Participants in the FC cohort must have fulfilled modified Rome III Criteria for child/adolescent FC. Ironwood expects to share these Phase III trial data at upcoming scientific meetings and via peer-reviewed publications. LINZESS is developed and marketed by Ironwood and AbbVie in the United States and is indicated for the treatment of adults with IBS-C or CIC. It is not approved for use in patients less than 18 years of age.
TIL

Hot Stocks

07:12 EDT Instil Bio appoints Tim Moore as COO - Instil Bio announced the appointment of Tim Moore to the role of COO. Prior to Instil, Mr. Moore was the President and COO of PACT Pharma, a cell therapy company focusing on neo-antigen directed TCR-T cell therapy.
MDXG

Hot Stocks

07:11 EDT MiMedx sees FY22 AWC products sales at low end of previous outlook - The Company provided an update on its revenue outlook for 2022. For the full year ending December 31, 2022, the Company currently expects net sales of its continuing portfolio of Advanced Wound Care, or AWC, products, which were $240.0M in 2021, to be in the low end of the 11% to 14% growth range disclosed in its earnings release for the year ended December 31, 2021. Similar to other companies, the easing of COVID-19 travel restrictions has resulted in increased levels of travel and vacations at customer accounts, lower procedure volumes during the summer months for our customers, and softer sales of our products. Despite this, the Company notes it expects to report growth in total net sales, which were $63.1M in the Q3 of 2021, for the Q3 of 2022. The Company also expects net sales of its AWC products in the Q3 of 2022 to grow in the mid-single digits as a percentage compared to net sales of its AWC products in the Q3 of 2021, which were $62.3M.
AVTX

Hot Stocks

07:11 EDT Avalo Therapeutics announces AVTX-008 has entered IND-enabling studies - Avalo Therapeutics announced that its human B and T Lymphocyte Attenuator agonist fusion protein, AVTX-008, has now entered IND-enabling studies, with a target IND submission date of 2024. The company is currently evaluating a number of immune dysregulation disorders to pursue. BTLA is an immune checkpoint and a key component of the LIGHT-signaling network and complements AVTX-002, the company's fully human anti-LIGHT monoclonal antibody, currently in the Phase 2 PEAK Trial for non-eosinophilic asthma. In June 2021, Avalo acquired rights to the BTLA fusion protein technology discovered by Dr. Carl Ware and colleagues at the Sanford Burnham Prebys in La Jolla, CA. Under the terms of the agreement, Avalo obtained an exclusive license to a portfolio of issued patents and patent applications covering a lead molecule and derivatives. Avalo has identified a lead, has initiated IND-enabling activities and expects to submit an IND in 2024.
SCHL

Hot Stocks

07:10 EDT Scholastic announces acquisition of Learning Ovations - Scholastic Corporation announced that it has acquired Learning Ovations, the creator of A2i, a literacy screening, progress monitoring assessment and instructional planning system for classrooms and community organizations. The addition of A2i and the Learning Ovations team will advance the development of Scholastic Education Solutions' literacy platform. The terms of the transaction were not disclosed. "Carol Connor was a teachers' teacher, dedicated both to helping every child learn to read - regardless of background, disadvantage or learning challenge - and to supporting teachers with tools that are both deeply rigorous and easy to use," said Rose Else-Mitchell, Executive Vice President, President, Scholastic Education Solutions. "We are committed to those same values of equity, engagement and effectiveness at Scholastic. We feel privileged to continue Carol's work and welcome the mission-aligned Learning Ovations team of researchers, practitioners and technologists to Scholastic, as we continue to advance our mission to help kids learn to read, read to learn, and discover the joy in reading."
AKTS

Hot Stocks

07:10 EDT Senator Chuck Schumer tours Akoustis semiconductor fab in Upstate NY - Akoustis Technologies announced that U.S. Senate Majority Leader Charles Schumer recently toured Akoustis' semiconductor fab in Upstate New York with Akoustis founder and CEO, Jeff Shealy, Co-Chairman of the Board, Jerry Neal, and Director, Suzanne Rudy. The recently passed bipartisan Chips and Science Act of 2022 legislation was introduced by New York Senator Schumer to boost U.S. competitiveness with foreign competitors, including China, by allocating billions of dollars toward domestic semiconductor manufacturing and science research. Senator Schumer expects the CHIPS Act "will help build more resilient domestic supply chains to help lower costs for families, address inflation, and strengthen national security by manufacturing more microchips in America." Akoustis senior management has worked closely with the local, regional, and state government of New York, along with Senator Schumer's office to support the passage of the Act, which will present a significant opportunity for the revitalization of Upstate New York's semiconductor presence, and in particular, the greater Rochester area, where Akoustis' manufacturing facility is located.
MDXG APEN

Hot Stocks

07:08 EDT MiMedx appoints Todd Newton as interim CEO - MiMedx Group announced that K. Todd Newton, a member of the MIMEDX Board of Directors, has been appointed interim CEO. Newton replaces Timothy R. Wright, who served as MIMEDX's CEO since May of 2019. The Board has appointed a special committee to direct the search for a new CEO. The Search Committee comprises M. Kathleen Behrens, James L. Bierman and William A. Hawkins III, and will retain a leading executive search firm to support the process. In connection with today's announcement, Wright is no longer a member of the Board of Directors, and the Board has been reduced to eight members. Newton joined MIMEDX's Board in 2019, and has since served as Chair of the Audit Committee and as a member of the Ethics and Compliance Committee. Mr. Newton previously served as Chief Executive Officer and as a member of the Board of Directors of Apollo Endosurgery (APEN), a medical device company, from July 2014 until March 2021.
CTT PCH

Hot Stocks

07:08 EDT CatchMark Timber announces proxy firms recommendation for PotlatchDeltic merger - CatchMark Timber (CTT) announced that independent proxy advisory firms Glass, Lewis & Co. and Institutional Shareholder Services, or ISS, have recommended that the company's stockholders vote for the previously announced merger of the company with PotlatchDeltic (PCH) at the company's upcoming special meeting of stockholders scheduled for September 13.
MFGP...

Hot Stocks

07:08 EDT Micro Focus extends its cloud solutions to Google Cloud Marketplace - Micro Focus (MFGP) announced the availability of its Enterprise Suite for application modernization on Google (GOOG;GOOGL) Cloud Marketplace. With this new Marketplace availability, organizations can more quickly deploy an enterprise-grade mainframe infrastructure solution on Google Cloud at a time when companies are seeking new and cost-effective ways to deliver on IT strategies through continuous modernization and digital transformation initiatives. The announcement brings together Micro Focus' application modernization capabilities with the powerful security, availability, scalability, and administration features Google Cloud offers as well as Google Compute Engine services. "Moving critical workloads from legacy infrastructure and onto a flexible, scalable, and innovative platform like Google Cloud is an important step in digital transformation. It is imperative that organizations ensure their core business applications can meet the demands of today's ever-changing technology and business needs. Because of this, research shows that 72 percent of COBOL application owners are considering modernization as the best way to digitally transform their strategic core business systems," said Neil Fowler, General Manager and VP of the Application Modernization and Connectivity business at Micro Focus.
PRTC

Hot Stocks

07:08 EDT PureTech data for LYT-100 supports dosing design range trial for IPF - PureTech Health announced a poster presentation describing the rationale and design for the Phase 2 trial of LYT-100 in patients with IPF at the European Respiratory Society, ERS,International Congress. The poster also reviews the results from a Phase 1 crossover trial of LYT-100 in healthy older adults, which supports the dose selection for the Phase 2 trial. LYT-100 is a therapeutic candidate in PureTech's Wholly Owned Pipeline and is being advanced for the treatment of conditions involving inflammation and fibrosis, including IPF. The data from the Phase 1 trial demonstrated that LYT-100 showed a lower incidence of adverse events or AEs, compared to pirfenidone at comparable exposure levels. Key outcomes of this trial that are supportive of the observed improved tolerability of LYT-100 were reported in January. Additionally, this trial supports the dosages that were selected for the Phase 2 trial of LYT-100, which began in June .
ATHA

Hot Stocks

07:08 EDT Athira Pharma adapting LIFT-AD study to focus on fosgonimeton monotherapy - Athira Pharma announced an update to its plans for the ongoing LIFT-AD clinical trial of fosgonimeton, a small-molecule positive modulator of the HGF/MET neurotrophic factor system, in patients with mild-to-moderate Alzheimer's disease. The completed, exploratory ACT-AD study was designed to better understand fosgonimeton's effect on biomarkers, psychometric measures and safety over six months as well as to inform the larger ongoing LIFT-AD study in the same mild-to-moderate AD population. Study results from ACT-AD suggested positive effects on measures of cognition, function and neurodegeneration in patients taking fosgonimeton alone without background acetylcholinesterase inhibitors during the study period. Leveraging these results, the company will amend the LIFT-AD trial to investigate the effects of fosgonimeton compared with placebo, without background AChEIs. The overall design of LIFT-AD remains unchanged, including the Global Statistical Test as the primary endpoint. An independent, unblinded interim analysis will be conducted to inform the required sample size needed to appropriately power the primary endpoint in the target patient population. ACT-AD was an exploratory, randomized, double-blind, placebo-controlled, parallel-group 26-week trial evaluating fosgonimeton compared to placebo in patients with mild-to-moderate Alzheimer's disease. The study enrolled 77 patients in the United States and Australia. Patients were allowed to continue receiving AChEIs; 60 percent remained on stable doses of AChEIs and 40 percent were not receiving AChEIs during the study. Patients were randomized 1:1:1 to receive placebo or fosgonimeton at either 40 mg/day or 70 mg/day. The primary endpoint for ACT-AD was Event-Related-Potential P300 Latency, a functional measure of working memory processing speed. Secondary endpoints included ADAS-Cog11, a measure of cognition; ADCS-CGIC, a measure of global clinical change; and ADCS-ADL23, a measure of functional change. Safety data were evaluated throughout. As previously reported, the ACT-AD study did not meet the primary endpoint of a statistically significant change in ERP P300 latency. However, the data showed a numerical improvement in the functional measure of ADCS-ADL23, which evaluates patients' activities of daily living as assessed by their caregivers, compared to placebo at 26 weeks. Additional analyses of the data from patients treated with fosgonimeton alone suggested a potentially beneficial change in ERP P300 latency as well as cognitive improvement, as measured by ADAS-Cog11, compared with placebo at 26 weeks. Among patients treated with fosgonimeton alone, there was a statistically significant improvement of plasma Neurofilament light Chain, a validated fluid biomarker of neurodegeneration. These encouraging findings further support the decision to focus the ongoing clinical evaluation on fosgonimeton alone without background AChEIs. Athira reports that, to date, more than 90 percent of patients completing the ACT-AD and LIFT-AD studies have elected to participate in the ongoing open label extension study.
DYN

Hot Stocks

07:06 EDT Dyne Therapeutics doses first patient in Phase 1/2 DELIVER clinical trial - Dyne Therapeutics announced that the first patient has been dosed in its Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 for the treatment of Duchenne muscular dystrophy, or DMD, mutations amenable to exon 51 skipping. The DELIVER trial is a Phase 1/2 global clinical trial evaluating DYNE-251, consisting of a 24-week multiple ascending dose randomized placebo-controlled period, a 24-week open-label extension and a 96-week long-term extension. The trial, which is designed to be registrational, is expected to enroll approximately 46 ambulant and non-ambulant males with DMD who are ages 4 to 16 and have mutations amenable to exon 51 skipping therapy. The primary endpoints are safety, tolerability and change from baseline in dystrophin levels as measured by Western blot. Secondary endpoints include measures of muscle function, exon skipping, and pharmacokinetics. Dyne anticipates reporting data from the MAD placebo-controlled portion of the DELIVER trial on safety, tolerability and dystrophin in the second half of 2023.
GGR

Hot Stocks

07:06 EDT Gogoro, Metro Motor, Paz Group launch two-wheel battery swapping in Israel - Gogoro announced the launch of its industry leading battery swapping system and Smartscooters in the Tel Aviv metropolitan area. In partnership with market leaders Metro Motor and Paz Group, the companies expect to launch in other cities in Israel in the future. Metro Motor is a top two-wheel vehicle distributor in Israel and Paz Group is a leading energy, gas and retail group in Israel. The companies are launching with 10 battery swapping locations and anticipate deploying to 35 battery swapping stations by the end of 2022 and more than 150 stations within 4 years. "Gogoro is excited to be launching its battery swapping in Tel Aviv. We are focused on driving the mass market shift to smart electric mobility and battery swapping is one clear path to solving a city's mobility and energy demands in a safe, sustainable, and scalable way. As one of the world's most innovative cities, the people of Tel Aviv can now embrace a new era in smart mobility innovation using Gogoro's Smartscooters and battery swapping," said Horace Luke, founder, chairman, and chief executive officer of Gogoro. "Metro Motor and Paz Group are two industry leaders in Israel, and together, we are introducing a new urban mobility experience that is smart, sustainable and available to everyone. Customers in Tel Aviv can now purchase the high-performance Gogoro S2 ABS or the versatile Gogoro 2 Plus at Metro retail stores in the city."
BLCO

Hot Stocks

07:05 EDT Bausch + Lomb, Novaliq announces US FDA accepted NDA for NOV03 - Bausch + Lomb announced that the U.S. Food and Drug Administration, FDA, has accepted the New Drug Application, NDA, filing for investigational treatment NOV03. A potential first-in-class eye drop with a novel mechanism of action, NOV03 is an investigational therapy to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction. NOV03 has been assigned a Prescription Drug User Fee Act, PDUFA, action date of June 28, 2023. "With the FDA commencing review of the NDA filing, we are one step closer to bringing an important new treatment option to the millions of Americans affected by dry eye disease associated with Meibomian gland dysfunction," said Joseph C. Papa, CEO, Bausch + Lomb. "NOV03 is distinct from anti-inflammatory and immunomodulatory agents, and, if approved, would be the first prescription eye drop to address excessive tear evaporation. The approval would also mark a significant milestone for Bausch + Lomb, as the company's first FDA approval for a prescription medicine since becoming a publicly traded company earlier this year." The clinical development program for NOV03 includes two Phase 3 studies, both of which demonstrated statistically significant improvement vs. control for both primary and key secondary sign and symptom endpoints as early as day 15 and through day 57. NOV03 was well tolerated in both studies.
CAH

Hot Stocks

07:04 EDT Cardinal Health enters board cooperation agreement with Elliot - Cardinal Health announced initiatives aimed at positioning the company for long-term success, building on Cardinal Health's previously announced growth plans. These initiatives have benefited from input received from Elliott Investment Management. In connection with these initiatives, Elliott has also entered into a cooperation agreement with Cardinal Health, and Elliott's Steven Barg will join the company's board of directors. As part of Cardinal Health's ongoing commitment to board refreshment and the initiatives announced, the governance and sustainability committee of the board has recommended and the board has approved the appointment of four new independent directors: Steven Barg, Michelle Brennan, Sujatha Chandrasekaran and Christine Mundkur. With these immediate appointments, Cardinal Health's board will be made up of 15 Directors, 14 of whom are independent under the company's director independence standards. Two existing directors - Dean Scarborough and John Weiland - have announced their intentions to conclude their board service at the end of their previously elected terms this fall and will not stand for re-election at Cardinal Health's 2022 annual meeting, resulting in a 13-member board. Cardinal Health's board has also formed a new board committee, the Business Review Committee, to support a comprehensive review of the Company's strategy, portfolio, capital-allocation framework. The Business Review Committee will be chaired by CEO Jason Hollar; Barg and Akhil Johri will also serve on the committee. The committee, with the assistance of the company's legal and financial advisors, will make recommendations to the full board. The company expects to conduct an investor day in the first half of calendar 2023 to share the Board's conclusions and to provide additional guidance. The cooperation agreement that the company has entered into with Elliott contains customary standstill, voting, confidentiality and other provisions.
DYN

Hot Stocks

07:04 EDT Dyne Therapeutics begins ACHIEVE Phase 1/2 clinical trial evaluating DYNE-101 - Dyne Therapeutics announced the initiation of its ACHIEVE Phase 1/2 clinical trial evaluating DYNE-101 for the treatment of myotonic dystrophy type 1, or DM1. The ACHIEVE trial is a Phase 1/2 global clinical trial evaluating DYNE-101, consisting of a 24-week multiple ascending dose, or MAD, randomized placebo-controlled period, a 24-week open-label extension and a 96-week long-term extension. The trial, which is designed to be registrational, is expected to enroll approximately 64 adult patients with DM1 who are 18 to 49 years of age. The primary endpoints are safety and tolerability; secondary endpoints include pharmacokinetics and pharmacodynamics, including change from baseline in splicing, as well as measures of muscle strength and function. Dyne anticipates reporting data from the MAD placebo-controlled portion of the ACHIEVE trial on safety, tolerability and splicing in the second half of 2023. The ACHIEVE trial is designed to efficiently optimize dose level and frequency. In the MAD portion of the trial, patients will be randomized to receive DYNE-101 or placebo intravenously every four weeks or every eight weeks for 24 weeks, depending on cohort. Patient cohorts will be dosed from 1.8 mg/kg to 10.2 mg/kg (approximate ASO dose) across four cohorts. Following the placebo-controlled period, patients will transition to DYNE-101 treatment in the open-label portion of the trial and in the long-term extension.
SYBX RHHBY

Hot Stocks

07:04 EDT Synlogic receives milestone payment und research collaboration with Roche - Synlogic (SYBX) announced that it has received a milestone payment for the achievement of prespecified success criteria under the research collaboration agreement with Roche (RHHBY) for the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease. Under the terms of the agreement, Synlogic and Roche will collaborate to develop a Synthetic Biotic addressing an undisclosed novel target in IBD. At the conclusion of the research period, Roche will have the exclusive option to enter a licensing and collaboration agreement for further development and commercialization of the program.
GLYC

Hot Stocks

07:03 EDT GlycoMimetics appoints Edwin Rock, M.D. as CMO - GlycoMimetics announced that Edwin Rock, M.D., Ph.D. has joined the executive leadership team as Chief Medical Officer, CMO. Dr. Rock brings nearly two decades of biopharmaceutical clinical development experience, most recently serving as CMO for Partner Therapeutics, a privately-held commercial stage biotech based in Massachusetts. "We are thrilled to have Ed join the GlycoMimetics team. His proven biopharmaceutical leadership in the development and commercialization of novel hematologic therapies will be a significant asset as we prepare for the readout of uproleselan's pivotal Phase 3 data in relapsed/refractory AML," said Harout Semerjian, Chief Executive Officer. "With this hire we continue to build a world-class leadership team dedicated to delivering our transformation from a research company to a commercially focused organization that improves outcomes for patients."
PSTV

Hot Stocks

07:03 EDT Plus Therapeutics receives FDA approval for ReSPECT-GBM Phase 2 trial - Plus Therapeutics announced a summary of its Type C Clinical meeting minutes with the FDA relating to its lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome, or 186RNL, for the treatment of patients with recurrent glioblastoma, GBM. The FDA and Plus Therapeutics agreed that the ReSPECT-GBM clinical trial should proceed to the planned Phase 2. The key focus areas of clinical investigation of the Phase 2 trial will be: further dose exploration, including both increased dosing and multiple doses, and collecting additional safety and efficacy data to inform the design of the future registrational trial. Furthermore, there was agreement that in a planned future registrational trial, overall survival should be used as the primary endpoint. The Company and the FDA also agreed to hold future meeting to consider the use of external data to augment the control arm in the registrational trial.
LPTX

Hot Stocks

07:02 EDT Leap Therapeutics announces appointment of Schilsky to board of directors - Leap Therapeutics announced the appointment of Richard Schilsky, MD, FASCO, FACP, FSCT to its Board of Directors, effective September 1, 2022. Dr. Schilsky brings over 40 years of experience in medicine and clinical research, specializing in new drug development and clinical trials for a wide range of cancers. Dr. Schilsky is the former Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology, and served as its President from 2008-2009.
PLUR

Hot Stocks

07:02 EDT Pluri announces EUR 7.5M grant for PROTO project - Pluri announced that a EUR 7.5 million non-dilutive grant from the European Union's Horizon Europe program has been awarded to PROTO, an international collaboration led by Charite, Berlin Institute of Health Center for Regenerative Therapies. The goal of the PROTO project is to utilize Pluri's PLX-PAD cells in a Phase I/IIa study for the treatment of mild to moderate knee osteoarthritis. The project is currently under grant agreement preparation number 101095635. Final approval of the grant is subject to completion of the consortium and Horizon Europe grant agreements. The funds from the grant are expected to be allocated between Pluri and other members of the consortium in accordance with budget and work packages which will be determined by the consortium. The Phase I/IIa study will be carried out by Charite, Pluri and other members of the international consortium under the leadership of Professor Tobias Winkler, Principal Investigator at the Berlin Institute of Health Center for Regenerative Therapies, Julius Wolff Institute and Center for Musculoskeletal Surgery. Professor Winkler was also the lead PI in the Phase II and Phase III muscle regeneration studies using Pluri's PLX-PAD cells.
ZOM

Hot Stocks

07:01 EDT Zomedica's PulseVet named as Official Shock Wave Therapy by NCHA - Zomedica announced that the PulseVet system has been named the Official Shock Wave Therapy of the National Cutting Horse Association, or NCHA. Zomedica's PulseVet system is the leader in electro-hydraulic shock wave technology for treating a wide variety of conditions in veterinary patients. The non-invasive therapy utilizes high-energy sound waves to stimulate cells and release healing growth factors in the body that reduce inflammation, increase blood flow, and accelerate bone and soft tissue development. PulseVet's technology is clinically proven to treat tendon, ligament and muscle injuries, osteoarthritis, degenerative joint disease, navicular syndrome, chronic back and neck pain, fractures, and wounds.
MTZ IEA

Hot Stocks

06:59 EDT MasTec announces expiration of HSR waiting period for IEA deal - MasTec (MTZ) announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, for the previously announced acquisition of IEA (IEA) by MasTec has expired. The expiration of the HSR waiting period was a condition to the closing of the pending transaction. Completion of the transaction is expected in October, subject to the satisfaction of the remaining customary closing conditions, including approval of the transaction by IEA stockholders.
BSX

Hot Stocks

06:57 EDT Boston Scientific receives FDA approval to expand labeling for LAAC Device - Boston Scientific has received FDA approval to expand the instructions for use labeling for the current-generation Watchman Flx Left Atrial Appendage Closure, or LAAC, Device to include a 45-day dual anti-platelet therapy, or DAPT, option as an alternative to 45-day oral anticoagulation plus aspirin for post-procedural treatment of patients with non-valvular atrial fibrillation.
DWAC

Hot Stocks

06:57 EDT Digital World Acquisition falls 23% following report of failed TMTG extension - Shares of Digital World Acquisition are down 23% in pre-market at $19.19 - the lowest level since October of 2021 - following a Reuters report that the SPAC has failed to secure enough shareholder support for a one-year extension to complete the deal with Trump Media and Technology.
CIH

Hot Stocks

06:56 EDT China Index Holdings forms special committee to evaluate acquisition proposal - China Index Holdings announced that its board of directors has formed a special committee consisting of two independent directors, Mr. Jianping Ye and Mr. Jason Chenyang Wei, to evaluate and consider the previously announced preliminary non-binding acquisition proposal letter dated August 23, 2022 from Fang Holdings to acquire all of the outstanding shares of the Company not currently owned by Fang, or any potential alternative transactions, and that the Special Committee has retained Gibson, Dunn & Crutcher LLP as its U.S. legal counsel to assist it in the evaluation of the Proposed Transaction and any potential alternative transactions.
ALVO

Hot Stocks

06:55 EDT Alvotech says CRL for BLA of AVT02 noted deficiencies at Reykjavik facility - Alvotech announced yesterday that the company received communication from the U.S. Food and Drug Administration detailing its assessment of the March 2022 inspection of Alvotech's manufacturing facility in Reykjavik, Iceland and Alvotech's subsequent written responses to the FDA. The FDA's Complete Response Letter to the initial biosimilar Biologics License Application, or BLA, for AVT02 noted certain deficiencies related to the Reykjavik facility and stated that satisfactory resolution of the deficiencies is required before FDA may approve this BLA, the company reported. "Alvotech looks forward to addressing the deficiencies outlined in the post-application action letter and continuing to work with the FDA to close out the facility inspection. We aim to satisfactorily address the issues before the Biosimilar User Fee Act, BSUFA, goal date for the interchangeable biosimilar BLA in December. We are committed to bringing AVT02 to patients worldwide and anticipate being launch ready by our expected launch date in the U.S. of July 1, 2023," said Mark Levick, CEO of Alvotech.
TKR

Hot Stocks

06:53 EDT Timken to acquire GGB Bearing Technology, sees accretion - Timken has reached an agreement to acquire GGB Bearing Technology, or GGB, a division of Enpro. Founded in 1899, GGB serves a variety of diverse customers, markets, geographies and applications with a product portfolio that complements existing Timken industry-leading engineered bearing solutions. GGB revenue is expected to be around $200M in FY22. With manufacturing facilities across the United States, Europe and China, GGB employs approximately 900 people and has a global engineering, distribution and sales footprint. The company's tribology solutions in plain bearing coatings complements Timken's leading positions in roller and ball bearings. GGB's products are used mainly in industrial applications, including pumps and compressors, HVAC, off-highway, energy, material handling and aerospace. Timken will fund the transaction with cash on hand and its existing revolving credit facility. The deal is subject to customary closing conditions and is expected to close in the fourth quarter of this year. Timken anticipates the acquisition will be accretive to earnings in the first full quarter after closing.
LBRT

Hot Stocks

06:53 EDT Liberty Energy makes investment in Natron Energy - Liberty Energy announced an investment in Natron Energy. Liberty and Natron will collaborate to introduce sodium-ion batteries as an energy storage solution to provide uninterruptible backup power for Liberty's digiFrac electric frac pumps. Liberty's digiFrac is the industry's first purpose-built, fully integrated electric frac pump with high power density and significantly lower emissions compared to the best available frac pump technology in the market. Natron's sodium-ion batteries are expected to be used to maximize uptime and optimize generator utilization ensuring the lowest possible emissions footprint for onsite power generation. Natron plans to use the funds to accelerate the production of its sodium-based battery technology, including industrial power and energy markets. Natron's Prussian blue sodium-ion technology offers higher power density, longer service life, and unique safety characteristics over other battery technologies. These qualities are crucial for the safe and successful deployment in pressure pumping applications with highly variable power load requirements. Natron leverages existing lithium-ion manufacturing facilities for production, and its supply chain requires zero lithium, cobalt, copper, nickel, or other minerals that are difficult to source.
LAZ JPM

Hot Stocks

06:52 EDT Lazard appoints Timothy Donahue as MD, vice chairman, U.S. Investment Banking - Lazard (LAZ) announced that Timothy Donahue has joined the firm as a Managing Director and Vice Chairman of U.S. Investment Banking, effective immediately. Based in New York, Mr. Donahue will help lead Lazard's growing practice of providing advice pertaining to capital structures and raising private credit. Mr. Donahue will collaborate with the Capital Markets Advisory Group, and Restructuring and Capital Solutions Group, to best serve corporate and financial sponsor clients. Mr. Donahue joins Lazard from J.P. Morgan (JPM), where he was a Vice Chairman of Capital Markets, and former Head of Leveraged Finance Debt Capital Markets.
YRD

Hot Stocks

06:40 EDT Yiren Digital announces up to $20M share repurchase program - Yiren Digital announced that its board of directors has adopted a share repurchase program, which approves and authorizes the company to repurchase through one or more transactions up to $20M worth of its own American depositary shares representing its ordinary shares. The share repurchase program previously adopted by the company in 2018 has been simultaneously terminated.
JAGGF

Hot Stocks

06:40 EDT Jaguar Mining announces results from exploration at Turmalina Gold Mine Complex - Jaguar Mining announced results from exploration completed at its Turmalina Gold Mine Complex, located in the Iron Quadrangle in the state of Minas Gerais, Brasil. In - mine and mine-contiguous drilling at Turmalina is part of the Company's ongoing growth exploration strategy. At Orebody C Northwest drilling targeted shallow strike and depth extensions proximal to and accessible from underground development. At Pontal South, drilling has defined a newly identified mineralized zone occurring in the gap area between the Pontal and Faina Areas. Drill intersections reported from both areas are outside currently defined mineral resource limits and highlight the potential to add additional mineral resources to the Company's mineral resource inventory. Vern Baker, President, and CEO of Jaguar Mining stated: "Our tenements surrounding the Turmalina Mine have always excited us with their potential. The exploration work and drilling at Pontal South continues to confirm the large-scale continuity of structure and mineralization starting at the Turmalina Mine, running through the Faina resource and on to the Pontal resource - a trend now estimated to be approximately three kilometers in length. The excellent intercepts at CNW demonstrate down plunge continuity of a zone that appears to be of mineable grade and thickness. Drilling at CNW and at Pontal South is continuing with the aim of further identifying potentially economic mineral resources, as well as supporting the extensive engineering and metallurgical work being done following the recent completion of infill drilling on the Faina mineral resource. Development headings have already commenced from workings in our C-Central portion of Orebody C into the CNW structure identified by this in-mine exploration drilling."
ZOM

Hot Stocks

06:39 EDT Zomedica announces sponsorship with National Cutting Horse Association - Zomedica announced that the PulseVet system has been named the Official Shock Wave Therapy of the National Cutting Horse Association.
MKTX

Hot Stocks

06:38 EDT MarketAxess announces August total trading average daily volume $30.6B - Chris Concannon, President and COO of MarketAxess commented: "A 27% year-over-year increase in total credit ADV and a 55% increase in U.S. Treasury ADV led to our best August results on record. Improved credit trading conditions and solid market share gains in our international product areas led to the strong volume growth in August. Open Trading estimated transaction cost savings were a total of $90 million in August, which equates to approximately $1,155 per million saved for our clients. Year-to-date estimated transaction cost savings are now approximately $604 million, 49% above the prior year, reflecting the powerful benefits of our unique, all-to-all liquidity pool. The investments we have made to expand our product and geographic diversification are paying off, the benefits of our differentiated liquidity are driving strong cost savings for clients, and our total credit average fee per million is stable. We believe more normal levels of yields and volatility are setting the foundation for stronger growth in the months and quarters ahead." Reports strongest ever month of August, with $30.6 billion in total trading average daily volume, up 44%, driven by a 55% increase in U.S. Treasury ADV to $20.2 billion and a 27% increase in total credit ADV to $10.2 billion, reflecting increasing momentum quarter-to-date. The preliminary average fee per million for total credit was $168 per million in August, up from $166 in July and $166 in the second quarter of 2022.
EBS

Hot Stocks

06:36 EDT Emergent BioSolutions doses first patient in Phase 1 study of EBS-LASV - Emergent BioSolutions announced that it has dosed the first participant in its Phase 1 study evaluating the safety and immunogenicity of EBS-LASV, a recombinant VSV-vectored Lassa virus vaccine candidate being developed for prevention of disease caused by Lassa virus infection. Emergent and CEPI are co-funding this program. This Phase 1 study, a randomized, placebo-controlled, dose-escalation study, will evaluate the safety and immunogenicity of Emergent's rVSV-vectored Lassa virus vaccine in approximately 36 healthy adults at the Navrongo Health Research Centre and Kintampo Health Research Centre in Ghana. View the clinical trial registry.
NPO

Hot Stocks

06:35 EDT EnPro announces agreement to sell GGB to Timken for $305M - EnPro Industries announced that it has entered into agreements to sell GGB, its mission critical surface engineering solutions business, with exclusive negotiations with respect to the French operations of GGB, to The Timken Company for $305M in cash, subject to customary closing date adjustments. Following the transaction, Enpro will have a focused portfolio composed of its Advanced Surface Technologies and Sealing Technologies segments, both of which are enduring, high-margin businesses with significant aftermarket exposure and recurring revenue streams. The transaction with Timken is expected to close by year-end and is subject to regulatory approvals and works council processes. Further to the planned divestiture of the GGB business, Enpro is pursuing a strategic review of its pipeline sealing and electrical isolation product manufacturing business, Garlock Pipeline Technologies, the sale of which, if completed, would conclude the divestiture portion of Enpro's portfolio reshaping initiative. GGB and GPT comprise the company's Engineered Materials segment. Accordingly, Enpro expects to classify the Engineered Materials segment as discontinued operations when it reports its Q3 results. Enpro expects to receive approximately $290M in after-tax net proceeds from these two Engineered Materials divestitures combined. The Company intends to use the proceeds to advance its capital allocation priorities, including further debt reduction, while continuing to invest in organic growth opportunities and selectively pursuing strategic acquisitions. BofA Securities is serving as the exclusive financial advisor to Enpro. Robinson Bradshaw is Enpro's lead legal counsel with Bird and Bird supporting internationally.
ARES

Hot Stocks

06:34 EDT Ares Wealth Management Solutions, iCapital expand partnership - iCapital and Ares Wealth Management Solutions announced an expansion of their partnership to provide financial advisors and registered independent advisors with greater access to a broadened menu of alternative investment solutions and a comprehensive set of tools to support the development of client portfolios. AWMS is leveraging the broad capabilities of iCapital's technology to offer investment solutions tailored for the global wealth management community across Ares Management's credit, private equity, real estate and secondaries asset classes. AWMS will launch an Ares-branded, iCapital-powered site to support the AWMS team as they manage the distribution, marketing and client management activities for various investment solutions, including evergreen, drawdown, exchange and '40 Act funds. With approximately 110 dedicated professionals backed by the scale of the Ares investment management platform, AWMS is one of the most resourced wealth distribution and client service teams in the alternative investment industry. iCapital will provide feeder fund structuring and management, present the investment for the offering and facilitate the ongoing servicing. This includes investor onboarding, electronic subscription processing, fund servicing and reporting for the life of the investments.
NILE

Hot Stocks

06:33 EDT BitNile's TurnOnGreen acquired by other subsidiary Imperalis Holding - BitNile Holdings announced a divestiture of the Company's subsidiary, TurnOnGreen, an electric vehicle charging and power solutions company, to Imperalis Holding, a publicly traded subsidiary of BitNile. Completing this transaction constitutes a significant step in BitNile's planned distribution of TurnOnGreen's securities to its stockholders. Today TurnOnGreen closed upon the securities purchase agreement with Imperalis, whereby Imperalis acquired all of the outstanding shares of common stock of TurnOnGreen from BitNile. As a result of the Acquisition, TurnOnGreen became a subsidiary of Imperalis. As part of the Acquisition, BitNile eliminated all of the intercompany accounts between itself and TurnOnGreen evidencing historical equity investments made by BitNile in the approximate amount of $36,000,000, and Imperalis issued BitNile 25,000 shares of Series A Preferred Stock, with each such share having a stated value of $1,000. The Series A Preferred Stock has an aggregate liquidation preference of $25 million, is convertible into shares of Imperalis common stock at BitNile's option, is redeemable by BitNile, and entitles BitNile to vote with the common stock on an as-converted basis. Imperalis, which intends to change its name to TurnOnGreen as soon as practicable, will operate through TurnOnGreen's two subsidiaries, TOG Technologies Inc. and Digital Power Corporation. Imperalis intends to dissolve its remaining dormant subsidiary. Now that the Acquisition is completed, BitNile will assist TurnOnGreen in pursuing an uplisting to the Nasdaq Capital Market, subject to Nasdaq's seasoning rules and other criteria for listing. The Company anticipates setting a record date soon whereby stockholders of BitNile will receive a dividend of securities of TurnOnGreen. BitNile expects to distribute to BitNile's stockholders approximately 140 million shares of TurnOnGreen common stock and warrants to purchase an additional 140 million shares of TurnOnGreen common stock, subject to regulatory approval and compliance with US federal securities laws. The Company plans to cause Imperalis to apply to have the warrants publicly traded. Upon the closing of the Acquisition, Imperalis appointed Amos Kohn as its Chief Executive Officer and the Chairman and member of its Board of Directors, as well as appointed Marcus Charuvastra as the President of Imperalis.
HUT...

Hot Stocks

06:32 EDT Hut 8 Mining increases Bitcoin holdings by 375 in August - Hut 8 Mining increased its Bitcoin holdings by 375 in the period ending August 31, bringing its total self-mined holdings to 8,111 Bitcoin. Overall, 375 Bitcoin were generated, resulting in an average production rate of approximately 12.1 Bitcoin per day. Keeping with our longstanding HODL strategy, 100% of the self-mined Bitcoin in August were deposited into custody. Total Bitcoin balance held in reserve is 8,111 as of August 31. Installed ASIC hash rate capacity was 2.98 EH/s at the end of the month, which excludes certain legacy miners that the company anticipates will be fully replaced by the end of the year. Hut 8 produced 125.8 BTC/EH in August.
NPRO

Hot Stocks

06:31 EDT Napro Biotheraputics appoints Will Abbey to the board of directors - EnPro Industries announced that Will Abbey has been appointed to the company's Board of Directors. Abbey brings more than 25 years of experience in the semiconductor industry and a deep knowledge of the evolving global semiconductor ecosystem to Enpro. Abbey currently serves as Senior Vice President of Sales and Partner Enablement at global semiconductor leader Arm, owned by SoftBank Group. He has held a number of leadership roles since joining Arm in 2004, including General Manager of Arm's Physical Design group and Vice President of Commercial Operations for the Physical IP Division.
PDRDF

Hot Stocks

06:27 EDT Irish Distillers announces EUR 250M investment plan for Midleton distillery - Irish Distillers has announced it will invest 250 million euro to build a new distillery in Midleton Co. Cork in order meet demand and ensure the necessary future production capacity for its portfolio of Irish whiskeys globally. The distillery will produce Irish whiskeys, including Jameson, Powers, Redbreast, Midleton Very Rare, the Spot family and Method and Madness. The new distillery will be situated on a 55-acre site adjacent and connected to the Midleton Distillery. Subject to a successful planning application and meeting all licensing requirements, the new distillery will distil pot still and grain whiskey with grain intake, brewing, fermentation, and distillation facilities incorporated into the new 55-acre site. The new distillery is expected to generate up to 100 highly skilled new jobs for the region over time once the distillery is operational in 2025, and circa 800 jobs during the construction phase. Irish Distillers recently announced plans to invest EUR 50 million to fund projects aimed at transforming Midleton Distillery into a carbon neutral operation by the end of 2026 by leveraging breakthrough emissions reducing technology to reduce energy use. In line with Irish Distillers' ambition, the new distillery will also be a carbon neutral operation. The new site will also incorporate various environmental projects which will be developed in order to enhance biodiversity and protect local wildlife. An expanded distilling capacity is expected to increase Midleton Distillery's requirement for barley and malted barley by up to 50%, which the company intends to source from Irish farmers. A planning application is expected to be submitted to Cork County Council towards the end of 2022 and, if successful, construction will commence in 2023 with plans for the distillery to be operational in 2025.
PTEN

Hot Stocks

06:24 EDT Patterson-UTI reports average of 127 U.S. drilling rigs operating in August - PATTERSON-UTI ENERGY reported that for the month of August 2022, the Company had an average of 128 drilling rigs operating in the United States. For the two months ended August 31, 2022, the Company had an average of 127 drilling rigs operating in the United States.
MRRDF

Hot Stocks

06:23 EDT Meridian Mining UK provides update on Cabacal Mine Corridor program - Meridian Mining UK provides an update on its Cabacal Mine Corridor exploration program. The recent completion of a Gradient Array Induced Polarization survey has linked the open C4-A gold-silver precious metal discovery[1], to the Cabacal copper-gold deposit 1.8km to the northwest. Multiple enhanced chargeability responses along this new trend, provide strong targets for follow-up evaluation and next drill programs. The Company has also retrieved an additional 1,625 historical multielement soil sample records from archival maps of BP Minerals following improved survey control. It has connected the Sucuri prospect, the Santa Helena Mine and the Alamo prospect into a highly prospective 6.5 km copper-gold-silver VMS trend. After the Cabacal deposit, this will be the focus of future resource development and exploration programs. The C2 Trend is part of the 50km long Cabacal VMS copper-gold system that has been overprinted by a late-stage gold event. Highlights Reported: Meridian's IP survey links C4-A gold-silver discovery to the Cabacal deposit 1.7km to the northwest; Geological flexures and structural intersections provide immediate targets for drill programs; IP anomaly links C4-A gold-silver discovery with BP hole JUSPD258 that returned 26.2 g/t Au over 0.6m, 1km to the northwest; Meridian defines highly prospective 6.5km long copper-gold-silver C2 Trend; Newly digitized BP data connects Sucuri to Santa Helena and Santa Helena to Alamo creating the "C2 Trend"; C2 Trend host historical resources, drill results, VTEM plates and extensive surface mineralization and has been overprinted by the late stage Cabacal gold event, including; JUCHD011: 140g/t Au over 1.0m from 53.0m; C2 Trend's copper-gold-silver mineralization and historical resources to be evaluated for its open-pit potential; C2 Trend remains open along strike along the southeast projection of the Cabacal Belt; and Cabacal maiden resource statement on schedule for end of Q3, 2022. Dr Adrian McArthur, CEO and President comments: "Our Mine Corridor development teams continue to deliver a strong pipeline of targets at Cabacal. The confirmation of a structural link between the Cabacal Mine and the C4A gold-silver discovery has defined a focussed corridor to test this open mineralization and to potentially link it with JUSPD258 located 1km to the northwest that returned 26.2 g/t Au over 0.6m. These new IP results, recent field mapping was combined with historical data and defined further structural intersection and flexures, that we consider strongly prospective to host gold mineralization related to the late stage high-grade gold overprint extensively defined at the Cabacal and Santa Helena mines. Today we are also announcing that a new focussed copper-gold-silver trend has been defined; the C2 Trend. The C2 Trend was historically thought to be separate individual VMS centres of mineralization. Over the last nine months, we completed a program of detailed desktop studies and extensive confirmation field checks confirming the presence of gossanous veining in undrilled positions and in areas of now included historical data. Creating a geological model, mapping the Cabacal style of VMS mineralization and structures associated with the Cabacal's late-stage gold overprint, from the Sucuri prospect in the northwest, extending southeast to the Santa Helena Mine and beyond to the Alamo target. Creating a major new focus for the Company's strategy to build a belt scale and long term copper-gold mining project centred on the pending Cabacal resource."
MNKD

Hot Stocks

06:18 EDT MannKind completes Phase 1 study of clofazimine inhalation suspension - MannKind announced that it has successfully completed a Phase 1 study of clofazimine inhalation suspension, or MNKD 101, and is planning discussions with the FDA regarding results and the ongoing clinical program. Clofazimine is being developed as an inhalation treatment option for nontuberculous mycobacterial lung disease. Study MKC-CI -001 was a Phase I randomized, double-blind, placebo-controlled, single- and multiple-ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of MNKD-101 in healthy volunteers. The key safety findings of the study included: Clofazimine inhalation solution found to be generally well tolerated at daily doses of up to 90 mg over a seven-day period, and no lab abnormalities, QT prolongation, or serious adverse events identified. In the SAD portion of the study, 24 adults were enrolled in one of three cohorts that received a single inhaled dose of 30 mg, 60 mg or 90 mg clofazimine, respectively.
KRKNF

Hot Stocks

06:16 EDT Kraken Robotics receives $9M contract from NATO Navy - Kraken Robotics signed a follow-on contract to supply minehunting systems as part of a contract for new Mine Countermeasure Vessels for a leading NATO Navy. Kraken's KATFISH system has been in full production since 2017, and since 2020 Kraken has delivered several KATFISH towed Synthetic Aperture Sonar, Tentacle Winch and Autonomous Launch and Recovery System to customers in North America, Europe and the Middle East. As part of this new contract, Kraken will deliver additional KATFISH, Tentacle Winch and ALARS and topside systems. Kraken's sonar equipment will be integrated onboard new MCMVs, with deliveries occurring in 2023 and 2024. Kraken also announces that it has issued 100,000 stock options to an employee. These options have a five-year term, with vesting in three equal instalments consisting of six months from the date of grant and on the one and two-year anniversaries of the initial grant. The exercise price on the options is $0.37.
MUX

Hot Stocks

06:14 EDT McEwen Mining subsidiary enters into binding term sheet with Kennecott - McEwen Copper, a subsidiary of McEwen Mining, announced that it has entered into a binding term sheet with Kennecott Exploration Company, a subsidiary of Rio Tinto, for an option to earn a 60% interest in and joint venture the Elder Creek property in Nevada by spending $18M. The principal terms of the agreement are: KEX will have the right to earn a 60% interest in Elder Creek by investing $18M over a maximum of seven years; KEX will be the operator of the Elder Creek project during the term of the agreement; Following completion of the Expenditure Commitment, KEX and McEwen Copper will form an unincorporated 60:40 joint venture.
TNMCF

Hot Stocks

06:13 EDT Titan Mining receives permit for Sphaleros open pit mine - Titan Mining Corporation announces that its Empire State Mines has received the permit from New York State Department of Environment and Conservation, allowing it to begin mining activities on the Sphaleros open pit mine project. The Sphaleros open pit incorporates the Hoist House, Pump House and Turnpike pits which comprises a Measured Mineral Resources of 105,000 tons at a grade of 3.34% zinc, Indicated Mineral Resources of 595,000 tons at a grade of 3.09% zinc and Inferred Mineral Resources of 217,000 tons at a grade of 3.37%. With this permit in hand, ESM is moving immediately to complete construction of a 1.8 mile haul road from the Sphaleros project to the existing mill facility and start waste stripping and site preparation around the open pits. Titan also announces that it has entered into a fixed zinc pricing arrangement for 50% of the Company's budgeted zinc production for the remainder of 2022 at a price of $1.61 per pound of zinc.
SVA

Hot Stocks

06:12 EDT Sinovac Biotech announces approval of phase 2 trial of COVID-19 vaccine in Chile - Sinovac Biotech announced that the Chilean Public Health Institute, or ISP, approved a phase II clinical trial for its inactivated Omicron strain COVID-19 vaccine and trivalent COVID-19 vaccine on August 31st. The clinical trial will evaluate the immunogenicity and safety of one booster dose of the two candidate vaccines in adults who had received two booster doses of CoronaVac, mRNA, or adenovirus vector COVID-19 vaccine. This study is the world's first study researching multivalent inactivated COVID-19 vaccine. In this phase II randomized, double-blind, multicenter clinical trial, 826 fully vaccinated adults will be recruited.
ISEE

Hot Stocks

06:11 EDT Iveric bio says GATHER2 Phase 3 trial met primary endpoint - IVERIC bio announced topline results from GATHER2, the Company's second Phase 3 clinical trial of Zimura, a novel investigational complement C5 inhibitor, for the treatment of geographic atrophy. GATHER2 met its prespecified primary endpoint of mean rate of growth in GA area at 12 months with statistical significance and a favorable safety profile. In GATHER2, there were no events of endophthalmitis, no intraocular inflammation events, and no ischemic optic neuropathy events through month 12. The most frequently reported ocular adverse events were related to the injection procedure. The incidence of choroidal neovascularization in the study eye through month 12 was 15 patients in the Zimura 2 mg group and 9 patients in the sham control group. Similar to GATHER1, the Company's first Phase 3 clinical trial of Zimura in GA, an independent masked reading center assessed the CNV cases in GATHER2 at the 12-month timepoint for exudative macular neovascularization and non-exudative macular neovascularization. The pre-specified primary endpoint, mean rate of growth in GA area over 12 months, was measured by fundus autofluorescence and was calculated using the square root transformation of the GA area. The FAF images were assessed by an independent masked reading center. The Company also analyzed the mean rate of growth in GA area without square root transformation. The Company also analyzed the mean change in GA area from baseline to month 12 in GATHER2 using a point analysis, which was the pre-specified primary endpoint in GATHER1. This analysis was performed based on FAF readings at the same three time points as the primary efficacy analysis (baseline, month 6, and month 12) using the square root transformation and the observed GA area. The results for the 12-month point analysis were consistent with the slope analysis. Details are provided in the accompanying supplement. As part of the pre-specified statistical analysis plan for GATHER2, the Company also analyzed the mean rate of growth in GA area for Zimura 2 mg as compared to sham for pre-specified patient subgroups based on baseline lesion size, baseline visual acuity, baseline autofluorescence pattern, age, and gender. Zimura 2 mg showed a reduction in the mean rate of growth in GA area for all analyzed subgroups. The pre-specified supportive endpoints in GATHER2 included the mean change in best corrected visual acuity and the mean change in low luminance best corrected visual acuity from baseline to month 12. For BCVA, a favorable trend for Zimura 2 mg was observed consistent with GATHER1. For LL BCVA, a favorable trend was not observed. In a post-hoc analysis of GATHER2, the Company analyzed the reduction in mean rate of growth in GA area over 12 months for patients receiving Zimura by geographic region. The reduction for patients receiving Zimura in the U.S. was 25.5% using square root transformation and 32.0% using observed GA area. Patients in the U.S., who accounted for 42.7% of enrolled patients, had a mean baseline lesion size that was 13% smaller than patients outside the U.S. The Company's preliminary hypothesis for regional variation is disease stage. The Company previously hypothesized that Zimura may be more impactful in earlier stages of GA, based on post-hoc analysis of the GATHER1 data. Consistent with this finding, patients in the U.S. in GATHER2 may have been recruited at an earlier stage of the disease as evidenced by the smaller baseline lesion size. The Company plans to continue to explore this hypothesis.
PPTA

Hot Stocks

06:09 EDT Perpetua Resources expects to have public review of USFS statement in Q4 - Perpetua Resources announced that the Company expects the U.S. Forest Service, or USFS, to publish a Supplemental Draft Environmental Impact Statement, or SDEIS, for public review in the Q4. The USFS has confirmed that cooperating agency review is complete and the SDEIS is currently progressing through final reviews in Washington D.C. The USFS is concurrently working with Idaho tribes to inform meaningful consultation. Perpetua is confident the additional evaluation contained within the SDEIS will show improved environmental outcomes that directly address issues raised during the public review of the 2020 Draft Environmental Impact Statement and believes the additional analysis and detailed review should lead to the USFS designating a preferred alternative in the SDEIS. The Stibnite Gold Project in central Idaho is designed to restore environmental conditions at a legacy mine site while responsibly developing one of the highest-grade, open pit gold resources in the U.S. and becoming the only domestically mined source of the critical mineral antimony. Antimony is essential to defense, technology and energy products and is a listed critical mineral by the United States Geological Survey and a mineral of interest by the Department of Defense and Defense Logistics Agency.
NYC

Hot Stocks

06:06 EDT New York City REIT advisor, affiliates make $2.5M share purchase - New York City REIT announced this morning that the Company's advisor and its affiliates have acquired 784,105 shares of NYC Class A common stock in the aggregate. Specifically, affiliates of NYC's advisor purchased an aggregate of 632,911 NYC Class A shares on September 2, 2022. In addition, NYC's advisor made an election to receive stock in lieu of cash for its advisor services. As of September 2, 2022, NYC's advisor and its affiliates own over 2.6 million NYC Class A shares, providing increased alignment and demonstrating their depth of commitment to NYC's long-term value.
GIIX FOOT

Hot Stocks

06:05 EDT Gores Holdings VIII, Footprint amend terms to definitive merger agreement - Footprint and Gores Holdings VIII announced strategic amendments to the terms of their previously announced definitive merger agreement. These amendments and associated incremental capital sources strongly position Footprint for long-term growth and underscore the collective commitment of Footprint and Gores Holdings VIII to drive long-term value creation for all stockholders. Footprint delivered record revenue in the first half of 2022 and is on track to meet its target of $924 million in revenue under contract by the end of 2022. Footprint continues to experience strong demand as a result of regulatory restrictions across several US states and the European Union banning single-use plastic and opting for plant-based fiber solutions. Footprint is well positioned to capitalize on increased consumer demand for sustainable alternatives to plastic as well as corporate commitments to reducing CO2 emissions and plastic landfill waste moving forward. The company continues to partner with an expanding range of premier consumer brands, representing the largest and most significant food and beverage, retail and consumer products companies globally including McDonald's, Kraft, Wal-Mart, Conagra, Proctor & Gamble, Albertsons, Sweetgreen and more. In light of developing market conditions, the parties agreed to adjust the pro forma enterprise value of Footprint to $1 billion, down from $1.6 billion. In connection with the updated transaction, Footprint secured an approximately $300 million standby equity facility available upon the closing of the transaction. Footprint has access to a minimum of $100 million under the facility and up to $300 million at the company's discretion. Additionally, Footprint has received approval for an initial $280 million facility to fund equipment purchases through the end of 2023. Furthermore, Koch Strategic Platforms has upsized its prior investment and, along with Gores Sponsor VIII LLC and certain other investors, has agreed to accelerate the funding of its investment. When combined with Koch Strategic Platforms' prior investments in Footprint, this has resulted in approximately $290 million of capital being funded to Footprint prior to the close of the business combination. This capital, combined with the PIPE proceeds, the standby equity facility, cash in trust, and the initial equipment financing facility, will deliver approximately $960 million in capital to Footprint in connection with the transaction. Upon closing of the proposed transaction, the combined company will be named "Footprint International, Inc." and will be listed on the Nasdaq under the ticker symbol "FOOT."
PPTA

Hot Stocks

06:05 EDT Perpetua Resources expects USFS to publish SDEIS in Q4 - Perpetua Resources announced that the company expects the United States Forest Service, or USFS, to publish a Supplemental Draft Environmental Impact Statement for public review in the fourth quarter. The USFS has confirmed that cooperating agency review is complete and the SDEIS is currently progressing through final reviews in Washington D.C. The USFS is concurrently working with Idaho tribes to inform meaningful consultation. Perpetua is confident the additional evaluation contained within the SDEIS will show improved environmental outcomes that directly address issues raised during the public review of the 2020 Draft Environmental Impact Statement and believes the additional analysis and detailed review should lead to the USFS designating a preferred alternative in the SDEIS. This key designation would further narrow the scope of review for the remainder of the process. Nearly two years of additional and comprehensive scientific analysis by the USFS and cooperating agencies, combined with the additional public review of the SDEIS, fortify the rigorous process mandated by the National Environmental Policy Act.
IDYA PFE

Hot Stocks

06:05 EDT Ideaya Biosciences begins Phase I trial to evaluate treatment for uveal melanoma - IDEAYA Biosciences announced that it has initiated an Investigator Sponsored Trial, or IST, in coordination with St. Vincent's Hospital, Sydney, to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma, or UM, patients. The study, captioned as "Neoadjuvant / Adjuvant trial of Darovasertib in Ocular Melanoma", is being led by principal investigator Professor Anthony Joshua, Head Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital in Sydney with participating sites of Alfred Health and the Royal Victorian Eye and Ear Hospital in Melbourne. Pursuant to the protocol, the NADOM study will evaluate darovasertib as monotherapy in eligible adult patients having ocular melanoma to determine the feasibility and tolerability of neoadjuvant treatment. Uveal melanoma is a rare, lethal form of melanoma that arises from melanocytes of the iris, the ciliary body, or most commonly the choroid, with an annual potential incidence of approximately 8,700 patients aggregate in US and Europe. Darovasertib, or IDE196, is a potent, selective small molecule inhibitor of protein kinase C, or PKC. Mutations in GNAQ or GNA11 have been identified in approximately 90% of patients with metastatic UM. These mutations are associated with activation of signaling pathways, including oncogenic RAS/RAF/MEK/ERK via Protein Kinase C, or PKC, activation, driving tumor progression. In April 2022, the FDA designated darovasertib as an Orphan Drug in Uveal Melanoma. In addition to supporting the NADOM study with St. Vincent's Hospital Sydney, IDEAYA is also evaluating the synthetic lethal combination of darovasertib and crizotinib, a small molecule cMET inhibitor, in metastatic uveal melanoma in an ongoing Phase 2 clinical trial pursuant to a clinical trial collaboration and drug supply agreement with Pfizer.
AZN

Hot Stocks

06:03 EDT AstraZeneca's Forxiga approved in China for treatment of kidney disease - AstraZeneca's Forxiga, or dapagliflozin, a sodium-glucose cotransporter 2 inhibitor, has been approved in China to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, cardiovascular death and hospitalisation for heart failure in adults with chronic kidney disease at risk of progression with and without type-2 diabetes . The approval by China's National Medical Products Administration is based on positive results from the DAPA-CKD Phase III trial. Reference Link
IDYA

Hot Stocks

06:02 EDT Ideaya Biosciences initiates darovasertib trial - Ideaya Biosciences announced that it has initiated an Investigator Sponsored Trial, or IST, in coordination with St. Vincent's Hospital, Sydney, to evaluate darovasertib as monotherapy in neo-adjuvant and adjuvant settings in primary, non-metastatic uveal melanoma, or UM, patients.
PAC

Hot Stocks

05:31 EDT GAP Airports reports August traffic up 22.5% - GAP Airports announced preliminary terminal passenger traffic figures for the month of August, which includes comparisons with the 2019 and 2021 figures to facilitate the reading and understanding of the passenger traffic trend. For August, the total number of terminal passengers at GAP's 12 Mexican airports increased by 19.8%, compared to the same period of 2019. Tijuana, Puerto Vallarta, Los Cabos and Guadalajara presented an increase in passenger traffic of 43.2%, 37.3%, 29.6% and 6.3% respectively, compared to August 2019.
TRQ RIO

Hot Stocks

05:27 EDT Rio Tinto to acquire 49% of Turquoise Hill for C$43.00 in cash - Turquoise Hill (TRQ) announced that, based on the unanimous recommendation of an independent special committee of its board of directors, it has entered into an arrangement agreement with Rio Tinto (RIO) and Rio Tinto International, a wholly-owned subsidiary of Rio Tinto, in respect of a transaction whereby Rio Tinto will acquire the approximately 49% of the issued and outstanding common shares of the company that Rio Tinto does not currently own for C$43.00 in cash per share, subject to approval by the Turquoise Hill minority shareholders and other customary closing conditions. The announcement is the culmination of negotiations that took place following the September 1 public announcement of the term sheet entered into in connection with the transaction. The purchase price of C$43.00 per share reflects a 67% premium to Turquoise Hill's closing price of C$25.68 per share on the Toronto Stock Exchange on March 11, being the last trading day prior to Rio Tinto's initial public proposal to acquire Turquoise Hill, and a 19% premium to Turquoise Hill's closing price of C$36.12 on August 31, being the last trading day prior to the September 1 announcement of the term sheet. The special committee was established by the Turquoise Hill board of directors to consider the initial proposal, as well as other alternatives available to the company and, if it deemed advisable, negotiate with Rio Tinto. Following an evaluation of the initial proposal and extensive negotiations between the special committee and Rio Tinto on price and other terms of the transaction, including amendments to the financing heads of agreement between the Company and Rio Tinto dated May 18 to address the company's near-term liquidity while the transaction is pending, the special committee unanimously recommended that the board approve the transaction. The board, having received the unanimous recommendation of the special committee, unanimously determined that the transaction is in the best interests of Turquoise Hill and fair to the shareholders of Turquoise Hill other than Rio Tinto and its affiliates and recommends that minority shareholders vote in favor of the transaction at the special meeting of shareholders to be held to approve the transaction. The transaction is to be effected by way of a court-approved plan of arrangement under the Business Corporations Act. The consummation of the transaction is subject to a number of conditions customary to transactions of this nature, including, among others: the approval of 66.67% of votes cast by the company's shareholders at a special meeting of shareholders; the approval of a simple majority of the votes cast by minority shareholders at such meeting and court approval. Completion of the transaction is not subject to any financing condition. The company expects to hold the special meeting of shareholders to consider and to vote on the transaction as early as possible in the fourth quarter. If approved at the meeting, the transaction is expected to close in the fourth quarter, subject to court approvals and other customary closing conditions. Further details regarding the terms and conditions of the transaction are set out in the arrangement agreement, which will be publicly filed by the company under its profiles. Additional information regarding the terms of the arrangement agreement, the background of the transaction and the independent valuation and fairness opinions will be provided in the information circular for the special meeting of shareholders
UMC

Hot Stocks

05:11 EDT UMC reports August sales of NT$25.35M, up 34.89%
CIGI

Hot Stocks

05:07 EDT Colliers International to acquire controlling interest in Pangea - Colliers announced that it has agreed to acquire a controlling interest in Pangea Property Partners, a capital markets advisor in Sweden and Norway. Pangea will merge with Colliers' existing company-owned operations in Sweden and establish a new Colliers company-owned operation in Norway. At the close of the deal, Colliers will establish a Nordic region with over 550 professionals in Denmark, Finland, Norway, and Sweden. The Nordic region will have more than 80 capital markets experts serving clients across the region. The Pangea partners, together with the existing leadership team of Colliers Sweden, will retain a significant equity stake in the combined business under Colliers' partnership model. The terms of the transaction were not disclosed. The combined operations will offer a full suite of services including, capital markets advisory, debt advisory, project finance, leasing and sales brokerage, valuations, and project management.
AMCR

Hot Stocks

05:05 EDT Amcor to invest $250,000 in Bloom Biorenewables, Nfinite Nanotechnology - Amcor has announced the first batch of recipients for its Amcor Lift-Off seed funding initiative. Launched in April, Amcor Lift-Off targets technologies that will further advance Amcor's initiatives to make the future of packaging more sustainable. Following multiple pitch rounds, the winners of the initial Lift-Off program are: Bloom Biorenewables, a chemical and biomaterials company, which converts plant waste into chemicals used in packaging and Nfinite Nanotechnology, an advanced materials company, which leverages smart nanocoatings to make packaging recyclable and compostable. Each company will receive investments of $250,000 and access to Amcor's research and development resources.